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Abstract
Abstract
A common finding of many reports evaluating ligand-based virtual screening methods is
that validation results vary considerably with changing benchmark datasets. It is widely
assumed that these dataset specific effects are caused by the redundancy, self-similarity
and cluster structure inherent to those datasets. These phenomena manifest themselves
in the datasets’ representation in descriptor space, which is termed the dataset topology.
A methodology for the characterization of dataset topology based on spatial statistics is
introduced. The method is non-parametric and can deal with arbitrary distributions of
descriptor values. With this methodology it is possible to associate differences in virtual
screening performance on different datasets with differences in dataset topology. More-
over, the better virtual screening performance of certain descriptors can be explained by
their ability of representing the benchmark datasets by a more favorable topology. It is
shown, that the composition of some benchmark datasets causes topologies that lead to
over-optimistic validation results even in very “simple” descriptor spaces. Spatial statis-
tics analysis as proposed here facilitates the detection of such biased datasets and provides
a tool for the design of unbiased benchmark datasets.
Based on the aforementioned results, general principles for the design of benchmark
datasets, which are not affected by topological bias, were developed. Refined Nearest
Neighbor Analysis was used to design benchmark datasets based on PubChem bioactivity
data. A workflow is devised that purges datasets of compounds active against pharmaceu-
tically relevant targets from unselective hits. Topological optimization using experimental
design strategies monitored by Refined Nearest Neighbor Analysis functions was applied
to generate corresponding datasets of actives and decoys that are unbiased with regard to
analogue bias and artificial enrichment. These datasets provide a tool for an Maximum
Unbiased Validation (MUV) of virtual screening methods. The datasets and a MATLAB
toolbox for spatial statistics are freely available on the enclosed CD-ROM or via the in-
ternet at http://www.pharmchem.tu-bs.de/lehre/baumann/MUV.html.
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Zusammenfassung
Ein gemeinsames Ergebnis vieler Arbeiten zur Validierung von Methoden des ligand-
basierten Virtuellen Screenings ist die Tatsache, dass die erzielten Ergebnisse stark von
den verwendeten Validierdatensätzen abhängen. Es wird angenommen, dass diese daten-
satzspezifischen Effekte durch die Redundanz, Selbstähnlichkeit und Clusterstruktur verur-
sacht werden, die in vielen dieser Datensätze auftreten. Die Abbildung eines Daten-
satzes im Deskriptorraum, die “Datensatztopologie” (engl. Dataset Topology), spiegelt
diese Phänomene wider. Im Rahmen der Arbeit wird eine nicht-parametrische Methode
aus dem Bereich der räumlichen Statistik (engl. Spatial Statistics) zur Charakterisierung
der Datensatztopologie eingeführt. Mit dieser Methode ist es möglich, Unterschiede in
den Ergebnissen von Validierexperimenten mit Unterschieden in der Datensatztopolo-
gie zu erklären. Darüberhinaus kann das bessere Abschneiden einiger Deskriptoren mit
deren Fähigkeit erklärt werden, günstigere Topologien im jeweiligen Deskriptorraum zu
erzeugen. Die Zusammensetzung mancher Validierdatensätze bedingt Topologien, die
zu überoptimistischen Validierergebnissen führen. Die vorgestellte Methodik aus dem
Bereich der räumlichen Statistik ermöglicht es, solche Datensätze vor der Validierung zu
erkennen. Weiterhin kann die Methode verwendet werden, um zielgerichtet Datensätze
zu konstruieren, die unverfälschte, nicht von der Datensatzzusammensetzung beeinflusste
Validierergebnisse sicherstellen.
Auf diesen Ergebnissen aufbauend werden generelle Kriterien für die Konstruktion
von Validierdatensätzen ohne topologiebedingte Verzerrung entwickelt. Mit Hilfe von
Methoden der “Verfeinerten Nächster Nachbar Analyse” (engl. Refined Nearest Neighbor
Analysis) werden verzerrungsfreie Datesätze zur Validierung von Techniken des Virtuellen
Screenings generiert. Als Basis dienen Datensätze von Substanzen mit Bioaktivität gegen
pharmazeutisch relevante Zielproteine aus PubChem. Ein im Rahmen der vorliegenden
Arbeit neu entwickeltes Verfahren ermöglicht es, Substanzen mit unspezifischer Bioak-
tivität aus diesen Datensätzen zu entfernen. Durch Optimierung der Datensatztopolo-
xiv
Zusammenfassung
gie werden korrespondierende Datensätze von Aktiven und Inaktiven erstellt, die eine
Maximal Unverfälschte Validierung (MUV, engl. Maximum Unbiased Validation) von
Techniken des Virtuellen Screenings ermöglichen. Diese Datensätze und eine MATLAB
Toolbox für räumliche Statistik sind auf der beiliegenden CD-ROM oder im Internet unter
http://www.pharmchem.tu-bs.de/lehre/baumann/MUV.html frei verfügbar.
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Chapter 1
Introduction
1.1 Virtual Screening in the Process of Drug Discovery
1.1.1 Screening: An Entry-Point to Drug Discovery
The initial search for chemical compounds that exert a pharmacological effect is an impor-
tant step in modern pharmaceutical research. Such lead compounds are the starting point
of medicinal chemistry programs that produce large series of derivatives of the lead com-
pound in order to optimize its pharmacological and biological properties. Traditionally,
lead compounds were found - if not by serendipity - by the isolation of active compounds
from e.g. plants, fungi, microorganisms or animal poisons.1 Although the purification,
synthesis or modification of natural products has lead to some major successes of phar-
maceutical research, the difficulties in synthesizing and purifying more complex natural
products and their derivatives have proven to be a major bottleneck.1,2
In 1904, Paul Ehrlich and Kiyoshi Shiga conducted a ground-breaking experiment,
when they tested a chemical library of 100 azo dyes for their effect on mice infected with
Trypanosoma.2,3 This research resulted in the discovery of Nagana Red, the first synthetic
drug against bovine nagana disease. In the wake of this success, an extensive medicinal
chemistry program was conducted including the testing of thousands of derivatives and
resulting in the discovery of Suramin in 1916,2 which is still in use today as one of
the major therapeutics against Trypanosomiasis.4 Nowadays, this screening of chemical
1
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libraries is established as the first step in drug discovery research. However, in contrast to
the days of Paul Ehrlich, screening is usually no longer conducted using animals as test
systems.
Today, before the start of a drug discovery campaign, a molecular target of pharma-
ceutical relevance is usually identified by molecular biology methods.5 Knowledge about
the biochemistry, structure or cellular biology of this target is then utilized to screen large
libraries often consisting of several hundreds of thousands of compounds. In order to
cope with the magnitude of this task, two major techniques of screening for promising
lead compounds have been established in recent years: Experimental High-Throughput
Screening (HTS) and computer based Virtual Screening (VS), which are also often re-
ferred to as in vitro and in silico screening, respectively.
1.1.2 Experimental High-Throughput Screening (HTS)
Most pharmaceutical companies employ a series of miniaturized and automated in vitro
tests as the first step in lead identification, once a biological target has been identified
and validated.6 Using such assays, it is possible to screen more than 100.000 chemical
compounds against the isolated protein target or a specialized cell system in a reasonable
amount of time. Such experimental High-Throughput Screening (HTS) has become a
routine step in every drug discovery program of large pharmaceutical companies.6
Basically, HTS is an automated process, that rapidly assays large numbers of com-
pounds against a biological target. (Figure 1.1) Robotic systems are employed to auto-
matically subject each compound in a large collection of chemicals to a miniaturized bi-
ological assay. Usually, only a single standard concentration of each compound is tested
in these primary screening experiments. Since this approach is prone to a relatively high
occurrence of errors,7–9 compounds showing promising results in the primary screen are
later re-assessed using classical low-throughput techniques in a so-called confirmation
assay. The assay technologies used in modern HTS can be traced back to three different
origins, which prevail today for a rough classification of assay formats and functions.10
2
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Figure 1.1: Typical High-Throughput Screening (HTS) workflow. A large number of
compounds from a repository of chemical samples is screened using fast, automatized
biological assays. Compounds are ranked according to their measured biological activity.
Since automated HTS has a relatively high error rate,7–9 a top-ranking subset is chosen
and re-examined using classical low-throughput biological assays.
3
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1.1.2.1 Common HTS Assay Formats
Cellular Growth and Proliferation Assays. Assays measuring the inhibition of cel-
lular growth or proliferation have a long tradition of application in the search for leads
in the fields of anti-infectives or cancer.10 They simply measure if a certain chemical is
able to reduce or inhibit the growth of a test population of cells. Growth and proliferation
assays are prototypes of so-called “phenotypic” assays, meaning that the assignment of
activity or inactivity is solely based on the “phenotypic” observation of reduced growth,
without any knowledge about the underlying molecular target or mechanism. Indeed, it
is impossible to identify the molecular target of active compounds in many cases. The
simple technical realization of growth and proliferation assays is therefore often balanced
by the difficulty of discriminating pharmacologically meaningful results from cytotoxic
effects.10
Functional Cell-based Assays. Classical pharmacological bioassays frequently relied
on measurements of the contractile state of smooth muscle cells. It was realized early,
that sensitivity and specificity towards a specific kind of cell-surface receptor were es-
sential for the bioassay to generate meaningful results.10 Recent advances in molecular
biology provided cell-lines specifically expressing drug target proteins as cell-surface re-
ceptors. Equally specific down-stream effects, such as Ca2+ release or reporter gene ac-
tivity provide experimental readouts amenable to a high-throughput approach. Although
functional cell-based assays involve a phenotypic observation and therefore share sev-
eral of the shortcomings of growth and proliferation assays, the observed effect is usually
highly specific for an interaction with the examined target. A special advantage of func-
tional cell-based assays is the possibility to test for all types of modulation, i.e. inhibition,
activation and allosteric interactions in one assay.
Enzymatic Assays. Because of recent advances in molecular biology, biochemistry and
biotechnology, many target proteins can be recombinantly expressed and purified in suffi-
cient amounts to facilitate high throughput screening using isolated enzymes. A great va-
riety of enzymatic binding assays based on competition with labeled ligands or substrates
4
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is available. It is evident, that enzymatic assays ensure the highest degree of specificity
for the observed effect, while providing the experimenter with a well defined system in
which different sets of parameters can easily be tested.10 However, it is often difficult or
impossible to detect activation or allosteric modulation in competitive binding assays. In
contrast to cell-based assays, enzymatic assays also exclude any effects exerted by cellular
membranes or cellular compartmentalization from the test. However, such effects might
be of considerable pharmaceutical relevance in later development stages. Moreover, en-
zymatic assays are highly sensitive towards the tendency of certain chemical compounds
to form aggregates when diluted in small volumes of liquid as they are common on HTS
micro-plates.11
1.1.2.2 PubChem: HTS Data for the Public Sector
HTS is an established approach in the pharmaceutical industry and is considered one of
the main resources for the discovery of new drugs.10 However, due to its high costs,
the public and academic sector has not been able to make extensive use of the technol-
ogy. Therefore, the Molecular Libraries Initiative (MLI)12 was devised as part of the
NIH Roadmap for Medical Research13,14 to provide academic researchers with results
from HTS campaigns conducted by a consortium of public sector screening facilities,
the Molecular Libraries Screening Centers Network (MLSCN). The screening data pro-
duced by the MLSCN laboratories is stored centrally in a data repository called Pub-
Chem,15 which is publicly available via the internet and can be automatically interfaced
by web capable computer programs.16 PubChem is composed of three major databases:
(i) PCCompound provides chemical structures of the compounds tested as part of the NIH
Roadmap effort. (ii) PCBioAssay lists bioactivity data for presently (July 2008) more than
640,000 compounds, derived from readouts of more than 1100 bio-assays, which include
both, primary and confirmation screens. (iii) PCSubstance contains data such as supplier
information, registration IDs or links to other databases for the actual physical samples of
substances tested in the HTS assays. If the contents of these samples are chemically char-
acterized, PCSubstance also provides links to the respective structures in PCCompound.
5
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The fact that all data in PubChem is public and easily accessible by computer pro-
grams, makes PubChem an invaluable tool for chemoinformatics analyses of bioactivity
data of small molecules. It will therefore serve as one of the main data resources of this
study. (see Chapter 3)
1.1.3 Virtual Screening (VS)
Although experimental High-Throughput Screening has generated considerable success
and consequently is one of the mainstays of modern drug discovery, its considerable costs
and the storing capacities needed for ever-growing compound libraries have put limita-
tions to its use.17 Therefore, computer based methods such as Virtual Screening (VS) are
today applied as a standard technique in almost every drug discovery campaign, both in
industrial and academic environments. Their main goal is to narrow down large databases
of chemical compounds to a level, where experimental scientists or automated systems
can cope with testing the substances for biological activity.6 That way the number of com-
pounds actually subjected to costly biological testing procedures is greatly reduced. (Fig-
ure 1.2)
Virtual screening methods can be roughly divided into structure-based and ligand-
based approaches.18,19 This study will focus on ligand based virtual screening (LBVS).
However, both approaches will be introduced briefly using two well-known inhibitors of
the target protein Cyclooxygenase 2 (COX2), Celecoxib and Rofecoxib (Figure 1.3), as
examples.
1.1.3.1 Structure Based Virtual Screening (SBVS)
The basic rationale of structure based virtual screening (SBVS) approaches is Fischer’s
“Lock and Key” principle, a central paradigm in biological chemistry and medicinal
chemistry.20 According to Fischer’s principle, the exertion of a pharmacological effect
by a chemical compound on a target protein requires the formation of a specific, energeti-
cally favorable, three dimensional pattern of chemical interactions.20 The goal of SBVS is
to predict for each compound in a virtual library of potential leads or drugs, if and to what
6
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Figure 1.2: Virtual Screening (VS) for lead compounds. A great advantage of VS is
the fact, that the compound library needed for screening is virtual, i.e. the screened
compounds do not need to be present in physically. The virtual library is screened by
a computer program applying either structure based virtual screening (SBVS, see Sec-
tion 1.1.3.1) or ligand based virtual screening (LBVS, see Section 1.1.3.2) techniques.
The result is a rank ordered list of the molecules in the database, sorted according to their
predicted activity. From this list, a subset of top-ranking compounds is chosen for bio-
logical testing. Provided the top-ranking compounds are enriched in active compounds,
the amount of tested compounds can be greatly reduced, thereby shortcutting the first
iteration of experiments in the HTS workflow. (compare Figure 1.1)
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Figure 1.3: COX2 inhibitors: Celecoxib and Rofecoxib.
extent it can interact energetically favorably with a given target protein. Therefore, a pre-
requisite for the conduction of SBVS is the availability of a three-dimensional structure
of the respective protein target either from experiments or computational predictions.18 If
this condition is met, “molecular docking”, i.e. the prediction of complexes of the target
and a compound, can be conducted in a two step process. “Posing” (Figure 1.4) consti-
tutes the enumeration of an ensemble of possible binding modes between compound and
target. “Scoring” assigns a score, that is proportional to the predicted binding energy, to
each of the generated poses.21 The basic assumption of SBVS is that compounds with
large negative, i.e. favorable, predicted binding energy, bind the target specifically and
might exert a pharmacological effect. Following this assumption, compounds are classi-
fied as presumably active or inactive against the target by the score of their best docking
pose.21
1.1.3.2 Ligand Based Virtual Screening (LBVS)
In contrast to SBVS approaches, ligand based virtual screening (LBVS) does not require
any knowledge about the three-dimensional structure of the target protein. This is of
considerable advantage in the quest for binders of targets or target classes, for which it
is difficult to obtain structural data. Some of these target classes, such as for instance
G-protein coupled receptors (GPCR)26 or ion channels,27 are of considerable pharma-
8
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Figure 1.4: One possible binding mode (pose) of Rofecoxib in Cyclooxyge-
nase 2 (COX2) as predicted by the docking program FRED2.22 Knowledge about the
three-dimensional structure of COX2 is essential to derive the geometry and contours of
the binding pocket (Inset). Steric complementarity between the coxib scaffold and the
binding pocket is observable. Binding of the methyl sulfonyl moiety to the side pocket
of the binding site (Inset: lower right) increases COX2 selectivity.23 Docking: OpenEye
FRED2,22 Visualization: PyMol,24 OpenEye VIDA325
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Figure 1.5: Overview of the ligand based virtual screening (LBVS) process. (A) Query
and database compounds are encoded by pharmacophore patterns or descriptor vectors.
(B) Chemical similarity between query and database compounds is quantified. (C) The li-
brary compounds are ranked according to their similarity with the query.
ceutical relevance. The omission of structural information is possible, because LBVS
relies on another fundamental paradigm of medicinal chemistry that is independent of
the target protein. This is the so-called similarity principle, which states that chemically
similar substances are likely to share similar biological activity.28–31 As a consequence,
the basic precondition for the conduction of LBVS is the knowledge about one or several
compounds active against the target under scrutiny. These compounds are often called the
“query”. The goal of LBVS is to rank a database of potential leads or drugs according to
their similarity with the query, following the assumption that compounds, which are very
similar to the query, are likely to exhibit the same, i.e. the desired, biological activity.
LBVS involves three basic steps (Figure 1.5):
Encoding of compounds. The physical and chemical properties of the molecules in
the query and the database to be screened must be represented numerically so that they
can be used as input for a mathematical quantification of chemical similarity. A large
variety of approaches exists for this encoding process,19 which can be roughly divided
into pharmacophore methods (Figure 1.6) and descriptor methods. (Figure 1.7)
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Figure 1.6: Pharmacophore search using Celecoxib as a reference structure. (A) From the
three-dimensional structure of Celecoxib, a geometric pattern of two aromatic rings (yel-
low spheres) and a H-Bond acceptor (blue sphere) can be derived as one possible element
crucial for COX2 inhibition. (B) This pharmacophore can be used to search a database
of potential drugs. (C) Rofecoxib matches the requirements of the pharmacophore query
and is identified as a COX2 inhibitor. Visualization: MOE34
A pharmacophore is a specific geometric arrangement of a set of structural features
in a molecule that is recognized at a receptor site and is responsible for that molecule’s
biological activity.32,33 Pharmacophore queries can be derived from one or several active
compounds either manually or algorithmically. (Figure 1.6)
Descriptors are vectors calculated from the chemical structure of a compound. A
large variety of such descriptors with different levels of sophistication and complexity has
been developed.19 However, among the literally thousands of available descriptors35 three
coarsely grouped classes prevail: (i) substructure binary fingerprints, where each bit codes
for the absence or presence of a distinct substructural feature in the molecule, (ii) topolog-
ical and geometric descriptors based on mutual distances between molecular features and
(ii) molecular property vectors formed of the numerical values of physico-chemical prop-
erties like the logarithm of the octanol/water partition coefficient (logP) or the molecular
weight.19 (Figure 1.7) In addition to “pure” implementations of the concepts of pharma-
cophores and descriptors, combined approaches exist, in which the presence, absence or
abundance of certain pharmacophoric patterns in a molecule is used to calculate a finger-
print or descriptor. These approaches have proven especially useful, since they combine
the biochemical relevance of the pharmacophore concept with the mathematical versatil-
ity of descriptor vectors.36–39
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Figure 1.7: Molecular features such as the number of H-Bond acceptors and the number
of ring systems in a molecule, or physico-chemical properties like LogP can be calculated
from the molecular structure. If they are utilized to form the components of descriptor
vectors, these vectors provide a means for the mathematical quantification of molecular
similarity by mapping chemical compounds to a vector space. Vicinity in this descriptor
space is equivalent to chemical similarity, which can be measured by geometric distance
measures such as the Euclidean distance dE .
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Quantification of chemical similarity. Based on the numerical representation by phar-
macophores or descriptors, the chemical similarity between query and database com-
pounds needs to be quantified. Here, descriptors have the unique advantage of being
vectors. This allows the use of a large variety of distance measures that are well estab-
lished in analytical geometry.29 The most widely used are the Euclidean distance for con-
tinuous descriptor vectors and the Tanimoto-Jaquard coefficient for bitstring fingerprint
vectors.40,41
The Euclidean distance is given as:
dE =
√
∑
i
(xi− yi)2; (1.1)
where xi, yi are the ith components of the descriptor vectors x and y of two molecules.
The Tanimoto-Jaquard coefficient is given as:
Tc =
nxy
nx+ny
; (1.2)
where nxy is the number of bits set “on” in the vectors of both molecules and nx, ny
the number of bits set “on” in the vectors x or y, respectively.
In addition to these important measures for descriptor similarity a large variety of other
distance functions exist, that can map all levels and nuances of molecular similarity.29 In
this context, spatial vicinity in the vector space spanned by the respective descriptor -
often called “descriptor space” - is equivalent to molecular similarity.42 (Figure 1.7) In
contrast to this, classical pharmacophore searches can only determine if a given molecule
does or does not match a certain pharmacophoric pattern.
Database ranking Given a molecular query and a database encoded by pharmacophores
or descriptors and a method for the quantification of molecular similarity, an algorithm
must be applied to generate a ranking of the compounds most similar to the query. A
wide range of search methodologies are available to accomplish this task.19,29 The most
basic approach is to rank-order the screening database compounds according to their sim-
ilarity to a single query molecule. Aside from these most basic “single query” similarity
13
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searches, methods featuring all levels of complexity exist, including for instance consen-
sus methods,43 artificial neural networks (ANN)44 or support vector machines (SVM).45
Recent results have also demonstrated the usefulness of quantitative structure activity re-
lationship (QSAR) models in LBVS applications.46 A particularly efficient method for
LBVS with multiple query molecules is similarity searching using data fusion according
to the “MAX”-rule.47,48 The similarity of each molecule in the screened database with
each molecule in the query is calculated, and the maximum of these values of similarity,
i.e. the nearest neighbor similarity, determines the rank of the molecule in the search out-
put. This approach has proven to be extremely powerful both in our own experience with
the conduction of virtual screenings and in comparative studies in the literature.47–49
The focus of this study will be descriptor based techniques for ligand based virtual
screening. However, the presented results and methods are readily applicable to phar-
macophore searches and require only minor modifications for the application to SBVS
methods.
1.2 Validation of Virtual Screening Techniques
1.2.1 Objectives of Validation Experiments
The utilization of similarity in descriptor space as a predictor of biological activity poses
a question of obvious importance: how much chemical similarity is enough to ensure
similar biological activity? Put more mathematically: An estimate is required for the
numerical cut-off value of similarity that is sufficient to predict similar biological activity
with minimum error.
In a seminal paper, Martin et al. have shown that it is not possible to determine an
explicit numerical similarity-cutoff in descriptor space that ensures common biological
activity in the general case.30 However, in two earlier papers Brown and Martin assessed
the ability of various descriptors to discriminate actives from inactives50 and to predict
physico-chemical properties relevant to receptor binding51 using datasets of molecules for
which these parameters were experimentally determined. This benchmark dataset based
14
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validation methodology has become a standard procedure for the evaluation of chemical
similarity methods, structural descriptors and search algorithms, because it estimates a
parameter deemed critical for prospective virtual screening campaigns: the number of
hits to expect for a particular method. There are typically two types of VS validation
experiments: (i) In “benchmarking” experiments, the objective is to identify the method
with the best VS performance across a range of datasets. Experiments of this kind are
most often applied to show how well a novel VS method performs in relation with avail-
able ones52–54 or by pharmaceutical companies in order to determine which software to
acquire.55,56 (ii) “Suitability testing” experiments are employed to determine the method
or set of operational parameters of a method best suited for a particular target or target
class. Results from suitability testing experiments may vary considerably depending on
the dataset of active compounds and their respective target. Experiments of this type are
usually employed in the preparation of prospective VS campaigns in order to facilitate
a rational choice of the optimal method for the target under investigation. Although the
final results and conclusions obtained from suitability testing and benchmarking are not
comparable, two basic tasks for VS validation can be formulated, that are valid under both
experimental settings:
(1) Compare the performance of different virtual screening methods.
(2) Estimate the number of hits a method is likely to retrieve from a database.
1.2.2 Validation Procedures and Figures of Merit (FoM)
For both, benchmarking and suitability testing, a validation procedure normally starts with
the selection of a set of molecules with known activity against the target under scrutiny.
Part of this set is chosen (often randomly) to act as query. The rest is pooled with a usually
large number of inactive molecules (frequently called “decoys”) to become the validation
set. The VS method to be validated is then applied to the validation set and assessed based
on the produced ranking. For descriptor based LBVS methods, both sets, the query and
the validation set, are encoded by the descriptor to be validated and the validation set is
ranked according to its similarity with the query. (Figure 1.8)
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Figure 1.8: Typical validation process. A database of inactive compounds (decoys, black)
is spiked with a set of known actives (red) to become the validation set. The VS method
to be validated is applied to the validation set to produce a ranking. This ranking is used
to assess the performance of a VS method. Plots of the fraction of found actives vs. the
fraction of the database screened, so-called enrichment plots, are used to assess the quality
of a method. These plots are also the basis for the calculation of Figures of Merit, such as
RT R1% and AUCROC.
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A common way of visualizing the retrieval of known active substances in the resulting
VS ranking is to plot the fraction of found actives against the fraction of the ranking con-
taining it. These plots are generally called “enrichment plots”. (Figure 1.9A) The recall or
retrieval rate (RTR) at one percent of the ranked validation set (RT R1%) is the fraction of
active compounds that is retrieved in the first percent of the ranking generated by the val-
idation run. It can be read out from an enrichment plot at x = 0.01 (= 1%). (Figure 1.9B)
The RT R1% has been established as a widely used figure of merit for the performance of
VS methods.47,48 It is evident, that the RTR can be used to compare methods and to esti-
mate the expected number of hits. Thereby it fulfills both basic tasks of VS validation as
stated above. Often so-called “enrichment factors” (EF)57 are calculated from the RTR,
that are meant to normalize to the null hypothesis of uniformly distributed active mole-
cules in the final ranking list. Bender and Glen have shown that enrichment factors tend to
overestimate performance, since EFs quantify the performance of a method relative to the
hypothesis of uniformly distributed actives in the final ranking, which is not realistic.58
Moreover, several authors have criticized the RTR and EF metrics for the fact of being
susceptible to changes in the ratio of the sizes of benchmark dataset vs. background and
the inability to reflect the position of the found actives before the threshold.59,60
In order to avoid these issues, the area under the receiver operating characteristic curve
(AUCROC, Figure 1.9D) was used in a number of studies for the analysis of VS validation
rankings.61–64 In receiver operating characteristic curves (ROC), the true positive rate (the
fraction of found actives) is plotted against the false positive rate (the fraction of found
decoys). (Figure 1.9C) The AUCROC metric has one important shortcoming: it is unable
to address the so-called “early recognition” problem. Since usually only a small fraction
of a VS ranking can be tested experimentally, a good metric for VS should reflect the
enrichment of actives at the beginning of the ranking. In addition, ROC metrics do not
provide a direct estimate of the number of expected hits. Recent efforts have sought to
develop VS performance metrics that combine the statistic stability of the AUCROC with
the “early recognition” properties of the RTR or the EF.59,60 However, due to their novelty,
these metrics have not yet found extensive use in VS validation studies and it is therefore
17
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Figure 1.9: (A) Enrichment plot (blue) and receiver operating characteristic curve (red)
for an artificial ranking in which two out of a total of two actives are found at rank r =
4,8 in a database of 10 compounds. (B) Enrichment plot (blue) and receiver operating
characteristic curve of a ranking obtained from an actual VS validation with 50 actives
among roughly 90000 decoys. Both, RT R1% = 0.42 and AUCROC = 0.92 indicate quite
satisfactory validation results.
difficult to compare the results obtained with these metrics to those of other works. Thus,
in this study, RT R1% and AUCROC were used in a complementary manner for the analysis
of VS rankings.
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1.3 Benchmark Datasets
1.3.1 Available Benchmark Datasets for VS Validation
A basic condition for the conduction of validation experiments as proposed by Brown
and Martin50,51 is the availability of commonly employed benchmark datasets. A number
of such benchmark datasets have been published for both, ligand based virtual screening
and structure based virtual screening .47,48,56,64–67 They range in size from tens to several
hundreds of active compounds. The sources of these datasets vary, including the medici-
nal chemistry literature, public databases like the PDB,68 commercial databases like the
MDL Drug Data Report (MDDR)69 or proprietary data of pharmaceutical companies. As
a consequence, the experimental conditions leading to the qualification of a compound
as active usually vary within each dataset. It is often tedious, in the case of literature
datasets, or impossible, in the case of proprietary data, to examine and compare these
experimental conditions. In addition to these difficulties regarding the datasets of actives,
many literature benchmark datasets share a significant shortcoming: the inactivity of the
decoy compounds is not experimentally determined but merely assumed.47,48,56,64–67,70
The decoys are usually extracted from large databases of drug-like compounds, such as
ZINC71 or the MDL Drug Data Report (MDDR)69, simply by using compounds with no
reported activity against the target under scrutiny.47,48,56,64–67,70
However, regardless of the shortcomings they may have, benchmark datasets are vital
for a rational evaluation of VS methods. Especially the datasets referenced above have
proven to be highly valuable to the field of VS validation studies. From these, the datasets
provided by Hert and Willet in two seminal papers47,48 stand out as the ones most widely
accepted for the validation of virtual screening methods. They comprise 11 datasets, each
consisting of several hundreds of compounds with known activities against a range of
therapeutically relevant targets and were extracted from the MDDR.47,48 These datasets
will also be used in this study.
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1.3.2 Impact of Dataset Composition on Validation Results
Although the validation and calibration of VS methods on benchmark datasets is now
an established methodology, a number of problems arise from its empirical nature. In a
study on the evaluation of the docking program GOLD, Verdonk et al. have shown that
results are highly influenced by the composition of the dataset of decoys.72 They proved
that if the background significantly differs from the set of actives regarding “low dimen-
sional” properties like molecular weight or number of hydrogen bond donors/acceptors,
it may lead to “artificial enrichment”. That is the classification is actually caused by the
differences in bulk or global molecular properties rather than specific interactions with
the target. They conclude that focusing the library of inactives to the same range of low
dimensional properties as the actives is essential for the results of VS validation to be
representative. Recently DUD (“Directory of useful decoys”), a collection of validation
sets for molecular docking seeking to fulfill these requirements, has become available for
public use.67
As mentioned above, Bender and Glen showed that the random ranking hypothesis
underlying the calculation of enrichment factors often leads to overoptimistic estimations
of a method’s performance.58 They suggest normalizing the RTR of any VS method by
the RTR of a so-called “dumb” descriptor like molecular weight or atom counts, which
is basically a vectorized form of the chemical sum formula. Since the sum formula is
highly correlated with molecular weight and hydrogen bond donor/acceptor counts, this
approach implicitly covers many of the phenomena discussed by Verdonk et al. and can
effectively be used as a negative control when validating VS methods utilizing similarity
searching.
While the works by Verdonk et al. and Bender et al. precisely highlight the ef-
fect the composition of the background dataset has on the outcome of VS validation,
three papers by Good and coworkers concluded that datasets of actives extracted from
databases constructed from drug discovery projects, such as the MDDR, are prone to
over-representation of certain scaffolds or chemical entities.73–75 It was shown, that un-
less the benchmarking datasets and the background are chosen with care, the figures of
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merit for ligand based virtual screening may be over-optimistic due to the so-called “ana-
logue bias”.
Recently, Vogt and Bajorath proposed a measure of divergence between the descrip-
tor distributions of the benchmark dataset and the background that relates to VS perfor-
mance and can thus be used to estimate performance rates in descriptor-based virtual
screening.76,77 Their approach is based on a number of assumptions about the descrip-
tor distribution. As opposed to this, the method presented in the course of this study is
non-parametric, i.e. can deal with arbitrary distributions of benchmark dataset and back-
ground.
1.3.3 Chemical Space
Many of the concepts discussed so far already implied an interpretation of chemical data
in the context of analytical geometry and spatial relations. The application of distances29
and other geometric analogies to chemical datasets and databases has proven to possess
enormous descriptive power. Therefore, the discipline of chemoinformatics has widely
adopted the concept of so-called “chemical space”. Basically, chemical space is defined
as the multitude of all molecules that can theoretically exist given the rules of chemistry.
Current estimations suggest that this comprises about 1023 theoretically feasible mole-
cules.78 Inside this huge chemical universe, several subspaces exist that are defined by
a certain property common to all molecules in this subspace.79 Well known examples
include “drug-like” chemical space or “peptide space”.
A very important class of chemical subspaces are those formed by all compounds
active against a certain molecular target. These so-called activity spaces are central to the
analysis and design of VS benchmark datasets. A good benchmark dataset should cover
the activity space of its target comprehensively.
In the context of descriptor based ligand based virtual screening, chemical space can
be defined more stringently. For any class of molecular descriptor, chemical space is
defined as the set of coordinates that can be occupied by vectors belonging to chemical
compounds represented by this descriptor. Analogously, the activity space of target X is
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Figure 1.10: Cartoon representation of the continuum of chemical space and the sub-
spaces occupied by molecules with specific biological activities. One possible way of
defining subspaces is the grouping of molecules by the gene families of their targets, e.g.
proteases (green), GPCRs (red), kinases (grey) or nuclear receptors (green). The activity
space of a particular GPCR would itself be a subspace of GPCR space. Figure adapted
from Lipinski et al.79
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the subset of coordinates occupied by compounds with activity against X. The concept of
chemical space and the spatial description of the extent and shape of various subspaces
will be central to this study.
1.3.4 Benchmark dataset topology
When comparing the benchmark datasets proposed by Hert et al.47,48 with datasets of ac-
tives that form the input of real-life virtual screening campaigns, the most striking feature
is their size. Whereas the benchmark datasets consist of several hundreds to more than
thousand substances, usually only a small number (∼ 10− 20) of active substances are
available at the beginning of a VS campaign, rendering the benchmark datasets redun-
dant with respect to real-life VS. Furthermore, the potential presence of large scaffold
families in the datasets introduces analogue bias, as stated above. These phenomena and
their variations across datasets manifest themselves as spread, self-similarity, patchiness
and clustering of the datasets’ representation in descriptor space. We will refer to this
mapping of dataset composition into descriptor space as the dataset topology. Both, the
calculation of molecular similarity and the subsequent ranking of the screened database,
which are the most crucial steps in the conduction of virtual screening, are based on the
respective molecules’ representation by descriptors. It is therefore reasonable to quantify
analogue bias, redundancy and other phenomena influencing VS performance by their
representation in descriptor space, i.e. by dataset topology.
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Impact of Dataset Topology on VS
Validation
2.1 Objectives
The works of Verdonk et al.,72 Bender et al.58 and Good et al.73–75 described the impact
of benchmark dataset composition on VS validation results in a qualitative manner. Im-
portant termini like “artificial enrichment” and “analogue bias” were introduced, but lack
means for their quantification. As a consequence, no quantitative correlation between the
occurrence and degree of artificial enrichment or analogue bias in a dataset and the results
of VS validation has yet been demonstrated. Therefore, the first objective of this study is
to develop a methodology for the quantification and description of dataset composition.
The methodology will be based on a spatial analysis of the datasets’ topology in descriptor
space. The extensive impact of benchmark dataset composition on VS validation results
will be demonstrated by application of the methodology on literature benchmark datasets
combined with retrospective VS simulations.
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2.2 Methods
2.2.1 Methodological Strategy
The basic idea of this part of the study is to sample sub-sets with different topologies
from the well established Hert-Willett benchmark datasets.47,48 (see Section 1.3.1) By
comparing the results of retrospective VS simulations on these sub-samples, the influence
of dataset topology on the validation results can be observed. Various sampling strategies
are employed to generate archetypal sub-samples from the literature benchmark datasets:
(i) maximum diversity subsets, (ii) space filling samples and (iii) subsets with minimum
intra-set diversity. The analysis of the varying VS performance on these prototype datasets
allows us to assess if and to what extent dataset topology affects the validation of virtual
screening. Here, it is essential to ensure that no other factors influence the outcome of the
VS runs, which is achieved by a careful design of the experimental setup. The magnitude
of factors of variance that can not be controlled by the experimental setup is estimated by
bootstrapping methods. (Figure 2.1) Spatial statistics techniques are introduced here to
explore and quantify the effect of benchmark dataset topology in more detail. In order to
get an idea how encoding by different descriptors influences dataset topology in descriptor
space, two kinds of descriptors are used for the experiments: MOE molecular descriptors
and “simple” descriptors acting as a negative control. After using artificial sub-samples
to show that dataset topology has an effect on the outcome of VS validation and that it
can be quantified by spatial statistics methods, the methodology is applied to the complete
benchmark datasets.
2.2.2 Datasets
The datasets as described by Hert et al.47,48 and two additional datasets containing in-
hibitors of angiotensin converting enzyme (ACE) and acetylcholineesterase (AChE) were
extracted from the MDDR69 (MDL Drug Data Report) by their activity indices. An
overview of the datasets is provided by Table 2.1. The remaining 93925 molecules in the
MDDR that did not belong to at least one of the activity classes, were assumed to be inac-
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Figure 2.1: Schematic outline of the experimental setup. Sub-samples with controlled
topology are extracted from literature benchmark datasets. 100 random splits of the sub-
sample into query and validation set are generated for retrospective VS. The arithmetic
mean and the variance of the figure of merit (FoM) under scrutiny over all splits estimates
the VS performance on the sub-sample and its statistical error, respectively. Bootstrapping
is used to determine to what extent this statistical error is caused by factors other than
topology.
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Table 2.1: Hert-Willett Benchmark Datasets with Activity Against the Specified Targets
Extracted from the MDDR.
Activity Dataset size
Angiotensin converting enzyme (ACE) inhibitors 355
Acetylcholine esterase (AChE) inhibitors 701
Angiotensin II Type 1 Receptor Blockers 943
Cyclooxygenase (COX) inhibitors 636
D2 antagonists 395
HIV protease inhibitors 750
5HT1A agonists 827
5HT3 antagonists 752
5HT reuptake inhibitors 359
Protein kinase C (PKC) inhibitors 452
Renin inhibitors 1130
Substance P inhibitors 1246
Thrombin inhibitors 803
tive and were used as decoys as described by Hert et al.47,48 This excludes potential over-
lap between the sets of actives as a factor distorting validation results. SD-Files80 of all
datasets and the background were cleaned from small fragments like counter ions and sol-
vents using MOE (Molecular Operating Environment)34 and converted to 3-dimensional
structures with CORINA.81
2.2.3 Descriptors
For all datasets and the set of decoys, MOE molecular properties descriptors34 were com-
puted. Properties are grouped into three classes: 2D (computed from the 2-dimensional
topology of a molecule), i3D (properties that depend on internal 3-dimensional coordi-
nates) and x3D (calculated from a grid surrounding the 3-dimensional structure of the
molecule). Since the x3D class depends on a common spatial frame of reference for all
molecules, i.e. an alignment of all molecules in a spatial grid, which is not feasible for
VS applications, only the 2D and i3D classes were used for experiments. The numerical
values of properties in MOE descriptors have significantly different ranges. Molecular
weight, for instance, typically varies between 0 and ∼ 1000, whereas logP often has a
value roughly between -1 and 5 for drug-like molecules. Therefore the data matrix con-
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sisting of MOE descriptor vectors for the complete MDDR was autoscaled columnwise
by subtracting the mean and dividing by the standard deviation of each column. Columns
whose properties had constant values for the complete MDDR were removed from the
matrix. After this pre-treatment, the matrix had a dimensionality of 180. In order to re-
duce noise in the descriptor matrix, principal components analysis (PCA)82 was applied.
An analysis of the resulting eigenvalues showed that > 99% of the total variance could be
explained by the first 54 components. Thus the first 54 scores from the PCA were used as
the final descriptors for the VS simulations.
Following the approach suggested by Bender and Glen,58 the database was also en-
coded by negative control “simple” descriptors, which consisted of the respective counts
of all atoms, heavy atoms, boron, bromine, carbon, chlorine, fluorine, iodine, nitrogen,
oxygen, phosphorous and sulfur atoms in each molecule as well as the number of H-bond
acceptors, H-bond donors, the logP, the number of chiral centers and the number of ring
systems. These properties were generated from the SD-Files of the datasets using Open-
Eye BABEL383 (atom counts) and OpenEye FILTER84 (acceptors, donors, logP, chiral
centers, ring systems). The respective output files were parsed with an in-house PERL
script to provide the final descriptors.
These descriptors are central to this study, because they capture all molecular prop-
erties associated with analogue bias and artificial enrichment.72–75 They are a valuable
tool for the detection and prevention of bias in VS validations introduced by benchmark
dataset composition. Thus, they will be utilized extensively throughout the course of this
study. For the sake of brevity, they will be denoted simple descriptors from now on in the
text.
The simple descriptors for the MDDR datasets used in this Chapter were not au-
toscaled, since it was deemed important to preserve their chemical meaning. This fa-
cilitates a comparison of MOE descriptors with crude molecular properties. Autoscaling
of descriptors is most important for the design of datasets with specific topological prop-
erties, such as in Sections 2.2.4 and 3.2.10. For such purposes, it is desirable that the
design is determined equally by all dimensions of a descriptor vector. In this Chapter,
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all design steps are based on PCA scores of MOE descriptors, which are centered, au-
toscaled and orthogonal. Therefore an autoscaling of simple descriptors was not essen-
tial. In Chapter 3, Section 3.2.10, however, simple descriptors are used as the basis for
dataset design. Accordingly, the simple descriptors used in Chapter 3 were centered and
autoscaled. (see Section 3.2.8)
2.2.4 Sub-Samples with Defined Topology
Various methods exist to generate subsets of compounds based on a descriptor represen-
tation of the original dataset. Based on the MOE representation of the data, from each
of the benchmark datasets a subset of k = [50,100,150,200,250,300] compounds was
generated for each of the three following sampling strategies. D-optimal design85,86 was
used to provide subsets with the maximum intra-set diversity for the respective number
of compounds. For the generation of subsets sampling the respective dataset in a space
filling manner, D-optimal onion design87 was applied. Around the center of mass of each
dataset 5 shells were defined, of which each contained 20% of the data. In contrary to
shells of equal distance, this approach ensures the presence of an adequate number of dat-
apoints in each shell in spaces of high dimensionality.88,89 In order to reflect the datasets’
density distribution in the sub-samples, an equal number of k/5 compounds were cho-
sen from each shell by the D-optimality criterion. Both, D-optimal design and D-optimal
onion design were implemented using the Statistics Toolbox of The Mathworks MAT-
LAB 790. Subsets with a minimum sum of intra-set all against all distances, i.e. by a
Minimum Diversity Design were generated using an in-house row exchange algorithm91
also implemented in MATLAB 7. All three sampling strategies are deterministic, i.e. for a
given k one optimum sub-sample from the original dataset is selected. By this procedure
three prototypes of sub-samples were created for every k: (i) A “worst-case scenario”
for which VS using MOE descriptors would be very difficult was generated by the max-
imum diversity criterion using D-optimal design. (ii) An intermediate case with active
compounds equally spread across MOE descriptor space with varying density depending
on k was generated by the onion design approach. (iii) Finally, a “best-case scenario”
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with multiple active compounds concentrated in a tight cluster resulted from the mini-
mum diversity design. In order to observe how dataset topology and VS performance are
affected by different descriptor representations, the identical sub-samples, i.e. the same
compounds chosen by the different design strategies for MOE descriptors, were compiled
for the simple descriptor representation. This excluded sub-sample composition as a fac-
tor of variance when comparing the performance of different descriptor representations.
2.2.5 Retrospective Virtual Screening Simulations
A variety of methods is available for the conduction of ligand based virtual screening. It
was not the goal of this study to figure out the descriptor, similarity measure, or search-
ing method that presumably generates best results for virtual screening, but to determine
the influence of dataset topology on method performance. Therefore we settled for one
type of searching procedure and one similarity measure, which we kept constant for all
experiments. For similarity searching with multiple query molecules, data fusion accord-
ing to the “MAX”-rule47,48 has proven to be very powerful (see Section 1.1.3.2) and was
therefore used for all experiments presented in this Chapter. All simulations of virtual
screening described in this Chapter were carried out using ten active compounds cho-
sen randomly from the sub-samples described above as query and pooling the remaining
actives with the decoys. Similarity was measured by the Euclidean distance and the re-
spective validation sets were ranked accordingly. This was repeated 100 times to assess
the variability of the results and to obtain a mean value that is not affected by the random
choice of the query molecules. To obtain an estimate of the statistical error of the re-
spective rankings, 1000 bootstrapping runs were carried out on the ranking resulting from
each of these query / validations set combinations, randomly leaving out 20% of both the
actives and the background compounds in each run, respectively.
2.2.6 Figures of Merit (FoM) for Virtual Screening Performance
The ability for early recognition of active compounds was measured by the mean fraction
of retrieved actives in the first percent of the ranked validation set RT R1%. Additionally,
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the area under the receiver operating characteristic curve (AUCROC) was determined for all
rankings in order to rule out any bias introduced by the hard 1% cutoff of the RT R1%. The
mean Retrieval Rates and mean areas under the receiver operating characteristic curves
obtained from the 100 random query / validation set splits, which were generated for each
dataset sub-sample, will be denoted mean(RT R1%) and mean(AUCROC) throughout the
text.
2.2.7 Variance Decomposition for Figure of Merit Statistical Errors
The standard deviation of both RT R1% and AUCROC is often used to estimate the statistical
error of VS validation results. In the context of this study, it is desirable to isolate the
component of error that is caused by the topology of the dataset used in the respective
validation experiment. In their recent paper, Truchon and Bayly not only introduced a
new metric for the validation of VS methods, but also provided a remarkably concise and
comprehensive analysis of the factors influencing the variance of VS rankings and the
resulting figures of merit.60 According to them, the variance is mainly influenced by the
following parameters: N, the absolute number of decoy molecules and Ra, the fraction of
actives in the ranking (i.e. size of the dataset of actives). Furthermore, the “goodness” of a
ranking itself (denoted λ by Truchon and Baily) has considerable impact on the variance
of the figures of merit. This is caused by the fact, that for a very “successful” screening
run the actives are far less spread over the ranking, since they are concentrated at its
beginning. Furthermore, they discuss a “saturation effect” that affects metrics measuring
early recognition if the number of active compounds is higher than the number of ranks
in the part of the ranking that is considered “early”.
In our setting, the number of decoys was kept constant (N = 93925) for all experiments
and can therefore be ruled out as a factor affecting the results of the VS simulations. Since
the size of the biggest subsets of actives used here is 300, which is clearly smaller than the
number of ranks in the first percent of the rankings (v 940), the RTRs reported here are
not subject to the saturation effect. ROC metrics have no early recognition features and
consequently are not prone to the respective saturation effects. There are, however, two
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parameters that can not be kept constant in this experimental setting: λ : This parameter
is used by Truchon and Bayly to denote rankings with varying VS performance. How-
ever, the rankings discussed in their paper are derived from sampling a model probability
density function rather than real VS runs. In our setting, the “goodness” λ of the ranking
can not be determined before the experiment. Ra: The sampling strategy for the design
of subsets with different topology requires subsets of actives with differing sizes. The
magnitude of the variance component introduced by changing Ra and λ can be estimated
by the bootstrapping procedure described above. As indicated in Figure 2.1, 1000 boot-
strap samples were drawn from each ranking obtained from a particular query / validation
set split. The variance σ2bt,i with i = 1..100, is an estimate of the statistical error caused
by the particular combination of λ and Ra for each of the 100 splits. According to the
law of total variance for experiments with a nested design the overall variance σ2, can be
decomposed to yield a variance component σ2top associated with dataset topology:92
σ2 = σ2top+mean(σ
2
bt,i); (2.1)
which can be written as:
σ2top = σ
2−mean(σ2bt,i); (2.2)
With all other factors constant, the only factor affecting σ2top is the dataset topology. A
corrected standard deviation providing an estimate of the statistical error of the validation
results associated with dataset topology can then be calculated as:
stdtop(FoM) =
√
σ2top; FoM = RT R1% or AUCROC (2.3)
2.2.8 Spatial Statistics Analysis of Chemical Datasets
2.2.8.1 Basic Categories of Dataset Topology
One major goal of this study is to describe the topology of chemical datasets or sub-
samples of datasets by the relative positions of the datapoints in chemical space to which
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Figure 2.2: Representative datasets and their characterization by Refined Nearest Neigh-
bor Analysis. (A) Nearest neighbor distances in concentrated (red) and patchy (blue) sets
are smaller than in dispersed sets (green). However, patchy and concentrated sets can not
be distinguished by nearest neighbor distances, since these are not affected by the pres-
ence of multiple clusters. (B) By “flooding” the analyzed space with random points and
measuring their distances to the nearest event, gaps in the data can be detected and the
overall spread of the sets can be quantified, thereby differentiating patchy from concen-
trated sets.
the compounds in the dataset are projected by the application of a structural descriptor. In
the terminology of spatial statistics, the position of a compound belonging to the sample
under examination is an “event”. On the other hand, “points” denote arbitrary coordi-
nates in chemical space. Regarding virtual screening, there are three basic categories of
topology for a set of events. (Figure 2.2) (i) “Concentrated” sets consist of a single dense
cluster, well separated from the rest of chemical space. (ii) “Patchy” sets are composed
of multiple dense but separated clusters. (iii) “Dispersed” sets are regularly distributed
in chemical space, with comparatively large event-event distances. It should, however,
be kept in mind that this rather coarse categorization of dataset topologies is mainly used
here for the illustration of the basic properties of the spatial statistics functions presented
below. Real chemical datasets will usually incorporate all kinds of nuances and combi-
nations of the three basic categories of dataset topology. In the following two sections a
methodology within the framework of spatial statistics will be developed, that facilitates
the detection and identification of all major types of topologies and the quantification of
“dataset clumping” in chemical datasets. Refined Nearest Neighbor Analysis93,94 is a set
of spatial statistics methods that is especially useful for the analysis of large datasets. Its
mathematical foundations will be introduced in Section 2.2.8.2. Different approaches for
the implementation of the underlying functions will be discussed in Section 2.2.8.3.
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2.2.8.2 Refined Nearest Neighbor Analysis: Mathematical Foundations
Refined Nearest Neighbor Analysis is a mathematical framework for the analysis of
mapped point patterns. It is based on the calculation of two functions from the position
of points and events (Figure 2.2): G(t) is the proportion of events for which the distance
to the nearest neighbor is less than t. G(t) is called the “nearest neighbor function” and is
a cumulative probability distribution of the distance of any event to its nearest neighbor
event. Using G(t), it is possible to distinguish dispersed from concentrated and patchy
sets (green vs. blue and red in Figure 2.2A). In some cases, it is however not possible to
differentiate between patchy and concentrated sets (blue vs. red in Figure 2.2A). Since
only the nearest neighbor of each event is considered, the spacing between several dense
clusters has no effect on G(t), because the nearest neighbor of any event will always be
located in the same cluster. As a consequence, G(t) is neither sensitive to the presence
nor to the spacing of multiple clusters. This distinguishes the nearest neighbor function
from approaches based on average intra-set distances or methods based on more than one
neighbor. Let n be the number of events, then G(t) is given as:
G(t) =
∑
n
It(i, j)
n
; (2.4)
with It(i, j) = 1 if the distance of event i to its nearest neighbor j is smaller than t. Rep-
resentative graphs of G(t) for concentrated, patchy and dispersed sets are shown in Fig-
ure 2.3A.
In order to distinguish between concentrated and patchy sets, a large number of points
are sampled randomly from chemical space. F(t) is the proportion of these points for
which the distance to the nearest event is less than t. (Figures 2.2B, 2.3B) F(t) is a
cumulative probability distribution of the distance from a randomly chosen point to the
nearest event and is often called the “empty space function”, because it is sensitive to gaps
in the data. For a patchy set, the average distance from a random point to the nearest event
will be smaller than for a concentrated set. Depending on the number and the degree of
separation between the clusters less chemical space is unoccupied for patchy sets. On
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the other hand, because F(t) does not take into account event-event distances, it can not
differentiate between dispersed and patchy sets, if the clusters in the latter are far apart.
Figure 2.3B provides representative graphs of F(t) for concentrated, patchy and dispersed
sets. Let m be the number of random points, then F(t) is given as:
F(t) =
∑
m
It(j, i)
m
; (2.5)
with It(j, i) = 1 if the distance of point j to its nearest neighbor event i is smaller than t.
Incorporating the information of both functions into one equation, it is possible to
differentiate and quantify all types of dataset topology:
S(t) = F(t)−G(t); (2.6)
Figure 2.3C shows typical graphs of S(t) for the major topology types. By summing
up the values of S(t) over a range of distances ti, i.e. by numerical integration, the clus-
tering behavior of the set can be estimated by a single scalar:
ΣS =∑
i
S(ti); (2.7)
where ti represents a series of distances. The scalar value of ΣS provides a quick
and easily interpretable estimate of a set’s clumping or dispersion, with values of ΣS < 0
indicating clumping and values of ΣS > 0 indicating dispersion. Most real-life chemical
sets can not be strictly assigned to one of the basic categories of topology, but differ in
the number of clusters, their respective density and scaling. This is perfectly reflected
by the scalar ΣS, which provides a quantitative measure for the degree of clumping in a
sample. (Figure 2.3D)
Under certain conditions, it can be useful to calculate scalars analogous to ΣS from
G(t) and F(t). Summing up the values of both functions over a range of distances ti yields
two scalars
ΣG =∑
i
G(ti); (2.8)
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Figure 2.3: Exemplary graphs of Refined Nearest Neighbor Analysis functions. (A) The
graphs of G(t) for both concentrated (red) and patchy (blue) sets feature a steep ascent at
small values of t, caused by clusters of high density. Dispersed sets (green) can easily be
differentiated. (B) Patchy sets (blue) can be distinguished from concentrated ones (red)
by the earlier rise in F(t). For large separation between the clusters, the graph for patchy
sets would converge to the graph for dispersed ones (green). (C) Using S(t) the topology
of sets can be characterized unambiguously. Whereas dispersed sets (green) are marked
by positive values for S(t), different types of clustering exhibit characteristic curves in the
negative region. (D) ΣS, the area under the curve of S(t), provides an easily interpretable
estimate of the degree of clumping or dispersion of a set.
ΣF =∑
i
F(ti); (2.9)
that are robust estimates for the self-similarity (ΣG) in the sample of events, i.e. analogue
bias, and the separation between points and events (ΣF), i.e. artificial enrichment. Large
values of ΣG indicate a high level of self-similarity among events, whereas small values
of ΣF indicate a high degree of separation between points and decoys.
2.2.8.3 Refined Nearest Neighbor Analysis: Implementation
The implementation of both G(t) and F(t) requires a prior definition of the range of
distances ti at which they are calculated. This range of values ti depends on the particular
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application of Refined Nearest Neighbor Analysis and must be determined empirically.
For the analyses based on the Hert-Willett datasets presented in this section, preliminary
experiments identified ti = [0.01,0.02...12] as the best choice.
Later experiments (see Section 3.2.9.1) showed that the upper boundary of ti should be
set to a value tmax = c∗dmnn and that ti should be incremented in fractions of dmnn. Here,
dmnn is the median of the distance to the nearest neighbor for all molecules in the re-
spective descriptor space (the complete MDDR encoded by MOE and simple descriptors
respectively). c is a constant depending on the datasets under examination. The median
nearest neighbor distance in the complete MDDR is dmnn ≈ 5 for both, MOE descriptors
and non-scaled simple descriptors, rendering the choice of
ti = [0.01,0.02...12] = [0,
1
1200
, ...,1]∗2.4∗dmnn
consistent with these later findings.
With ti defined, implementing G(t) was straightforward. For any given dataset or
dataset sub-sample, the distance of each event (active compound) to its nearest neighbor
event was determined and G(t) was calculated according to Equation 2.4 using Algorithm
2.1. (For the source code see Appendix D.2.1)
Refined Nearest Neighbor Analysis was originally developed for the analysis of spatial
patterns in ecology and forestry.93,94 In these disciplines, the examined spatial phenom-
ena can usually be represented by points on 2-dimensional, finite maps, so-called “study
plots”. On such plots, the dataset of random points can be generated by Monte Carlo
samplings from a uniform 2-dimensional distribution of coordinates.
In the context of chemical space however, the implementation of F(t) (Algorithm 2.2)
faces the problem, that the descriptor spaces used in virtual screening - and in this study
- are of rather high dimensionality and non-finite. High dimensional spaces are subject
to the “empty space phenomenon”, i.e. they are inherently sparsely populated.89 As a
consequence, if F(t) was calculated based on random points uniformly distributed in such
a high dimensional space, its value would be dominated by the empty space inherent to
the dimensionality, not by the gaps in the data. Thus, any sampling of points must ensure
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Algorithm 2.1 Calculation of G(t) For a Dataset D. Also Applicable for Finite Study
Plots (Maps).
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that these points lie in the portion of chemical space actually populated by compounds,
but nevertheless provide representative coverage.
This was achieved using three approaches for the generation of sets of random points
(see Algorithm 2.2, Source code: Appendix D.2.2): (i) Bootstrapping from the complete
MDDR: 10000 compounds were randomly chosen from the union of the background and
all benchmark datasets. (ii) Boostrapping from the set of decoys: 10000 compounds were
chosen by random from the set of inactives. (iii) Convex pseudo-data: Following the
approach described by Breiman et al.95 10000 pseudo-data points were generated from
20000 compounds chosen randomly from the MDDR. Briefly, from two datapoints x1,
x2 a new pseudo-datapoint x3 is generated by selecting a random number v from the
interval [0,1]. Then x3 is given by the linear combination:
x3 = v∗x1+(1− v)∗x2 (2.10)
Thereby, artificial pseudo-datapoints are created that occupy the same region of chem-
ical space as the original population of datapoints.
For each sub-sample under scrutiny, this was repeated 20 times and F(t) was calcu-
lated using Equation 2.5 with ti = [0.01,0.02...12] for all samples of random points. The
final value of F(t) was determined as the arithmetic mean for all 20 sets of random points
for each sampling method. Results for F(t) were equal within the margin of statistical
error for all methods of random point sampling. Therefore, all results will be reported
for F(t) with bootstrapping from the complete MDDR. An additional advantage of this
procedure is, that there is no need for terms of edge correction in F(t) and G(t), which
are necessary in traditional spatial statistics applications on finite maps. S(t), ΣS, ΣG and
ΣF resulted from G(t) and F(t) as given by Equations 2.6, 2.7, 2.8 and 2.9.
2.2.9 Visualization of Topology by Self-Organizing Maps (SOMs)
Self-Organizing Maps (SOMs)96 are a special type of artificial neural networks, that
project high-dimensional data onto a two-dimensional lattice while preserving the topol-
ogy of the input data space. It is obvious, that this feature makes SOMs the ideal tool for
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Algorithm 2.2 Calculation of F(t) for a Dataset D and a Background Dataset I.
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the visual perception of dataset topology. Comprehensive reviews of the SOM algorithm
and its variations exist in the literature.97–101 All SOMs used here were generated and an-
alyzed using the SOM-Toolbox 2.0102 in The Mathworks MATLAB 7.90 Map topology
was chosen to be non-toroidal with a rectangular lattice. Since SOMs were only used for
visualization supporting a more detailed analysis of dataset topology by Refined Nearest
Neighbor Analysis, a map grid of 20 x 20 units was considered sufficient. For training,
the batch algorithm as implemented in the SOM-Toolbox was used.
2.2.10 Measures of Correlation
One of the goals of this study is to quantify the influence of dataset topology on the out-
come of VS validation experiments by the degree of correlation between scalar measures
of dataset topology and VS performance. (see Section 2.1) These measures span numeri-
cally different ranges, namely [−∞,∞] for measures of topology and [0,1] for measures of
VS performance. Moreover, none of the examined quantities can be safely assumed to be
normally distributed, nor is there any hard evidence for a linear relationship of VS perfor-
mance and dataset topology. Therefore, the Spearman rank correlation coefficient ρ 103
was used as the measure of correlation throughout this study. In contrast to the widely
used Pearson-product moment correlation coefficient,92 the Spearman rank correlation
coefficient can be utilized to detect a correlation between two variables X and Y even if
their relationship is non-linear.
For the calculation of the Spearman correlation coefficient, two sets of data X , Y are
first converted to ranks x, y by ordering the datapoints:
xi = rank(Xi); (2.11)
yi = rank(Yi); (2.12)
Where Xi, Yi constitute the ithdatapoints in the two datasets and xi, yi constitute the
corresponding ranks. Using these ranks xi, yi, the calculation of the Spearman correlation
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coefficient ρ is equivalent to the calculation of the Pearson correlation coefficient on the
rank tranfsormed data:
ρ =
n
(
∑
i
xiyi
)
−∑
i
xi∑
i
yi√
n
(
∑
i
x2i
)
−
(
∑
i
xi
)2√
n
(
∑
i
y2i
)
−
(
∑
i
yi
)2 (2.13)
with n the number of samples in the sets Xi and Yi, respectively. ρ takes values in
the interval [−1,1], with the sign of ρ indicating the direction of the correlation. Here,
a value of 1 indicates a perfect positive correlation among the two sets of ranks xi and yi
and a value of −1 indicates a perfect negative, or anti-correlation, whereas a value of 0 is
an indicator of no correlation at all.
The value of ρ , at which the null-hypothesis of no correlation can be rejected safely,
i.e. with a confidence level of 95%, can be calculated using random permutation tests. For
all measures of topology employed in this study only one respective direction of correla-
tion with VS performance, i.e. positive or negative correlation, is reasonable. Therefore
all levels of significance for ρ given in this study were calculated based on the one-sided
95% confidence interval of ρ for rejecting the null hypothesis of no correlation. Depend-
ing of the expected algebraic sign of the correlation, the boundary of this interval was cal-
culated as the 95th percentile (right tail) for positive correlations and as the 5th percentile
(left tail) for negative correlations of a distribution of correlation coefficients ρ0 generated
by 100000-fold random permutation of the respective samples.104 Table 2.2 provides an
overview of the signs of the respective correlation coefficients with VS performance and
the respective percentiles utilized as boundaries of the confidence intervals.
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2.3 Results
2.3.1 Characterization of Benchmark Dataset Sub-Samples by Re-
fined Nearest-Neighbor Analysis
Using the sampling procedure described above (see Section 2.2.4), six sub-samples of
different size were generated for every sampling strategy from any of the benchmark
datasets. Doing so, a total of 234 (6 sample sizes × 3 sampling strategies × 13 datasets)
sub-samples were generated featuring all types and nuances of topology, ranging from
dispersed (D-optimal Design) and patchy sub-samples (Onion Design) to concentrated
ones (Minimum Diversity Design). For all samples, topology was characterized using
Refined Nearest Neighbor Analysis. The differences in sub-sample topology were well
reflected by G(t), F(t), S(t) and ΣS. The degree of clumping for each sub-sample as
quantified by ΣS in MOE and simple descriptor space is given by Tables A.1 and A.2
(Appendix). An example for the visualization of sub-sample topologies and the results of
Refined Nearest Neighbor Analysis for four sub-samples from the dataset of Thrombin
inhibitors is provided by Figures 2.4 and 2.5, respectively.
2.3.2 Correlation of VS Performance and Dataset Clumping
As described in Section 2.2.5, retrospective VS validation experiments were carried out
for 100 query / validation set splits of each sub-sample using MOE-PCA and simple
Table 2.2: Algebraic Signs of Correlation Coefficients of Different Measures of Dataset
Topology with VS Performance.
Measure of Topology Sign of Correlation Coefficient Boundary of Confidence Interval
ΣS - 5th percentilea
ΣG + 95th percentilea
ΣF - 5th percentilea
gmedb + 95th percentilea
fmedb - 5th percentilea
AvDb - 95th percentilea
a)of a distribution of 100.000 correlation coefficients ρ0generated by random permutations of the examined data.
b)(see Section 2.3.4)
43
CHAPTER 2. IMPACT OF DATASET TOPOLOGY ON VS VALIDATION
Figure 2.4: Visualization of the topology of sub-samples from the dataset of Throm-
bin inhibitors using Self-organizing maps (SOMs). Sub-samples are generated from the
original dataset (black). The topology of the sub-samples varies according to sampling
strategy and sample size (k). D-optimal Design with small k (blue) generates a set with
the maximum degree of dispersion. Onion Design with large k (red) results in moderately
patchy datasets with comprehensive coverage of the original dataset. Minimum diversity
design with large (green) or small (magenta) k generates strongly patchy or concentrated
datasets, respectively.
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Figure 2.5: Topology analysis of four sub-samples from the dataset of Thrombin in-
hibitors. (A) Datasets from the Minimum diversity design (green, magenta) show the early
and steep ascent in G(t) characteristic for datasets with dense clumping. (B) The larger
portion of chemical space occupied by the Onion design sub-sample (red) is indicated by
the earlier and steep ascent in F(t) as opposed to the concentrated sub-sample (magenta)
from the Minimum Distance design. It is difficult to differentiate patchy (green) from dis-
persed (blue) datasets by F(t) alone. (C) S(t) facilitates an unambiguous characterization
of sub-sample topology. The sub-samples are identified as dispersed (blue), moderately
patchy (red), patchy with small separation (green) and concentrated (magenta). (D) ΣS
reflects the dispersion of the D-optimal sample and the varying degree of clumping in the
other samples.
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Table 2.3: Correlation Coefficients of VS Performance Figures of Merit
MOE Simple
ρ (mean(RT R1%),mean(AUCROC))a 0.92 0.85
Conf. Itv. Boundaryb 0.11
a) n = 234
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
descriptors. The resulting figures of merit as well as their variances and standard de-
viations (mean(RT R1%), mean(AUCROC), σ2, σ2top, σ2bt,i, stdtop(FoM)) are given in Ta-
ble A.3 (Appendix). Although mean(RT R1%) and mean(AUCROC) are numerically dif-
ferent representations of VS performance, they agreed well in the relative rating of VS
rankings for our experiments. In all the VS runs conducted here, there was no case where
performance was rated high by mean(RT R1%) and intermediate or low by mean(AUCROC)
and vice versa. The correlation coefficients of both figures of merit for MOE and simple
descriptors are given by Table 2.3. All figures of statistical error were generally higher for
RTR than for ROC. On the other hand, the discriminatory power of the RTR was found
to be higher, particularly for the upper and lower ends of the VS performance spectrum.
This kind of behavior is known and expected for these figures of merit and highlights
again the advantages of their complementary use.
Analyzing the data shown in Tables A.1 and A.3, a strong correlation was detected be-
tween ΣS and VS performance. In general, a higher degree of clumping (indicated by large
negative values of ΣS) accounts for better VS performance as measured by mean(RT R1%)
and mean(AUCROC), for both MOE and simple descriptors. A summary of the observed
correlation coefficients is given in Table 2.4 and an example for the relation of VS per-
formance and sub-sample clumping is shown in Figure 2.6. Since negative values of ΣS
indicate a higher degree of clumping, VS performance and ΣS are negatively correlated.
Therefore, values of ρ close to −1 indicate a high degree of correlation between dataset
clumping and VS performance.
ΣS only coarsely characterizes the degree of clumping in a dataset of compounds. The
complex inter-relation of features like the number of clusters, their respective size, density
and separation can not be reflected in detail by the simple scalar ΣS. In some pathological
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Table 2.4: Correlation coefficients of VS performance figures of merit with ΣS.
ρ (ΣS,mean(RT R1%))a ρ (ΣS,mean(AUCROC))a
MOE -0.93 -0.91
Simple -0.89 -0.96
Conf. Itv. Boundaryb -0.11
a) n = 234
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
Figure 2.6: A strong correlation exists between mean(RT R1%) and ΣS, shown here for
MOE descriptors. (A) Sub-samples generated by D-optimal Design from the dataset of
PKC inhibitors show a small degree of clumping indicated by positive or small negative
values of ΣS and low mean(RT R1%). (B) The high degree of clumping observed in Min-
imum Distance Design sub-samples of 5HT reuptake inhibitors is associated with high
mean(RT R1%).
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cases, the specific topology of two sub-samples can lead to very similar values of ΣS but
to different outcomes of VS validation. This is illustrated by the extreme example of two
sub-samples extracted from the dataset of Renin inhibitors (Onion D., k = 50) and 5HT
reuptake inhibitors (Onion D.,k = 300). (Figure 2.7) Both samples have a similar ΣS of
-454.4 and -453.8, but the mean(RT R1%) is 0.58 on the Renin inhibitors sub-sample and
0.18 on the sub-sample of 5HT reuptake inhibitors. When analyzing the graphs of G(t)
(Figure 2.7A), it is obvious that the average distances between actives in the sample of
5HT reuptake inhibitors are smaller, i.e. the density in the sample is higher. However,
the respective graph for F(t) (Figure 2.7B, red) with its prevalence of lower point-event
distances shows quite clearly that this is mainly caused by small, local clusters evenly
spread across chemical space. On the other hand, the sub-sample of Renin inhibitors
is well separated from the rest of chemical space, a fact that dominates the validation
result. (Figure 2.7B, blue) This is also well reflected in the graphs of S(t), in which
the separation of the Renin inhibitors from the background is indicated by a rightward
shift. (Figure 2.7C) A SOM representation of both sub-samples (Figure 2.7D) provides
an intuitive visualization of the respective conditions in the sub-samples. Summarizing,
ΣS usually provides a robust and easily interpretable measure for dataset clumping and
its effect on VS performance. However, to assess the topology in more detail, the graphs
of G(t), F(t) and S(t) have to be inspected. Here, visualization of dataset topology by
Self-Organizing Maps can be of great benefit as it facilitates the intuitive perception of
the information provided by the spatial statistics functions.
2.3.3 Topology Induced Component of Variance
The component of variance introduced by topology σ2top was found to be about 15 times
larger (average over all sub-samples) in magnitude than the component associated with
the experimental setup mean(σ2bt,i) for both, RT R1% and AUCROC. Thus, sub-sample
topology has a considerable impact on the statistical error of VS validations. However, it
was not possible to deduce any relationship or correlation with the measures for dataset
topology introduced here.
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Figure 2.7: In some pathological cases estimation of clumping by ΣS may lead to am-
biguous results. (A) The graph of G(t) for the sub-sample of 5HT reuptake inhibitors
(Onion D., k = 300; red) exhibits regions of higher density than the sample of Renin in-
hibitors (Min. Dist. D., k = 50, blue). (B) The smaller amount of empty space for the
5HT reuptake inhibitors sub-sample is evident from its graph for F(t) (red). The larger
amount of empty space present for the sample of Renin inhibitors (blue) indicates better
separation of the sample from the background, causing better VS performance. (C) In this
particular case, the graphs for S(t) of both sub-samples are similar in shape and shifted
on the x-Axis. Summing over S(t) does not capture the rightward shift of the blue curve
(Renin inhibitors) that indicates separation from the background. (D) The phenomena
discussed in (A-C) are easily visualized on a SOM projection of the sub-samples. (Renin
inhibitors: blue; 5HT reuptake inhibitors: red).
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2.3.4 Comparison of Refined Nearest Neighbor Analysis with Other
Approaches for Dataset Analysis
A commonly used measure to quantify dataset self-similarity in descriptor spaces is the
average of intra-set pairwise distances (denoted as avD). In order to investigate if the char-
acterization of dataset topology by Refined Nearest Neighbor Analysis really provides
additional information over avD, the latter was computed for all sub-samples in MOE
descriptor space. Since S(t) and thus also ΣS combine a statistic of the self-similarity
among actives in a dataset (G(t), ΣG) and a statistic of the separation between decoys and
actives in chemical space (F(t), ΣF), the question arises whether any one of them can ex-
plain the differences in VS performance alone. It is also possible that other scalar values
calculated from the cumulative distances functions G(t) and F(t), such as the respective
medians, provide a more accurate characterization of dataset topology. Therefore the me-
dian nearest neighbor distance gmed was obtained as the value for t, where G(t) = 0.5.
In an analogous fashion, the median distance fmed of a point to the nearest event was
determined as the value of t where F(t) = 0.5, for each of the 234 sub-samples encoded
by MOE descriptors. The values obtained for ΣG, ΣF , avD, gmed and fmed were corre-
lated with VS performance on all sub-samples in the same way as ΣS. Additionally, the
correlation coefficients were also determined separately for the different sub-sample de-
sign strategies (D-optimal D., Onion D., Min. Div. D.), in order to determine if any of the
methods can capture dataset topology of a certain type (dispersed, patchy or concentrated)
especially well.
Besides the already noted high correlation of mean(RT R1%) and ΣS, the results shown
in Table 2.5 indicate moderate to high levels of correlation with mean(RT R1%) over all
sub-samples of ΣG, avD and gmed , which are all based exclusively on active-active dis-
tances. The respective numbers for the different design strategies show however, that
these levels of correlation for avD and gmed are mainly caused by sub-samples with con-
centrated topologies (Min. Div. D.). This result can be explained by the fact that for
concentrated sub-samples, empty space will always be quite large with only marginal
variations. Consequently, the main factor for their discrimination is the distribution of
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Table 2.5: Correlation of several measures of dataset topology with mean(RT R1%).
ρ (mean(RT R1%), ...) ΣS ΣG ΣF avD gmed fmed
All sub-samplesa -0.93 0.83 -0.61 -0.77 -0.53 0.44
Conf. Itv. Boundaryb -0.11 0.11 -0.11 -0.11 -0.11 0.11
D-optimal D.b -0.92 0.81 0.23 -0.19 -0.07 0.31
Onion D.b -0.74 0.27 -0.49 -0.04 -0.21 0.39
Min. Div. D.b -0.95 0.76 -0.92 -0.79 -0.82 0.27
Conf. Itv. Boundaryc -0.19 0.19 -0.19 -0.19 -0.19 0.19
a) n = 234
b) n = 78
c) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
even-event distances, which is well captured by statistics like avD and gmed . However,
this also shows, that avD and gmed can explain differences in VS performance only for
concentrated datasets. Interestingly, ΣG retains a high level of correlation even for dis-
persed (D-optimal) sub-samples. Apparently, the characterization of the distribution of
active-active distances by its numerical integral provides considerable additional infor-
mation. A possible reason might be, that gmed only captures the shift but not the slope
of the ascent of G(t), which can indicate the presence of small local clusters. (See Sec-
tion 2.2.8.2)
On the other hand, ΣF captures considerable information for concentrated (Min. Div. D.)
and patchy (Onion D.) sub-samples. If a sub-sample is located in a region of chemical
space, which is sparsely populated by decoys (i.e. more empty space, small ΣF) VS
performance will increase. However, ΣF seems unable to capture this relation on D-
optimal sub-samples, whereas fmed shows low, but constant levels of correlation for all
sub-samples.
Summarizing, all of these measures are able to reflect the impact of dataset topol-
ogy on VS performance under certain conditions, but only ΣS provides a comprehensive
coverage across all types of dataset topology, as indicated by the consistently higher cor-
relation coefficients for ΣS in Table 2.5. Put another way, neither statistics about intra-set
distances, i.e. dataset self-similarity, nor information about empty space, i.e. separa-
tion between decoys and actives, can explain differences in VS performance alone. The
augmentation of the nearest-neighbor function G(t) by the empty space function F(t)
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provides a substantial amount of additional information.
2.3.5 Mapping Performance
It was shown above, that the success rate of virtual screening is higher on datasets that
have a clumpy topology in descriptor space. In a way, this is not surprising, since this is
exactly what chemical descriptors were invented for. Good descriptors map compounds
with similar bioactivities to similar points in descriptor space, thereby introducing clump-
ing. However, some descriptors are better at this task and some are worse. Put differ-
ently: If the same dataset (or in our case a sub-sample of a dataset) is encoded by two
different descriptors, VS performance should be better using the descriptor representation
that introduces the more favorable topology, i.e. more clumping. (Figure 2.8) Thus, the
“mapping performance” of one descriptor vs. another can be quantified by the additional
degree of clumping introduced by the former descriptor. Applied to the two descriptors
used in this chapter, the mapping performance of MOE descriptors vs. simple descriptors
is given by the difference in ΣS on a given dataset or sub-sample:
∆(ΣS) = ΣSMOE −ΣSsimple; (2.14)
with ∆(ΣS) the difference in clumping, i.e. the mapping performance. Since a higher
degree of clumping is associated with negative values of ΣS, negative values of ∆(ΣS)
indicate more clumping for the representation by MOE descriptors, i.e. a higher mapping
performance of MOE vs. simple descriptors.
For the two descriptors (MOE and simple) used here, the difference in VS perfor-
mance was calculated for each sample as:
∆(FoM) = mean(FoMMOE)−mean(FoMsimple); FoM = RT R1% or AUCROC (2.15)
for both RTR and ROC, respectively. Accordingly, ∆(FoM) is positive, whenever
MOE performs better and negative if the simple descriptors generate superior figures of
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Figure 2.8: A descriptor that maps a dataset to a more clumpy topology than another
descriptor will generate better results in VS validation experiments. The mapping perfor-
mance of a descriptor vs. another descriptor is given by the difference of the respective
values of ΣS on a given dataset ∆(ΣS).
Table 2.6: Correlation of the difference in VS performance with the mapping perfor-
mance of MOE vs. simple descriptors.
∆(RT R1%) ∆(AUCROC)
ρ(∆(ΣS), ...a -0.93 -0.88
Conf. Itv. Boundaryb -0.11
a) n = 234
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
merit.
For all sub-samples examined in this chapter, a strong correlation was found between
∆(ΣS) and ∆(FoM). The respective spearman correlation coefficients are given in Ta-
ble 2.6.
An example for sub-samples taken from the ACE inhibitors dataset is given in Fig-
ure 2.9. Better VS performance for a certain type of descriptors is closely associated by a
better mapping performance on the respective sub-sample. It should be recalled, that the
D-optimal Design sub-samples with k = 50 constitute an artificial absolute "worst-case"
scenario for performing VS with MOE descriptors. Thus, since it cannot get any worse,
it is not surprising that the representation of the same compounds in simple descriptor
space is more clumpy. Therefore both, the better mapping performance and the better
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VS performance of simple descriptors on these sub-samples are mainly an effect of the
sampling strategy.
2.3.6 Application to Whole Datasets
Using sub-samples generated by different design strategies, it was possible to observe the
impact of dataset topology on the results of VS validation. Furthermore, it was shown, that
this impact can be quantified using spatial statistics methods. However, when performing
a real-life validation of a ligand-based VS technique, one wouldn’t be interested in the
VS performance on artificial sub-samples, but on the complete benchmark datasets.
Table 2.7 and Figure 2.10 summarize the results of retrospective VS simulations fol-
lowing the procedure stated above (100 query / validation set splits, 10 query compounds,
MAX-rule data fusion) and Refined Nearest Neighbor Analysis on the complete bench-
mark datasets. Again, a strong correlation between dataset clumping and VS performance
as measured by ΣS, mean(RT R1%) and mean(AUCROC), respectively, can be observed
(Table 2.7). The somewhat smaller values for the correlation coefficients are mainly due
to the much smaller number of samples (13 complete datasets vs. 234 sub-samples) avail-
able for their calculation, so that deviations from the generally observed relationship have
a higher impact. Once more, it must be stated that ΣS is a robust but rough estimate of
dataset clumping, which can not explain all effects of dataset topology on VS performance
perfectly. Discrepancies from the overall correlation of ΣS and VS performance such as
those observed in Figure 2.10, can usually be explained by a more detailed inspection of
G(t), F(t) and S(t).
Also, the correlation of mapping performance and VS performance persists for the
complete datasets. (Figure 2.11, Table 2.9). Apart from minor discrepancies, ∆(ΣS) is
able to explain most of the differences in VS performance. Large gains in clumping are
always associated with much better performance of the respective descriptor and small
differences in topology coincide with small or no changes in VS performance. For an-
swering the question if a particular descriptor really improves VS performance in a real-
life VS campaign these more general trends are of higher importance.
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Figure 2.9: Mapping performance of MOE descriptors vs. simple descriptors for sub-
samples of the ACE inhibitors dataset generated by D-optimal Design (A) and Minimum
Diversity Design (B), respectively. (A) ∆(ΣS) is positive for k = 50, meaning that the
representation of the sub-sample by simple descriptors features a higher degree of clump-
ing. Accordingly, ∆(RT R1%) is negative for that sub-sample, indicating the better perfor-
mance of simple descriptors. For k > 50, ∆(ΣS) shows negative values and is associated
with positive values for ∆(RT R1%), which indicates that MOE outperforms simple with
respect to mean(RT R1%) and clumping. This is due to the fact, that the D-Optimum De-
sign sub-samples get clumpier with increasing k, since more datapoints from the bulk of
the dataset have to be selected. (B) The Minimum Diversity Design constitutes the "best-
case" scenario for MOE descriptors. Accordingly both, ∆(RT R1%) and ∆(ΣS) indicate
higher performance of MOE-PCA descriptors in these sub-samples. Here, the effect of
increasing k is inverse to the D-Optimum Design. Starting with the very set of minimally
diverse compounds at k = 50, more and more compounds from the outer regions of the
dataset have to be selected for larger k, rendering the sub-sample more diverse.
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Figure 2.10: VS performance and dataset clumping as observed on the complete bench-
mark datasets. As shown for the sub-samples of controlled topology, a strong correlation
exists between dataset clumping and VS performance. Arrows indicate datasets discussed
in more detail in the text.
Figure 2.11: Differences in VS performance and gain in clumping of MOE vs. simple
descriptors on the complete benchmark datasets. A strong overall correlation of ∆(ΣS)
and differences in VS performance can be observed.
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Table 2.8: Correlation of VS Figures of Merit with Dataset Clumping (ΣS) for the Com-
plete Benchmark Datasets.
ρ (ΣS,mean(RT R1%))a ρ (ΣS,mean(AUCROC))a
MOE -0.72 -0.77
simple -0.77 -0.97
Conf. Itv. Boundaryb -0.48
a) n = 13
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
Table 2.9: Correlation of the difference in VS performance with the mapping perfor-
mance of MOE vs. simple descriptors on whole datasets.
∆(RT R1%) ∆(AUCROC)
ρ(∆(ΣS), ...a -0.80 -0.94
Conf. Itv. Boundaryb -0.48
a) n = 13
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
2.3.7 Benchmark Dataset Bias
From the chart of ΣS for the benchmark datasets encoded by the simple descriptors (Fig-
ure 2.10), the high degree of clumping observed for the datasets of Renin inhibitors and
5HT3 antagonists is striking. The values of ΣS for these datasets show, that they can eas-
ily be distinguished from the background even by these absolutely simple descriptors that
do not encode molecular connectivity. Accordingly, it should not be difficult to achieve
good results when performing VS validation on these datasets. So, these datasets intro-
duce a bias towards good validation results, which is also reflected by the fact that the
highly complex MOE descriptors can not generate any significant gain in clumping over
simple descriptors on these datasets. Actually both, clumping and VS performance are
lower for the Renin inhibitors dataset with MOE than with simple descriptors. Thus, the
mean(RT R1%)’s of ∼ 0.3 and ∼ 0.5 achieved with MOE on these datasets, which would
normally be considered quite acceptable, are of no real value for the evaluation of the VS
capabilities of MOE descriptors. We term this tendency towards overoptimistic validation
results “benchmark dataset bias”. The results presented here show, that for ligand-based
virtual screening “benchmark dataset bias” does not only depend on the distances between
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Figure 2.12: Benchmark dataset bias is caused by both, high levels of intra-set self-
similarity in the datasets of actives and separation of actives from the background. Renin
inhibitors (blue) and 5HT3 antagonists (green) both show benchmark dataset bias caused
by a high degree of clumping in simple descriptor space. A comparison of the respective
graphs for G(t) and F(t) shows, that for the 5HT3 antagonists this is mainly caused by
small active-active (i.e. event-event) distances. On the Renin dataset, it is mainly due to
a high degree of separation from the rest of chemical space. In comparison, the dataset
of ACE inhibitors (red), which is not subject to benchmark dataset bias, exhibits neither
self-similarity nor separation from the background.
actives themselves (i.e. G(t)), but also on the separation between actives and inactives
(i.e. F(t)), a fact that should be taken into account in the design of validation experiments
comparing ligand based virtual screening methods (Figure 2.12). As a first consequence,
datasets that show a high degree of clumping in a simple reference descriptor space should
be avoided in VS validation experiments. If, for some reason they cannot be evaded, the
value of ΣS determined in a simple reference descriptor space can effectively be used to
estimate an expectation for VS performance. Moreover, using the information provided
by F(t) and G(t), it is possible to determine if the clumping in simple descriptor space is
mainly caused by a high degree of separation of the dataset from the background, e.g. the
dataset of Renin inhibitors (Figure 2.12). In this case, the problem can be solved simply
by choosing a more appropriate decoy dataset.
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2.4 Summary
The work presented in this Chapter introduces spatial statistics methods to the field of
chemoinformatics. Thus far, Refined Nearest Neighbor Analysis has been mostly applied
to problems from the sciences of ecology or forestry, in which spatial data can usually
be represented by two-dimensional, finite maps.93,94 The boostrapping procedure devel-
oped in Section 2.2.8.3 allows the application of Refined Nearest Neighbor methods to
high-dimensional, non-finite chemical spaces. Utilizing this adapted form of Refined
Nearest Neighbor Analysis, a framework was developed that provides tools for the topo-
logical analysis of chemical datasets in all degrees of detail, ranging from a quick estimate
of clumping to an in-depth analysis of clustering behavior. The cumulative distribution
functions describing the spatial relations between actives and decoys in a VS benchmark
dataset were employed to derive quantitative, scalar measures for both analogue bias (ΣG)
and artificial enrichment (ΣF). Furthermore, a combined measure of dataset clumping
(ΣS) comprising both, analogue bias and artificial enrichment, was introduced.
By correlation studies based on the results of topological analysis and retrospective
VS simulations carried out on dataset sub-samples with defined topology it was shown,
that the topology of benchmark datasets in descriptor space has a considerable impact on
the results of VS validation. These results point out that in contrast to molecular docking,
both, the mutual distances of the active compounds (i.e analogue bias) and their separa-
tion from the decoys (i.e. artificial enrichment) in descriptor space are of importance for
the validation of ligand-based virtual screening techniques. Furthermore, the methodol-
ogy proposed in this Chapter provides insights about the reasons for differences in the
VS performance of different descriptors. It was shown, that better VS performance of a
descriptor can be linked to a superior mapping performance.
The methodology for the characterization of dataset topology presented here does not
imply any prior assumptions or preconditions about the composition of the datasets. On
the contrary, it is actually suited to provide exactly this information, i.e. if the dataset is
composed of a single or multiple clusters and if these are close or separated in chemical
space.
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An obvious field of potential future use for this piece of information would be the
rational design of validation experiments comparing different algorithms for similarity
searching. On a patchy or dispersed dataset, for instance, any algorithm based on multi-
ple query molecules should be superior to an algorithm with only one query as an input.
This advantage would be annihilated on a concentrated dataset. In this context, an unbi-
ased selection of benchmark datasets could be greatly facilitated by the topology analysis
proposed here.
The methodology uses two basic functions for the elucidation of benchmark dataset
topology: The nearest-neighbor function G(t) reflects the distribution of intra-set “active-
to-active” distances, whereas the empty-space function F(t) represents the distribution of
“decoy-to-active” distances. As shown in Section 2.3.7, bias introduced to VS validation
experiments by the composition of benchmark datasets can be detected and quantified
by these functions. This opens up another field of application for the methodology: the
design of validation datasets that minimize dataset induced bias. The results presented in
this Chapter show that clumpy topologies in simple descriptor space are the cause for the
occurrence of analogue bias and artificial enrichment. Consequently, benchmark dataset
bias can be prevented by designing datasets with non-clumpy topologies regarding simple
descriptors. Chapter 3 will present a workflow that applies this rationale to the design of
unbiased datasets for LBVS benchmarking based on bioactivity datasets extracted from
PubChem.
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Chapter 3
Maximum Unbiased Validation (MUV)
Datasets
3.1 Objectives
The results obtained from the investigations described in Chapter 2 will be utilized to de-
rive criteria for the design of validation datasets without benchmark dataset bias. Based on
these criteria, objective functions will be formulated and and a workflow will be devised
for the rational design of Maximum Unbiased Validation (MUV) datasets. This proce-
dure will be applied to a collection of bioactivity data extracted from PubChem in order
to design publicly available unbiased datasets for benchmarking. The origin of PubChem
bioactivity data from high throughput screening (HTS) experiments and the associated
error rates (see Section 1.1.2) make it necessary to scrutinize the reported bioactivities
with extreme thoroughness. A data centered workflow will be developed that purges the
bioactivity datasets from compounds for which the respective activity may be subject to
any doubts.
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3.2 Methods
3.2.1 Criteria for Refined Nearest Neighbor Analysis Based Bench-
mark Dataset Design
In Chapter 2 it was shown that the validation of LBVS methods is affected by both, ar-
tificial enrichment and analogue bias. Indeed, datasets usually exhibit a combination of
both phenomena. Refined Nearest Neighbor Analysis, a non-parametric methodology
from the framework of spatial statistics, was used to quantify the effect of benchmark
dataset bias by an analysis of the dataset’s topology in chemical space. Refined Nearest
Neighbor Analysis provides the figures ΣS, ΣG and ΣF , which estimate “dataset clump-
ing”, self-similarity in the dataset of actives and separation between decoys and actives,
respectively. In particular, negative values of ΣS indicate dataset clumping, positive val-
ues indicate dispersion and values near zero a spatially random distribution of actives and
decoys. It was demonstrated in Chapter 2 that over-optimistic VS validation results and
benchmark dataset bias can be linked to dataset clumping.
For the design of unbiased benchmark datasets that are not affected by artificial enrich-
ment and analogue bias, ΣG and ΣF can effectively be employed as objective functions.
However, Refined Nearest Neighbor Analysis is based on a representation of datasets by
descriptors. Hence, for the calculation of ΣG and ΣF a descriptor must be utilized that
captures the molecular properties associated with benchmark dataset bias. For this pur-
pose, the “simple” descriptors introduced in Section 2.2.3 are perfectly suited, since they
have been shown in Section 2.3.7 to capture both, analogue bias and artificial enrichment.
As a first condition for unbiased validation experiments, datasets should always exhibit a
dispersed topology in the chemical space spanned by these simple descriptors. More pre-
cisely, active-active distances should be larger than or equal to decoy-active distances in
simple descriptor space, because otherwise similarity searching becomes trivial. Topolo-
gies of this type have been shown to prevent both, analogue bias and artificial enrichment
in Chapter 2.
Apart from these more general conditions for validation dataset design, it is important
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to keep in mind the existence of two basic experimental settings for VS validation as
discussed in Section 1.2.1.
Suitability testing is used to optimize a VS protocol for a specific target or target class.
As a consequence, datasets for suitability testing must cover the respective activity space
comprehensively. Differences between the activity spaces of different targets must be
truly reflected by suitability testing datasets.
The objective of this Chapter will be the design of datasets for benchmarking ex-
periments. In contrast to suitability testing, the goal of benchmarking experiments is to
identify the method with the best VS performance across a range of datasets. In order to
maximize the information of such experiments regarding the potential of different meth-
ods, it is desirable to minimize the influence of dataset topology on validation results.
Hence, the differences in dataset composition must be minimized, i.e. all datasets should
be adjusted to a common level of dispersion in simple molecular property space. Any
arbitrary level of dispersion would suffice for benchmarking experiments of this type, as
long as it is common to all datasets. However, the state of “spatial randomness” (ΣS≈ 0) is
especially advantageous, since it implies that the distribution of simple molecular proper-
ties between actives and decoys contains no information about the respective bioactivities.
The benchmark datasets presented here were therefore designed to be as close to spatial
randomness as possible given the topology of the original datasets.
As stated above, datasets with a spatially random topology in simple descriptor space
are unbiased with respect to analogue bias and artificial enrichment. Therefore, they
constitute a tool for the Maximum Unbiased Validation (MUV) of virtual screening tech-
niques.
3.2.2 MUV Benchmark Dataset Design Strategy
The design strategy for MUV datasets comprised three major steps (Figure 3.1):
(1) A collection of bioassays was extracted from PCBioAssay that justifies high con-
fidence in the respective bioactivities. The compounds found active and inactive, respec-
tively, formed the basis for the subsequent design steps. The resulting datasets of com-
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pounds were termed “potential actives” (PA) and “potential decoys” (PD). Filters were
applied to the PA datasets that further purged all compounds for which the specificity of
the respective bioactivities might be subject to any doubts.
(2) The chemical space around the PA compounds was examined statistically in order
to determine if the PA compounds are well embedded in decoys, a precondition for val-
idation set design. (3) Experimental design algorithms were applied to select subsets of
k = 30 actives and d = 15000 decoys from the PA/PD datasets with a spatially random
distribution of actives and decoys regarding simple molecular properties. With constant
dataset sizes of k = 30 and d = 15000, MUV datasets also minimize the variance of vali-
dation results as demonstrated by Truchon et al.60 The numerical values of k and d were
chosen arbitrarily based on the size of the available bioactivity datasets. In principle, k
and d could also be set to other values.
3.2.3 PubChem as a Source of VS Validation Datasets
As stated above (Section 1.1.2.2), PubChem15 is the central repository of small molecule
data of the Molecular Libraries Initiative12 of the NIH Roadmap for Medical Research13,14
and is composed of three major databases. Two will be used here: PCCompound, which
provides chemical structures of the tested compounds, and PCBioAssay, which lists the
respective bioactivity data. Each record in PubChem is assigned a unique ID (UID) by
which it can be easily accessed and retrieved. For PCCompound and PCBioAssay, these
IDs are termed compound ID (CID) and assay ID (AID), respectively. Compared to other
databases of bioactivity data, PubChem features several major advantages with respect to
the design of VS benchmark datasets:
(i) All data in PubChem, including structures of compounds, bioassay conditions and
experimental readouts are publicly accessible. (ii) Due to the specifications of the NIH
Roadmap initiative, the compound collections tested in each bioassay exhibit a remark-
able level of diversity. (iii) The vast majority of tested compounds are “drug-like”. (iv)
For each assay, compounds that were found to be inactive are listed in addition to those
found to be active. These inactive compounds can be used as decoys in validation ex-
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Figure 3.1: Synopsis of the MUV design workflow. Compounds with a potential for un-
specific bioactivity are removed by the Assay artifacts filter. Actives devoid of decoys are
removed by the Chemical space embedding filter. The spread of actives (ΣG) is adjusted
to a common level g. Correspondingly, the separation between actives and decoys (ΣF) is
adjusted to a common level f that is similar to g, thereby enforcing approximate spatial
randomness.
66
3.2. METHODS
periments, as done recently by Hsieh et al. for a single dataset in the validation of a
QSAR modeling approach.46 This provides the unique opportunity to design decoy sets,
for which the inactivity against the target is actually experimentally validated. (v) Pub-
Chem is fully integrated into the NCBI Entrez database system.16 Using the Entrez Pro-
gramming Utilities (E-Utilities)16 and the PubChem Power User Gateway (PUG)105 auto-
mated chemogenomics analyses are feasible, linking compounds with their bio-activities
and the protein or DNA information of their targets.106 On the downside however, most
of the bioactivity data available from PubChem is based on High-Throughput Screening
(HTS) experiments. HTS data is notoriously affected by experimental noise and arti-
facts.11,17,44,107 Thus, for the design of benchmark datasets it is essential to scrutinize
PubChem bioactivity data with extreme thoroughness.
3.2.4 Selection of Bioactivity Datasets
All assays with a specified protein target were extracted from PCBioAssay. From these,
pairs of primary and confirmatory bioassays against the same target were selected. In
these pairs, the bioactivity against the target is first determined for a large set (>50000) of
compounds in a primary HTS experiment. The hits from the primary screen are then sub-
jected to a low-throughput confirmatory screen testing for dose-response relationships.
(see Section 1.1.2) To be selected for the MUV design process, the confirmatory screens
were further required to contain associated EC50 values. The actives from the confirma-
tory screens, referred to as Potential Actives (PA) in the text, and the inactives from the
primary screens, referred to as Potential Decoys (PD), formed the basis for the generation
of MUV datasets as presented here. The resulting datasets are summarized in Table 3.1.
SD-files of the datasets were downloaded from PubChem by a Perl script that utilizes the
PubChem Power User Gateway.105
3.2.5 Assay Artifacts Filter
The requirement, that the bioactivity of all potential actives is determined by low-throughput
dose-response experiments, justifies some confidence in the reliability of these assign-
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ments. Nevertheless, screening experiments are prone to artifacts caused by the tendency
of some organic chemicals to form aggregates in aqueous buffers,11 to exert off-target
or cytotoxic effects108 or to interfere with the assay’s optical detection method.109,110 In
order to remove all compounds for which the specific mode of action could be subject
to doubts from the PA datasets, a range of filters was applied, namely the “Hill slope
filter”, “Frequency of hits filter” and the “Autofluorescence and Luciferase inhibition fil-
ter”. Together these filters form the “Assay artifacts filter”. The particular filters were
implemented as follows.
3.2.5.1 Hill Slope Filter
Aggregate formation is often associated with unusual Hill slope values (also referred
to as slope factors) in dose-response curves.9,11,107,111 For competitive inhibition at a
single-inhibitor binding site, the Hill slope h is expected to be approximately 1, based on
Michaelis-Menten kinetics.112 Although kinetic theory does not allow a ready application
of this expectation to cell based assays or assays screening for allosteric modulation, very
large Hill slopes nevertheless raise doubts about the specificity of the observed response.
Generally, Hill slopes exceeding 2 are interpreted as harbingers of unspecific activity.9,111
Hill slopes for the dose response curves of all PA compounds were determined. If the Hill
slopes were deposited in PCBioAssay, these values were used (Table 3.1). For all other
PA compounds, Hill slopes were calculated directly from PubChem dose-response data
using GraphPad Prism 4.113 For a PA compound to pass the Hill slope filter, its Hill slope
h was required to be in the interval h = [0.5,2]. The filter was supplemented by a list
of experimentally verified aggregators recently deposited in PCBioAssay (AIDs: 584,
585).111 Compounds identified as aggregators in this screen were removed from all PA
datasets. Algorithm 3.1 summarizes the functionality of the Hill Slope Filter.
3.2.5.2 Frequency of Hits (FoH) Filter
In addition to the special case of aggregate formation, bioassays are prone to a range
of artifacts caused by unspecific activity of chemical compounds. For cell-based reporter
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Algorithm 3.1 Flow-chart of the Hill slope filter. Compounds with undesirable Hill slopes
h and compounds that have been experimentally shown to be aggregators are filtered from
the PA datasets.
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gene assays, for instance, this is mainly caused by off-target or cytotoxic effects.108 These
artifacts have been associated with distinct molecular features and cellular actions of com-
pounds showing unspecific activity, which have been termed “frequent hitters”.44 Several
studies have tried to identify frequent hitters by first predicting their alleged mode of ac-
tion as off-target promiscuous binders, aggregators or cytotoxins. Frequent hitters are then
flagged based on this prediction.108,114,115 With a large resource of bioassay data such as
PubChem, it is possible to flag a compound as an unspecific binder based on the ratio of
the number of assays in which it occurs as a hit and the number of assays in which it was
tested. This ratio is termed Frequency of hits (FoH). It is expected to be small for specific
binders (tested in many assays, but a hit in few assays) and large for unspecific binders
(tested in many assays and a hit in most assays). The frequency distribution of FoH for
a large set of compounds typically features two peaks: one at small values reflecting the
population of specific binders and another one at large values of FoH indicating unspecific
binders. (Figure 3.2A) In order to distinguish the two populations, the first local minimum
of the distribution can be utilized as a conservative, empirical cutoff. At this point, the
descent of the FoH distribution after the first peak (specific binders) fades into the ascent
to the second peak (unspecific binders). Using piecewise bandwidth optimization, a local
polynomial P was fitted to the distribution of FoH determined for all PubChem com-
pounds active in at least five bioassays (Figure 3.2B). The first minimum was determined
as the second zero-crossing of the first derivative of P at FoH = 0.26. (Note, that the
first zero-crossing of the derivative occurs at the peak of specific binders.) Consequently,
compounds with a FoH larger than 0.26 were considered potentially unspecific binders
and thus removed from the PA datasets.
In this analysis, it is important to take into account, that some assays test for activity
against very closely related targets. Whereas for example a compound that was found
active in screens against four closely related cholinergic receptors might very well be a
real binder to all of them, a compound found active against a kinase, a protease and in
two cytotoxicity screens, is highly likely to be unspecific. Thus, it is desirable to correct
the FoH for the presence of closely related assays in PCBioAssay. As a first measure,
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Figure 3.2: (A) Histogram of FoH for all compounds active in at least five PCBioAssay
HTS screens. The histogram reflects two distinct populations of compounds: The left-
hand part of the distribution (small FoH) is dominated by specific binders. The right-
hand part (large FoH) reflects unspecific binders hitting in multiple assays. (B) The first
derivative of a polynomial P fitted to the histogram has its second zero crossing at FoH =
0.26, corresponding to the first minimum of the FoH distribution. This was determined
as the cutoff beyond which a compound was considered an unspecific binder.
only large scale (>10000 compounds) HTS assays were considered in the FoH analysis,
in order to exclude confirmation assays against identical targets from the statistic. The
remaining assays were weighted according to the sequence identity of their respective
protein targets. Of the 313 HTS assays in PCBioAssay, 163 were associated with pro-
tein target information. The respective protein sequences were downloaded from Entrez
Protein by a Perl script utilizing Entrez E-Utilities.16 Using ClustalW116–118 a multiple
sequence alignment was constructed for all sequences. The resulting guide tree was con-
verted into a distance matrix linking all assays by the pairwise percent sequence identity
of their respective targets (Figure 3.3). For each compound the set of assays, in which it
was active, was determined. Weights were calculated for each assay :
w = 1−%SI/100; (3.1)
with %SI the percent sequence identity with the most closely related target associated
to one of the assays in the set. All unrelated assays, including assays without protein tar-
get annotation, were weighted by 1. Using these weights, a weighted count of assays in
which it was found active (wAAC) was calculated for each compound. The FoH of each
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Figure 3.3: Heat-map visualization of the sequence similarity distance matrix of Pub-
Chem HTS assays with protein target annotation. Many groups of assays with closely
related protein targets are perceptible, most notably a cluster of Ras-related GTPases
(highlighted by the yellow circle).
compound was calculated as:
FoH = wAAC/TAC; (3.2)
with wAAC the weighted number of assays in which the compound was found active
and TAC the number of assays in which it was tested. This weighted FoH score was
actually used throughout the analysis of the PubChem datasets.
3.2.5.3 Autofluorescence and Luciferase Inhibition Filter
Assays based on optical detection are often affected by the chromo/fluorogenic proper-
ties of some compounds. Recently, a large scale fluorescence spectroscopic profiling of
PubChem substances has been carried out and been reported in PCBioAssay.110 Com-
pounds that were found to exhibit undesirable properties in this profiling (AIDs: 587,
588, 590, 591, 592, 593, 594) were removed from the PA datasets. In a similar fashion,
a recent screen tested a large set of PubChem substances for their potential to inhibit Lu-
ciferase.109 Compounds found active in this screen (AID 411) were also removed from
the PA datasets.
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3.2.6 Potential False Negatives in the Datasets of Decoys
In addition to false positives, which are addressed by the assay artifacts filter, HTS exper-
iments are also affected by false negatives, i.e. active compounds are falsely designated
as inactive. This constitutes a potential source of error for the decoy sets presented here.
In contrast to false positives, the data in PCBioAssay provides no means to detect poten-
tial false negatives. Furthermore, it is not possible to apply statistical methods such as
bootstrapping in order to get an estimate of the error introduced by false negatives, since
there is no way to reasonably estimate the rate of false negatives in PubChem single dose
HTS assays. In the future, results of quantitative high throughput screening (qHTS)8 ex-
periments may provide numerical data that might form the basis of such calculations. At
the moment however, these results are specific for the respective target, detection method,
compound library and tested compound concentration. Thus, they cannot be applied to
the decoy sets utilized here. (Personal communication: Christopher P. Austin, Direc-
tor NIH Chemical Genomics Center, National Institutes of Health and Douglas Auld,
Group Leader, Genomic Assay Technologies, NIH Chemical Genomics Center, National
Institutes of Health) In order to get at least some idea about the validity of the selected
decoys, a similarity search employing simple descriptors and MAX-rule data fusion was
performed on each MUV decoy set, using the complete set of actives as query. For each
MUV dataset, the five decoys most similar to the actives were recorded. For each of the
resulting 85 compounds, an extensive literature research was performed using SciFinder
Scholar.119 The results are summarized in Tables B.1 and B.2 (Appendix). In summary,
no reports could be found in the literature that suggested a specific activity of one of the
decoys against the target of its respective MUV dataset. Although this evidence is at best
anecdotal, together with the experimental result of inactivity in the HTS assay, it justifies
some confidence about the inactivity of MUV decoys. Especially compared to traditional
VS benchmark datasets, in which the inactivity of the decoys is merely assumed without
any experimental evidence whatsoever, this constitutes a considerable improvement.
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3.2.7 Chemical Space Embedding Filter
In order to prevent artificial enrichment, decoys are selected to be similar to the set of
actives regarding “simple” molecular properties. Usually, this is achieved by selecting a
set of neighbors for each active a from a set of potential decoys (Figure 3.4A). However,
if chemical space around a is devoid of decoys, no selection of decoys is possible, that
can prevent artificial enrichment (Figure 3.4B). Actives must be well embedded in de-
coys to allow unbiased decoy set design. Thus, actives inadequately embedded in decoys
were removed from the PA datasets by a “chemical space embedding filter”. In order
to quantitatively define “good embedding”, a comprehensive sample of drug-like chem-
ical space was compiled. Compounds were pooled from DrugBank,120 Prous Drugs of
the Future,121 the Sigma-Aldrich chemistry catalog122 and the MDDR.69 This collection,
which comprised 372021 unique compounds, will be referred to as the “chemical space
sample” in the remainder of the text. With exception of the MDDR, the chemical space
sample was downloaded in SD-Format80 from PubChem. Extremely large compounds
(i.e. proteins) were filtered from the sample using MOE sdwash.34 Small fragments and
counter ions were removed and 3-dimensional structures generated using CORINA.81
It is safe to assume that all actives are well embedded in this comprehensive collection
of compounds. All datasets and the chemical space sample were encoded by simple de-
scriptors. For each PA dataset, a random sub-sample of the same size as the corresponding
PD dataset was drawn from the chemical space sample. For each active a, the distance to
the 500th nearest neighbor in the random sample was determined. This was repeated 100
times and the 90th percentile d90 was recorded as the 90% confidence boundary for a good
embedding of a. (Figure 3.4C) The distance to the 500th nearest neighbor in the decoy set,
dDecoys, was determined in an analogous fashion. Actives were considered inadequately
embedded in decoys and thus removed from the PA datasets, if dDecoys was larger than
d90. (Figure 3.4D) The distance to the 500th nearest neighbor in the decoy set was chosen
as a criterion for chemical space embedding, because 500 decoys were selected for each
active in the process of MUV dataset design. (actives: k = 30, decoys: d = 15000)
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Figure 3.4: (A) A set of similar decoys (red) is selected for each active. Since active-
active distances are generally larger than decoy-active distances, artificial enrichment is
prevented. (B) If actives are inadequately embedded in decoys, decoy-active distances
result, that are larger than active-active distances even for the most similar decoys. Arti-
ficial enrichment is the consequence. (C) For each active (blue circles) the distance to the
500th nearest neighbor in a representative sample of compounds (grey dots) is determined.
This corresponds to the radius of a hypersphere incorporating the 500 nearest neighbor
compounds (red dots, five nearest neighbors are used here for the sake of clarity). d90 is
determined as a 90% confidence boundary of this distance in 100 samples of compounds.
(D) If an active is located in a region of chemical space that is significantly devoid of
decoys (black dots), the hypersphere containing the 500th nearest decoys, ddecoys has a
radius decoys larger than d90. Such compounds are inadequately embedded in decoys and
is excluded from the PA dataset.
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3.2.8 Descriptors
Simple descriptors (see Section 2.2.3) were calculated for dataset analysis and design. In
order to validate how other descriptors perform on the datasets, they were encoded by
three additional classes of descriptors: SESP a class of versatile, alignment-independent
2D topological indices based on atom pairs,38 MOE molecular properties descriptors34
and MACCS structural keys.123 Bias introduced by the 3D conformation generator CO-
RINA was excluded by using only the 2D class of MOE descriptors. Since the numerical
values of properties in descriptors have significantly different ranges, all PA/PD descrip-
tor matrices, except the ones encoded by MACCS keys, were autoscaled column-wise by
subtraction of the mean and division by the standard deviation of the respective column
in the chemical space sample. Columns with a standard deviation of 0 were removed
from all descriptor matrices including MACCS keys. After this pretreatment, the descrip-
tor matrices of simple, MACCS, MOE and SESP had a dimensionality of 17, 154, 184
and 418, respectively. In order to reduce noise, principal components analysis (PCA)82
was applied to the descriptor matrices of MOE and SESP. The loadings (eigenvectors)
were derived from a singular value decomposition (SVD)124 of the chemical space sam-
ple (see Section 3.2.7) encoded by the respective descriptors. An analysis of the resulting
eigenvalues showed that > 90% of the total variance could be explained by the first 70
components for MOE and the first 94 components for SESP, respectively. Thus, the first
70 (MOE) and the first 94 (SESP) scores from the PCA were used as the final descriptors.
3.2.9 Spatial Statistics for Benchmark Dataset Design
3.2.9.1 Preliminary Experiments for the Determination of ti
For the analysis of chemical datasets by Refined Nearest Neighbor methods it is important
to take account of the fact that the distribution of nearest neighbor distances in a dataset
greatly depends of the respective descriptor space. Depending on the dimensionality of
a descriptor (e.g. MOE p = 70 vs. Simple p = 17, p: number of components) and the
nature of the descriptor values (e.g. MOE [−∞;∞] vs. MACCS {0,1}), distances to
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the nearest neighbor compound might be generally larger in one descriptor space than in
another. Figure 3.5A shows graphs of G(t) for 100 random sub-samples taken from the
chemical space sample based on MOE and autoscaled simple descriptors, respectively.
Apparently nearest neighbor distances are considerably larger in MOE descriptor space
than in simple descriptor space for the same sub-samples of compounds. As long as the
topology of two or more datasets is assessed based on a single descriptor representation,
this effect is without consequence. The effect becomes critical, however, if the topology
of a dataset is compared across different descriptor spaces. Figure 3.5B shows graphs of
G(t) for the PubChem bioactivity dataset AID 846 in simple and MOE descriptor space
respectively. At first sight, it seems that the dataset is considerably more clumpy in simple
descriptor space. However, when comparing the graphs to the ones shown in Figure 3.5A,
it is evident that this is mostly caused by the generally shorter nearest neighbor distances
in simple descriptor space.
Especially when assessing a descriptor’s mapping performance (see Section 2.3.5), it
is essential to assess a descriptor’s ability to convert the specific molecular features of
a dataset of actives into. Clumpiness inherent to the descriptor space would distort the
results of such examinations. This can be prevented by scaling the range of distances ti,
which is the basis for the calculation of G(t) and F(t), by a factor that is proportional to
the expansion of the respective descriptor space. In order to do so, a maximum distance
tmax must be determined as:
tmax = c∗ fspatial; (3.3)
where fspatial constitutes the descriptor space expansion factor. c is a constant that can
be chosen arbitrarily, with the sole condition of being large enough to accommodate all
nearest neighbor distances in the datasets under examination. Furthermore, a resolution
∆t must be determined so that ti is incremented in an equal number of fractions of tmax for
all descriptor spaces:
∆t =
1
r
∗ tmax; (3.4)
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Figure 3.5: (A) Graphs of G(t) for 100 random chemical space sub-samples encoded
by Simple and MOE descriptors, respectively. Nearest neighbor distances are inher-
ently larger in MOE descriptor space than in Simple descriptor space. (B) Analyzing
the different levels of clumping of the representations of dataset AID 846, it is difficult to
distinguish mapping performance from effects caused by differences in descriptor space
expansion. (C) Scaling the range of distances ti using the descriptor space expansion fac-
tor dmnn, curves of G(t) are generated that are comparable across descriptor spaces. (D)
When applied to the curves of G(t) for dataset AID 846 in both descriptor spaces, scaling
of ti reveals that the nearest neighbor distances occurring in this datasets are roughly equal
in both descriptor spaces.
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The resolution factor 1r can be chosen arbitrarily based on computation time consid-
erations, as long as it is sufficiently small to capture the differences in nearest neighbor
distances in the examined datasets. The range of distances ti is then given as:
ti = [0,∆t, ..., tmax]; (3.5)
In order to determine a reasonable choice for the descriptor space expansion factor
fspatial , preliminary experiments were carried out. Based on the chemical space sample,
several measures describing a descriptor space’s expansion were calculated for each de-
scriptor space. These included the maximum distance of two compounds in the sample
dmax, the mean of all pairwise distances dMpw, the median of all pairwise distances dmpw,
the mean nearest neighbor distance dMnn and the median nearest neighbor distance dmnn.
1000 random sub-samples were extracted from the chemical space sample. G(t)was cal-
culated for all sub-samples with
tmax = 3∗ fspatial;
fspatial =
{
dmax,dMpw,dmpw,dMnn,dmnn
}
;
∆t =
1
500
∗ tmax;
for all descriptors used in this Chapter. (Simple, MOE, SESP, MACCS) By analyzing
the resulting curves visually, the mean nearest neighbor distance dMnn and the median
nearest neighbor distance dmnn of the chemical space sample in the respective descrip-
tor spaces were determined as the factors best suited for the generation of comparable
curves across all descriptor spaces. dMnn and dmnn were found to be identical up to the
fourth decimal. The median nearest neighbor distance dmnn was chosen as the descrip-
tor space expansion factor for the experiments described in the following section, be-
cause it is robust and does not depend on extreme observations. Figure 3.5C shows the
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graphs of G(t) for the same 100 random sub-samples as mentioned above calculated with
ti = [0, 1500 , ...,1]∗3∗dmnn for Simple and MOE descriptors. The distributions of nearest
neighbor distances in both descriptor spaces are now comparable. Consequently the com-
parison of the mappings of dataset AID 846 in the two descriptor spaces is much more
informative. (Figure 3.5D)
3.2.9.2 Spatial Statistics for PubChem Datasets
Based on the findings described above, tmax and ∆t were set to:
tmax = 3∗dmnn,Simple; (3.6)
∆t =
1
500
∗ tmax; (3.7)
for the PubChem bioactivity datasets. The values of c = 3 and r = 1500 were found
sufficient for the topologies encountered throughout this Chapter. Using the chemical
space sample (see Section 3.2.7), dmnn,Simple = 1.041 was determined as the median of
all nearest neighbor distances in simple descriptor space. Thus, G(t), F(t) and S(t) and
the respective numerical integrals ΣG, ΣF and ΣS were calculated according to Eqs. 2.4,
2.5, 2.6, 2.7, 2.8 and 2.9 utilizing Algorithms 2.1 and 2.2 with ti = [0,0.006,0.012, ...,3]∗
1.041.
3.2.10 Design of MUV Datasets
The goal of MUV design is to generate sets with a spatially random distribution of actives
and decoys in simple descriptor space. This was accomplished by a two step procedure.
First the datasets of actives were adjusted to a common level of spread. Subsequently,
decoy sets were selected with a common level of separation from the actives. Subsets
of k = 30 actives with the maximum spread possible in each PA dataset were generated
using the well established Kennard-Stone125 algorithm. Since this algorithm generates
the maximum spread for each individual dataset, the maximum common level of spread
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to which all datasets can be adjusted, is the lowest level of spread observed among all
Kennard-Stone subsets. This corresponds to the maximum value of ΣG among the subsets
of g = 312. A row-exchange algorithm91 (Algorithm 3.2, Source code: Appendix D.2.3)
was applied to reduce the spread of all datasets with ΣG > 312 to a level of ΣG ≈ 312.
With the respective Kennard-Stone subsets of actives as a starting design, compounds
were exchanged with the remaining PA compounds until the objective function
D =| g−ΣGDataset |; (3.8)
reached values of D≤ 2, with ΣGDataset representing ΣG of the dataset at the respec-
tive iteration, or if no exchange could be made that would further enhance ΣGDataset . As
an additional constraint, only compounds were allowed to be selected that had a nearest
neighbor distance larger than r = 0.8 to the compounds already in the selection. The dis-
similarity constraint r is used in analogy to the well-established OptiSim algorithm126 for
diverse subset selection.
Both the cutoff value of D ≤ 2 and r = 0.8 were determined empirically by prelimi-
nary experiments. While the main reason for the choice of D≤ 2 was keeping computing
time at a reasonable level, the value of r = 0.8 is critical for the properties of the result-
ing datasets. Here, larger values of r would constitute an excessively harsh dissimilarity
constraint, i.e. such values would exclude too many PA compounds from selection for the
datasets and consequently render the selection of 30 actives impossible. Smaller values
of r on the other hand would allow the selection of compounds that are very similar to
compounds already in the set. Since ΣG captures no information about the shape of the
curve of G(t), the design criterion of ΣG = 312 can also be fulfilled if G(t) increases
early but with a flat slope, i.e. by a dataset that contains a small number of very simi-
lar compounds. Such datasets however would be subject to considerable analogue bias.
Therefore r should be set to the maximum value at which the necessary number of actives
(here k = 30) can still be selected for all datasets. For the PubChem bioactivity datasets
used here, this value was r = 0.8.
For actives and decoys to exhibit a spatially random distribution, ΣF must be equal
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Algorithm 3.2 Row-Exchange Algorithm for the Selection of nsel Actives with Given
ΣG from a Larger Set of Potential Actives A.
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to ΣG. Therefore, a starting design of decoys was generated by selecting the 500 most
similar decoys for each active, resulting in a set of d = 15000 decoys for each dataset. ΣF
was adjusted to f = g = 312 by a genetic algorithm (Algorithm 3.3, Source code: D.2.4)
with
D =| f −ΣFDataset |; (3.9)
as the fitness function, with ΣFDataset representing ΣF of the dataset at the respective
iteration. Convergence was reached if D ≤ 2 or D remained constant for more than 10
iterations. Again, D ≤ 2 was determined as a reasonable fitness cutoff by preliminary
experiments.
3.2.11 Retrospective virtual screening simulations
In order to demonstrate the utility of the MUV datasets in VS validation experiments,
retrospective VS simulations were carried out. The datasets of actives and decoys were
encoded by all descriptors (simple, MOE, SESP, MACCS). For each run, a query of one
or ten compounds, respectively, was chosen randomly from the datasets of actives. The
remaining actives were pooled with the respective decoys to form the validation set. For
each MUV dataset of actives, 100 such random splits were generated, in order to ob-
tain a mean value of VS performance that is not affected by the random choice of the
query molecules. Similarity was measured by the Euclidean distance and the validation
sets were ranked accordingly. For queries consisting of ten compounds, MAX-rule data
fusion47,48 was applied to the ranking.
3.2.12 Figures of Merit (FoM) for Virtual Screening Performance
VS performance was measured by the area under the receiver operating characteristic
curve (AUCROC). Additionally, the ability for early recognition of active compounds was
quantified by the fraction of retrieved actives (Retrieval Rate, RT R1%) in the first percent
of the ranked validation set. The mean areas under the receiver operating characteris-
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Algorithm 3.3 Genetic Algorithm for the Selection of nsel Decoys with Given ΣF Based
on a Set of Actives A and a Set of Potential Decoys I.
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tic curves and mean Retrieval Rates obtained from the 100 random query / validation
set splits generated for each dataset, will be denoted mean(AUCROC) and mean(RT R1%)
throughout the text.
3.2.13 Unique Molecular Frameworks
A relatively recent concept regarding the validation of VS methods is the notion that good
virtual screening algorithms should be able to perform a so-called “scaffold hop”.37,127
Given a certain query molecule, a method should be able to extract actives from a database
that feature a novel scaffold, i.e. a chemical backbone different from that of the query
compound. In order to test for a method’s ability to perform scaffold hops, a benchmark
dataset of actives is required to contain a large number of distinct scaffolds, which is
equivalent to the requirement that each scaffold class in the dataset is represented by only
a small number compounds. More specifically, the ratio of compounds per scaffold class
should not considerably exceed 1.
Although “scaffold hopping” is one of the central concepts of modern virtual screen-
ing research, many definitions of the term “scaffold” exist in the medicinal chemistry
literature.37,127–130 Of these, the definition of scaffolds as “molecular frameworks” (Fig-
ure 3.6) proposed by Bemis and Murcko in their seminal paper128, is most widely adopted.
In their algorithm, a 2-dimensional representation of a molecule’s structure is first con-
verted to a molecular graph by ignoring all atom and bond types. In the second step all
side chain atoms and bonds are removed to produce the molecular framework.
In order to determine the number of unique molecular frameworks in the PubChem
bioactivity datasets before and after MUV design, all compounds in a dataset were con-
verted to molecular frameworks using an in-house MOE SVL script.34 (Source code:
Enclosed CD-ROM) Compounds were grouped according to their molecular framework
and the number of unique groups was recorded for each dataset.
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Figure 3.6: Based on the 2-dimensional representation of a molecule’s structure (A) a
molecular graph is generated by ignoring all atom or bond types. (B) A molecular frame-
work is generated by “pruning” the molecular graph for all side chain atoms and bonds.
(C) After this treatment, both Celecoxib and Rofecoxib are identified as members of the
Coxib scaffold class, which is distinct from the molecular framework of Cocaine. Conse-
quently, a dataset consisting of these three compounds would contain two unique molec-
ular frameworks and thus feature an average ratio of 1.5 compounds per scaffold class.
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3.3 Results and Discussion
3.3.1 Bioactivity Datasets Extracted from PubChem
From the bioactivity data available in PCBioAssay, 18 pairs of assays against pharma-
ceutically relevant targets were selected. Each of these pairs included a primary high-
throughput screen and a low-throughput confirmation assay against the same target. Ac-
tive compounds from the confirmation assays were used as the dataset of potential ac-
tives (PA) for the subsequent design steps. In a complementary fashion, inactive com-
pounds from the corresponding primary screens were used as datasets of potential de-
coys (PD). An overview of the respective pairs of bioassays is shown in Table 3.1. (Sec-
tion 3.2.4) High standards regarding the specificity of the bioactivities in the datasets
of actives were enforced by selecting only low-throughput confirmatory assays with as-
sociated dose-response information and EC50 values as PA datasets. An assay artifacts
filter further removed compounds with a potential for unspecific activity, including aggre-
gators, promiscuous binders and compounds interfering with optical detection methods
(Table 3.3). In addition to the datasets of actives, the specificity of the datasets of decoys
was enforced by utilizing only compounds for potential decoy (PD) datasets, whose in-
activity against the respective target was experimentally determined by HTS. Although
decoys that were false negatives in the HTS cannot be detected by these procedures, the
level of confidence in the inactivity of the MUV decoys is still higher than for benchmark
datasets that merely assume compounds without any annotated activity to be inactive.
3.3.2 MUV Benchmark Datasets: General Properties
Subsets of k = 30 actives and d = 15000 decoys were selected from each PA/PD pair of
datasets, that were as close to spatial randomness as possible. (see Sections 3.2.10 and
3.3.3) The resulting datasets contain a remarkably high number of distinct molecular scaf-
folds (Table 3.2). On average, MUV datasets contain only 1.16 compounds per scaffold
class, a ratio that effectively eliminates analogue bias. Here, scaffolds were defined as
reduced molecular graphs as proposed by Bemis and Murcko.128 Further, MUV datasets
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Table 3.3: Average Number of Lipinski’s Rule-of-5 Violations per Compound in MUV
Datasets
Target AID Actives Decoys
S1P1 rec. 466 0.07 0.02
PKA 548 0 0.01
SF1 600 0.03 0.01
Rho-Kinase2 644 0 0.01
HIV RT-RNase 652 0.10 0.01
Eph rec. A4 689 0.23 0.06
SF1 692 0.07 0.01
HSP 90 712 0 0
ER-a-Coact. Bind. Inh. 713 0.03 0.02
ER-ß-Coact. Bind. Inh. 733 0.03 0.02
ER-a-Coact. Bind. Pot. 737 0.07 0.03
FAK 810 0.10 0.04
Cathepsin G 832 0 0.01
FXIa 846 0 0.05
S1P2 rec. 851 0.13 0.08
FXIIa 852 0 0.05
D1 rec. 858 0 0.01
M1 rec. 859 0 0.01
provide a good representation of drug-like chemical space. As shown by Table 3.3, viola-
tions of Lipinski’s Rule of 5 occur with very low frequency, both in the datasets of actives
and decoys. Only 23 compounds in the PA dataset of S1P2 receptor inhibitors (AID 851)
passed all filters, a number that is insufficient for MUV design of the dataset of actives.
The dataset is kept here for illustrative purposes but will not be part of the final MUV
collection, which consequently consists of 17 benchmark datasets.
3.3.3 Spatial Statistics Analysis of MUV Datasets
Table 3.4 and Figure 3.7 show an overview of dataset clumping in simple descriptor space
before and after MUV dataset design. Before MUV design, all PA/PD datasets show con-
siderable clumping indicated by negative values of ΣS. Over-optimistic validation results
would be the consequence, if these datasets were used for VS validation without further
design. MUV datasets on the other hand, exhibit ΣS values close to 0, indicating mildly
dispersed distributions of actives and decoys close to spatial randomness. With only small
90
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Table 3.4: Measures of Dataset Topology for PubChem Bioactivity Datasets
No Design MUV
ΣS ΣG ΣF ΣS ΣG ΣF
S1P1 rec. 466 -46.12 368.53 322.41 2.08 311.77 313.84
PKA 548 -114.64 374.92 260.28 1.22 311.67 312.88
SF1 600 -39.53 337.86 298.33 1.11 310.67 311.78
Rho-Kinase2 644 -95.66 375.88 280.22 1.18 311.80 312.98
HIV RT-RNase 652 -64.05 369.64 305.60 0.33 310.60 310.93
Eph rec. A4 689 -61.49 326.45 264.96 0.51 311.50 312.01
SF1 692 -51.48 333.32 281.84 12.24 300.77 313.01
HSP 90 712 -65.05 330.98 265.93 10.90 308.40 319.30
ER-a-Coact. Bind. Inh. 713 -9.80 317.92 308.13 1.39 312.00 313.39
ER-ß-Coact. Bind. Inh. 733 -15.91 322.61 306.70 2.91 312.00 314.91
ER-a-Coact. Bind. Pot. 737 -43.05 318.12 275.07 0.92 312.07 312.99
FAK 810 -48.14 321.66 273.52 -1.83 311.07 309.23
Cathepsin G 832 -103.71 383.04 279.33 -3.58 315.83 312.25
FXIa 846 -138.68 397.72 259.04 2.07 311.10 313.17
S1P2 rec. 851 -70.14 277.04 206.90 25.87 266.77 292.64
FXIIa 852 -118.86 393.99 275.13 -1.33 311.77 310.44
D1 Rec. 858 -14.75 339.14 324.39 1.62 311.30 312.92
M1 Rec. 859 -38.62 354.87 316.25 1.46 311.50 312.96
Figure 3.7: Effect of MUV design on dataset topologies in simple descriptor space. With-
out MUV design all datasets show clumping (negative values of ΣSsimple), indicating the
potential for benchmark dataset bias. MUV datasets exhibit ΣSsimple values close to 0,
indicating spatial randomness of actives and decoys. Dataset AID 851 (arrow) does not
fulfill the criteria. No design is feasible on the respective dataset of actives, since it con-
tains less than 30 compounds after application of the assay artifacts filter.
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Figure 3.8: Effect of MUV design on the topology of benchmark datasets AID 548 and
AID 858 in simple descriptor space. (A) Different degrees of dataset clumping are ob-
servable in the raw datasets. The large shift of F(t) relative to G(t) in AID 548 indicates
extensive clumping. (B) MUV design reduces the differences in topology between the
datasets. Both, G(t) and F(t), show similar curves for both datasets. Comparing G(t) to
F(t), it is obvious, that G(t) is coarsely discretized. This is caused by the much smaller
number of active compounds used for the calculation of G(t) compared to the very large
number of decoys, which are the basis for the calculation of F(t).
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variations in topology between the MUV datasets, differences in VS performance between
the datasets are largely independent of simple molecular properties. Figure 3.8 illustrates
the effect of MUV design on the topology of datasets visualized in more detail for two ex-
ample datasets (AID 548, AID 858). Graphs of the nearest-neighbor function G(t) (red)
and the empty space function F(t) (blue) provide information about the self-similarity
in the set of actives and the separation between actives and decoys before (Figure 3.8A)
and after (Figure 3.8B) MUV design. Here, an early ascent in the cumulative distribution
of nearest neighbor distances G(t), i.e. the presence of many actives with a very small
distance t to their nearest neighbor, indicates high self-similarity among actives. On the
other hand a late ascent in F(t) implies the presence of a high proportion of decoys with
a large distance t to the nearest active, i.e. a high level of separation. Any rightward
shift of F(t) relative to G(t) results in negative values of ΣS and thereby indicates dataset
clumping. The objective of MUV design is two-fold: (i) minimize the differences in
dataset clumping between the datasets, i.e. generate similar curves of G(t) and F(t) for
all datasets. (ii) Generate spatially random topologies (ΣS ≈ 0), i.e. minimize the shift
between G(t) and F(t). Figure 3.8 shows, that both goals of MUV design are achieved
for the two datasets examined. Before MUV design (Figure 3.8A) both datasets exhibit
the rightward shift in F(t) relative to G(t) that indicates dataset clumping. Moreover, the
topologies of both datasets are clearly different, with a large extent of clumping in dataset
AID 548 and only mild clumping in dataset AID 858. After MUV design (Figure 3.8B)
both datasets show spatial randomness, i.e. no rightward shift between F(t) and G(t).
Furthermore, the curves of both functions are similar for both datasets, i.e. differences in
topology are minimized.
3.3.4 Application of MUV Datasets for LBVS Benchmarking
In order to demonstrate the utility of the MUV datasets, the PubChem bioactivity datasets
before and after MUV design were encoded by different descriptors: the aforementioned
simple descriptors and three additional classes of descriptors: SESP,38 which is based on
2D atom pairs, MOE molecular properties descriptors34 and MACCS structural keys,123,131
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both of which have found extensive use in the literature for VS validation tasks.77,132–134
Retrospective LBVS simulations were carried out on the original and on the MUV datasets.
From each dataset one or ten actives, respectively, were chosen randomly as query mole-
cules. The rest of the actives was pooled with the corresponding decoys and similarity
searching was carried out. For searches with 10 query molecules, MAX-rule data fu-
sion47,48 was applied to the ranking. This was repeated 100 times. To minimize vari-
ability caused by the random selection of the query set, the average VS performance for
the 100 query / validation set splits was measured by the mean area under the receiver
operating characteristic curve (mean(AUCROC), Figure 3.9 and Table B.3) and the mean
retrieval rate (mean(RT R1%), Table B.3). The mean(AUCROC) values obtained on the
MUV datasets are summarized by Figure 3.9.
At a first glance, Figure 3.9 shows that none of the datasets exhibited a mean(AUCROC)
considerably exceeding the random ranking expectation of 0.5, when encoded by simple
descriptors. This indicates that the spatial randomness of MUV datasets in simple descrip-
tor space is well reflected in the respective VS ranking. MOE descriptors and MACCS
keys generally performed best. Similarity searching with 10 query compounds and data
fusion worked better than single query searches. Moreover, the performance of SESP was
found to be superior to simple descriptors only in very few cases. This is expected, since
SESP is based on count statistics of atom pairs, which are highly correlated with the atom
counts employed by simple descriptors.
However, the goal of this section of the study is not to determine the best descriptor or
searching method. The objective of MUV dataset design is to prevent bias introduced by
benchmark dataset composition from distorting validation experiments. Such benchmark
dataset bias occurs, whenever the results of VS validation experiments largely depend
on the simple property composition of the employed benchmark dataset, rather than the
actual performance of the tested methods. Put differently, the validation of a method is
affected by benchmark dataset bias, if its performance is highly correlated with the topol-
ogy of the datasets in simple descriptor space. Consequently, benchmark dataset bias can
be detected numerically using the correlation coefficient ρ
(
ΣSsimple,mean(AUCROC)
)
be-
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Figure 3.9: Performance of different VS methods in retrospective VS simulations on
MUV datasets. (A) 1 query compound. (B) 10 query compounds. Generally, MACCS
and MOE perform best. The expectation of mean(AUCROC) = 0.5 for random rankings is
indicated by the dashed line.
tween the performance of a given VS method (mean(AUCROC)) and dataset clumping in
simple descriptor space ΣSsimple. Since negative values of ΣSsimple indicate a higher de-
gree of clumping, VS performance and ΣSsimple are negatively correlated. (also see Sec-
tion 2.3.2) Therefore, values of ρ
(
ΣSsimple,mean(AUCROC)
)
close to−1 indicate that the
validation results are biased by the simple molecular properties of the benchmark datasets.
Values near 0, on the other hand, indicate that the validation is not influenced by simple
molecular properties. Figure 3.10 shows graphs visualizing the correlation between the
mean(AUCROC) of the tested descriptors and ΣSsimple for similarity searches using 10
query compounds. A rank transformation was applied to the data, since mean(AUCROC)
and ΣSsimple span considerably different numerical regions and because there is no evi-
dence for a linear relation between them. (see Section 2.2.10) Before MUV design, a tight
correlation between ΣSsimple and the VS performances of all tested descriptors is easily
observable, both in the original data domain and after the rank transformation. Thus,
before MUV design, dataset composition regarding simple molecular properties domi-
nates the validation results of all descriptors, which means that the original datasets are
affected by benchmark dataset bias. After MUV design, this correlation no longer exists
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Figure 3.10: Plots of VS performance (mean(AUCROC)) obtained with four different
descriptors (Simple, MOE, MACCS, SESP) on the 18 benchmark datasets vs. dataset
clumping in simple descriptor space (ΣSsimple) before and after MUV design (similar-
ity searches, 10 query compounds). Before MUV design (top) a clear correlation be-
tween mean(AUCROC) and ΣSsimple is observable, both in the original data domain (left)
and after a rank transformation (right). MUV design (bottom) causes a de-correlation of
mean(AUCROC) and ΣSsimple. Benchmark dataset bias is prevented.
and benchmark dataset bias is effectively prevented. These observations are supported by
the results shown in Table 3.5, which provides the respective spearman rank correlation
coefficients ρ
(
ΣSsimple,mean(AUCROC)
)
for single and multiple query searches. On the
original datasets all tested descriptors exhibit large negative correlation coefficients that
indicate considerable benchmark dataset bias. MUV design reduces this correlation below
the level of statistical significance and thereby prevents benchmark dataset bias. Here, it
might be noteworthy, that in all tested cases, MOE descriptors exhibited the smallest ex-
tent of correlation with ΣSsimple. These results suggest that of the descriptors tested here,
MOE descriptors are least susceptible to benchmark dataset bias.
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Table 3.5: Correlation Coefficients Between ΣSsimple and mean(AUCROC) of Tested De-
scriptors.
ρ
(
ΣSsimple,mean(AUCROC)
)a No Design MUV
Simple MOE SESP MACCS Simple MOE SESP MACCS
1 query cmpd. -0.84 -0.43 -0.72 -0.80 -0.22 -0.08 -0.37 -0.41
10 query cmpds. -0.91 -0.69 -0.78 -0.79 -0.41 -0.17 -0.32 -0.41
Conf. Itv. Boundaryb -0.41
a) n = 17
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
3.3.5 Comparison of MUV with DUD
The directory of useful decoys DUD is a collection of VS benchmark datasets designed to
prevent artificial enrichment in the validation of structure based virtual screening meth-
ods.67 Since its publication, DUD has become the de facto standard for the validation
of docking methods. Briefly, DUD comprises a collection of 40 datasets of actives with
differing sizes compiled from various sources. All compounds in the ZINC database71
not described to be active against one of the 40 targets were used as potential decoys.
Potential decoys were required to have a Tanimoto similarity of less than 0.9 to any of the
actives based on CACTVS type 2 substructure keys135 in order to prevent the selection
of compounds, that could turn out to be active if tested. Using Schrödinger QikProp136
a vector of physical properties quite similar to the simple descriptors used here was cal-
culated for actives and potential decoys. Based on the QikProp descriptors, the 36 most
similar decoys were selected for each active from the set of potential decoys in order to
generate decoy sets with minimum separation.
In order to compare the DUD collection of benchmark datasets with MUV, SD-files80
of the DUD dataset (Release 2) were downloaded from the DUD web-site and encoded
by simple and MOE descriptors. MOE descriptors were chosen, because they were found
to be least susceptible to benchmark dataset bias. (see Section 3.3.4) Spatial statistics
analysis and retrospective LBVS simulations were conducted in an analogous fashion as
for the MUV datasets. The results are summarized in Figures 3.11 and 3.12 and Table 3.7.
Each DUD dataset consists of a set of actives and a set of decoys designed for these
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Table 3.6: Spatial Statistics Figures for DUD Datasets
Target ΣS ΣG ΣF
ACE -117.34 383.51 266.17
AChE -106.75 448.56 341.81
ADA -159.07 393.26 234.19
ALR2 -136.82 343.12 206.30
AmpC -177.32 370.29 192.96
AR -319.61 422.62 103.02
CDK2 8.66 327.94 336.60
COMT -195.89 365.18 169.29
COX1 -94.74 374.16 279.42
COX2 -117.17 420.67 303.50
DHFR -152.67 460.08 307.41
EGFR -124.37 453.03 328.67
ER-agon. -195.24 439.97 244.73
ER-ant. -133.68 447.56 313.89
FGFR1 -254.40 434.20 179.80
Fxa -137.26 395.29 258.03
GART -302.17 457.90 155.73
GPB -260.23 406.86 146.63
GR -241.64 448.53 206.89
HIVPR -135.16 368.15 232.99
Target ΣS ΣG ΣF
HIVRT -96.50 331.03 234.52
HGMR -261.75 425.57 163.83
HSP90 -196.56 419.71 223.15
INHA -163.98 396.59 232.61
MR -230.41 365.93 135.53
NA -182.47 410.04 227.57
P38 -141.92 442.53 300.61
PARP -84.35 414.48 330.13
PDE5 -121.10 341.96 220.86
PDGFRB -142.92 447.58 304.66
PNP -28.43 327.00 298.57
PPARg -154.26 412.38 258.12
PR -126.09 412.37 286.28
RXRa -223.82 419.50 195.68
SAHH -214.78 455.39 240.62
SRC -189.37 420.51 231.14
THROMBIN -148.49 399.88 251.38
TK -142.17 362.64 220.47
TRYPSIN -152.76 381.95 229.19
VEGFR2 -63.31 341.35 278.04
actives. As opposed to the union of all DUD decoys, these decoy sets are termed “own”
decoys by the DUD authors. These datasets of actives and the respective “own” decoys,
were used here.
Most DUD datasets exhibit high levels of clumping in simple descriptor space, in-
dicated by large negative values of ΣSsimple (Figure 3.11). Considerable differences in
dataset topology exist between the datasets. This corresponds with significant correlation
between the VS performance of both simple and MOE descriptors with ΣSsimple (Fig-
ure 3.12, Table 3.7). The large number of datapoints with mean(AUCROC)= 0.8 for sim-
ple descriptors (Figure 3.12A) is particularly striking. It indicates that retrieval of actives
from the DUD datasets is not very challenging, even for simple descriptors that do not
encode any type of higher level molecular information like connectivity or substructure
features.
Apparently, DUD is subject to considerable benchmark dataset bias. Although a de-
tailed analysis of the underlying reasons goes beyond the scope of this study, two main
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Figure 3.11: Dataset clumping of DUD benchmark datasets measured by ΣS in simple
descriptor space. Large negative values indicate considerable self-similarity and separa-
tion from the decoys regarding simple molecular properties. Asterisks indicate datasets
with less than 20 compounds, for which results of VS runs using 10 query compounds are
not representative.
Figure 3.12: (mean(AUCROC)) plotted against ΣSsimple for MOE and simple descriptors
(10 query cmpds.) on DUD benchmark datasets. (A) Original data domain. A tight
correlation is observable for both simple and MOE descriptors in the original data domain.
(B) The correlation persists also after rank transformation, although less obvious for MOE
descriptors. Asterisks indicate datasets with less than 20 compounds.
Table 3.7: Correlation Coefficients of DUD Dataset Clumping in Simple Descriptor
Space (ΣSsimple) and VS Performance of Tested Descriptors
ρ
(
ΣSsimple,mean(AUCROC)
)
Simple MOE
10 query cmpds. -0.92 -0.54
Significancea -0.27
a) n = 40
b) One-sided, 95%. Calculated using permutation testing. See Section 2.2.10.
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factors can be identified. (i) As shown recently by Good et al., DUD is seriously affected
by analogue bias.? Applying the same algorithm by Bemis and Murcko as in the analy-
sis of MUV datasets (see Section 3.3.2), the average number of compounds per scaffold
class in DUD was determined to be 4.56 (MUV: 1.16). This is in accordance with high
values of ΣG observed for all DUD datasets of actives (Table 3.6), indicating high levels
of self-similarity within the datasets. Here, it is important to point out, that DUD was
designed for the validation of docking programs and its application to LBVS is strongly
discouraged by the DUD authors.67,137 Consequently, no diversity selection was applied
to the datasets of actives in the generation of DUD, which explains the high number of
compounds per scaffold class. Since docking tools are less sensitive to the self-similarity
in the dataset of actives, this might be a valid approach. However, for the validation
of methods that incorporate any form of ligand information, as for instance recently by
Reid et al.,52 the analogue bias present in DUD is a critical factor. (ii) DUD decoy sets
also exhibit considerable levels of separation from the actives in simple descriptor space,
indicated by small values in ΣF (Table 3.6). This is surprising, because the explicit prin-
ciple of DUD design is the selection of decoys that are minimally separated from the
actives. Since we do not have access to the original DUD potential decoy set, it is difficult
to precisely specify causes for this problem. One possible reason might be that, accord-
ing to our analysis, on average 13% of the actives in DUD are inadequately embedded in
decoys, with peak values of 60% for the dataset of PDGFrb inhibitors and 51% for InhA
inhibitors. It is quite probable that this causes a certain degree of separation. Another
possible reason is that the Tanimoto dissimilarity criterion applied to potential decoys in
the design of DUD is too harsh. This might create "bubbles" devoid of decoys in chem-
ical space around actives. MUV datasets utilize decoys, for which inactivity against the
respective targets is experimentally determined, which renders a minimum dissimilarity
between actives and decoys obsolete. The associated problems in the design of decoy
datasets are thus circumvented.
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3.4 Summary
A collection of benchmark datasets for ligand based virtual screening methods was gen-
erated from PubChem bioactivity data. These datasets minimize the influence of bench-
mark dataset bias on validation results and therefore provide a publicly available tool for
the Maximum Unbiased Validation (MUV) of virtual screening methods. MUV is the
first collection of VS benchmark datasets featuring experimentally validated decoys and
incorporating the problem of chemical space embedding of actives in its design approach.
The MUV datasets specifically address the validation of ligand based virtual screening
techniques. Therefore both components of benchmark dataset bias, i.e. analogue bias and
artificial enrichment, are minimized in the MUV datasets. With these properties, how-
ever, MUV datasets also fulfill the criteria postulated by Verdonk et al.72 for the unbiased
benchmarking of molecular docking methods. Three dimensional structures are available
from the PDB for seven of the MUV targets (PKA, SF1, HIV RT-RNase, HSP90, FAK,
Cathepsin G, FXIa). The respective datasets are readily applicable to the validation of
SBVS methods. Furthermore, it can be safely expected that the number of MUV datasets
with associated 3-D protein target structures will rise, given the rapid growth of both Pub-
Chem and the PDB. Hence, MUV is a collection of benchmark datasets that is equally
unbiased for SBVS and LBVS methods. This might constitute an important progress to-
wards comparing the performance of docking programs with ligand based VS techniques
in an unbiased manner.
A workflow is presented that allows the generation of spatially optimized benchmark
datasets from raw bioactivity data. As a special benefit, this workflow provides a data
centered approach to detect HTS assay artifacts. The workflow is readily applicable to
custom datasets of prospective users. Thereby users can generate MUV datasets cus-
tomized to their specific virtual screening problems from their own in-house bioactivity
data. Moreover, the filters implemented in the workflow can also be used to purge datasets
for applications other than VS validation from potential unspecific binders. The workflow
is modular and easily extendable regarding two important aspects: (i) New bioactivity
datasets deposited in PubChem can readily be fed into the workflow, filtered for assay ar-
101
CHAPTER 3. MAXIMUM UNBIASED VALIDATION (MUV) DATASETS
tifacts and inadequately embedded actives, optimized spatially and thus be integrated into
the collection of MUV benchmark datasets. (ii) Because of the data centered nature of the
assay artifacts filter, new experimental screening and profiling data for assay specificity
can quickly be integrated. Thus, driven by the fast growth of screening data in PubChem,
the MUV dataset collection will continuously be extended with new targets and datasets.
Much the same way, the efficiency of the assay artifacts filter will be considerably aug-
mented by the rapidly accumulating knowledge available in the PubChem database. The
MUV collection of VS benchmark datasets (also see Appendix C) and a MATLAB90
toolbox for the spatial statistics analysis of chemical datasets (also see Appendix D) are
available on the enclosed CD-ROM or can be downloaded from the Baumann group’s
website: http://www.pharmchem.tu bs.de/lehre/baumann/MUV.html.
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Chapter 4
Conclusion and Outlook
The research presented in this study represents the first application of Refined Nearest
Neighbor Analysis in the field of chemoinformatics. Specifically, spatial statistics meth-
ods were utilized to get a deeper understanding on how the composition of benchmark
datasets influences the results of LBVS validation experiments. (Chapter 2) In the course
of the investigations, the topology of benchmark datasets in chemical space was identified
as a key factor affecting the measured virtual screening performance. Analogue bias and
artificial enrichment, which have previously been described as major factors affecting val-
idation results, can now be quantified in terms of dataset topology. It was shown that lig-
and based virtual screening is affected by both phenomena. The term “benchmark dataset
bias” was introduced for this combined effect. Based on these findings, general criteria
for the prevention of benchmark dataset bias were developed. These guidelines were im-
plemented with a workflow for the design of Maximum Unbiased Validation datasets for
virtual screening. ( Chapter 3) The resulting collection of unbiased benchmark datasets is
based on public data and is therefore freely available to the scientific community.
Several interesting lines of research emerge from this work. This includes the adaption
of the framework of spatial statistics to chemoinformatics purposes, which can now be
applied to the analysis of all kinds of chemical datasets. An obvious future use certainly
is the generation of unbiased datasets for suitability testing, i.e. to figure out the best
VS protocol for a particular application, complementing the MUV collection of unbiased
datasets for benchmarking. But there are promising applications outside the discipline of
103
CHAPTER 4. CONCLUSION AND OUTLOOK
VS validation, such as the field of library design, which seeks to optimize the chemical
compound repositories of pharmaceutical companies in terms of a maximum coverage of
chemical space. Here, Refined Nearest Neighbor Analysis, but also other spatial statistics
methodologies might be utilized in order to quantify the complementarity of a vendor
library with an in-house repository or to assess the chemical space coverage of a medicinal
chemistry series of derivatives. Other, more ambitious projects might also investigate the
inter-relations between the biological similarity of two pharmaceutical targets with the
spatial proximity or distance of their activity spaces, thereby applying spatial statistics to
the field of chemogenomics.138
The approach to identify frequent hitters based on PubChem data mining introduced in
Section 3.2.5 also represents a promising starting point for future research. It constitutes
the first completely data centered, prediction free method for the detection of frequent
hitters in the public domain and can be readily applied to all kinds of chemical datasets.
Moreover an FoH based analysis of PubChem can provide a large scale, high confidence
dataset of frequent hitters, which may provide a valuable tool for the validation of current
and future frequent hitter prediction algorithms.
One result that has not yet been extensively discussed in this study is the fact that
current LBVS approaches are apparently unable to generate consistently high retrieval of
actives in the absence of benchmark dataset bias. (see Figure 3.9, Table B.3) This might
explain to some extent the fact, that very few successful applications of LBVS methods
in prospective VS campaigns have yet been reported. As a consequence, the development
of more powerful and accurate tools for both, ligand and structure based virtual screening
poses a major challenge for the chemoinformatics community in the near future. Valida-
tion protocols providing maximum information about weaknesses or strengths of future
methods will be central to this task. In the editorial of a recent special issue on the valida-
tion of virtual screening techniques of the Journal of Computer-Aided Molecular Design,
Ajay Jain and Anthony Nicholls named three key areas on which future validation exper-
iments must improve: data sharing, dataset preparation and reporting of results.139 The
MUV datasets presented in Chapter 3 constitute an important advance for VS validation
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methods with regard to both data sharing and dataset preparation. As stated above, the
MUV collection of datasets is publicly available and can easily be shared by scientists
conducting validation experiments. The MUV workflow and the spatial statistics method-
ology presented in this study address the problem of dataset preparation with minimum
dataset induced topological bias. PubChem based services, such as the PubChem Stan-
dardization Service,140 ensure that all MUV datasets are prepared according to a com-
mon set of standards regarding tautomers, ionization, counter-ions etc. Summarizing, the
research presented in the course of this study addresses two of the key issues for VS val-
idation experiments as stated by Jain and Nicholls. Moreover, the results presented here
also have implications for the future reporting of VS validation results. Given the results
of this study, it is evident that the clumpiness of the employed datasets should be reported
with every VS validation result. Efforts are under way in our laboratory to provide an
open, community driven platform for the standardized reporting of VS validation results
and the topological analysis of the employed benchmark datasets.
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Appendix A
Supplementary Tables: Chapter 2
Table A.1: ΣS for all sub-samples in MOE descriptor space.
D-optimum Design
k 50 100 150 200 250 300
ACE inhibitors -121.3 -337.6 -421.6 -447.7 -482.1 -514.6
AChE Inhibitors -39.2 -172.2 -244.1 -305.2 -333.8 -369.3
Angio. R. Blockers -24.7 -151.8 -223.2 -271.6 -304.9 -334.3
COX inhibitors -36.6 -132.3 -209.2 -250.3 -271.4 -295.5
D2 antagonists -126.0 -230.8 -307.3 -350.9 -392.4 -419.9
HIV P. inhibitors 35.9 -76.6 -189.5 -249.8 -278.6 -316.5
5HT1A agonists -149.1 -219.3 -254.1 -303.3 -341.5 -375.3
5HT3 antagonists -170.4 -239.4 -307.9 -342.0 -380.4 -400.7
5HT reup. inhibitors -189.6 -264.5 -346.3 -408.5 -441.5 -460.3
PKC inhibitors 49.7 -113.2 -225.4 -306.6 -333.2 -351.4
Renin inhibitors -96.1 -233.9 -303.1 -359.3 -411.7 -445.2
Subst. P inhibitors 36.3 -113.9 -196.5 -243.7 -282.0 -313.3
Thrombin inhibitors 35.0 -112.8 -204.4 -256.9 -309.0 -336.6
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Table A.1: ΣS for all sub-samples in MOE descriptor space.
Onion Design
k 50 100 150 200 250 300
ACE inhibitors -337.6 -338.8 -360.0 -446.0 -494.6 -489.8
AChE Inhibitors -230.3 -286.2 -263.5 -291.3 -304.3 -316.5
Angio. R. Blockers -223.3 -288.8 -312.0 -309.8 -363.8 -332.7
COX inhibitors -196.0 -218.4 -225.4 -237.5 -272.6 -276.3
D2 antagonists -304.3 -348.4 -346.4 -346.7 -425.6 -397.1
HIV P. inhibitors -238.6 -259.2 -275.7 -260.7 -294.2 -305.2
5HT1A agonists -314.8 -312.3 -340.1 -356.2 -359.8 -358.8
5HT3 antagonists -351.5 -392.9 -372.2 -392.7 -400.3 -409.6
5HT reup. inhibitors -306.4 -347.8 -376.6 -409.9 -450.5 -453.8
PKC inhibitors -152.0 -213.0 -227.7 -245.1 -347.9 -303.4
Renin inhibitors -454.3 -489.3 -443.4 -426.5 -432.2 -444.7
Subst. P inhibitors -224.2 -230.1 -234.5 -214.0 -234.2 -253.2
Thrombin inhibitors -250.8 -274.3 -268.3 -284.9 -289.3 -301.7
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Table A.1: ΣS for all sub-samples in MOE descriptor space.
Minimum Diversity Design
k 50 100 150 200 250 300
ACE inhibitors -694.6 -665.4 -631.0 -612.6 -580.8 -560.4
AChE Inhibitors -748.9 -673.3 -614.9 -585.8 -572.7 -557.9
Angio. R. Blockers -925.8 -826.8 -783.0 -765.0 -743.2 -732.2
COX inhibitors -599.8 -511.6 -484.6 -471.6 -473.8 -462.5
D2 antagonists -691.9 -619.8 -586.9 -562.1 -543.3 -524.7
HIV P. inhibitors -886.7 -766.5 -799.3 -747.4 -734.0 -721.1
5HT1A agonists -706.5 -654.6 -632.8 -610.8 -607.4 -601.6
5HT3 antagonists -747.2 -700.8 -704.6 -685.6 -660.6 -655.8
5HT reup. inhibitors -643.9 -640.7 -575.5 -554.7 -523.9 -510.8
PKC inhibitors -687.6 -605.9 -565.1 -548.4 -501.4 -459.5
Renin inhibitors -968.1 -931.1 -907.7 -883.7 -863.3 -853.6
Subst. P inhibitors -763.7 -689.4 -655.1 -620.5 -579.3 -568.0
Thrombin inhibitors -849.3 -779.1 -696.1 -656.6 -642.5 -617.2
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Table A.2: ΣS for all sub-samples in simple descriptor space.
D-optimum Design
k 50 100 150 200 250 300
ACE inhibitors -160.9 -273.6 -290.9 -293.6 -303.2 -309.3
AChE Inhibitors -267.8 -308.8 -328.4 -333.0 -335.1 -351.3
Angio. R. Blockers -370.8 -397.0 -399.9 -380.9 -401.6 -416.9
COX inhibitors -319.4 -332.0 -335.1 -340.8 -345.8 -356.8
D2 antagonists -351.6 -370.1 -399.6 -385.1 -393.1 -394.8
HIV P. inhibitors -222.5 -305.7 -267.5 -286.0 -307.7 -326.9
5HT1A agonists -347.0 -357.8 -378.8 -381.7 -390.3 -397.1
5HT3 antagonists -443.6 -492.5 -504.8 -524.1 -500.9 -502.0
5HT reup. inhibitors -362.4 -356.3 -375.0 -381.8 -410.8 -416.0
PKC inhibitors -117.8 -132.5 -181.1 -207.0 -225.6 -252.5
Renin inhibitors -530.4 -583.8 -633.1 -649.8 -666.3 -679.4
Subst. P inhibitors -156.2 -158.5 -216.3 -235.3 -260.4 -275.7
Thrombin inhibitors -265.1 -262.9 -280.4 -290.6 -314.9 -320.0
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Table A.2: ΣS for all sub-samples in simple descriptor space.
Onion Design
k 50 100 150 200 250 300
ACE inhibitors -194.3 -286.5 -262.4 -288.0 -284.1 -316.9
AChE Inhibitors -339.2 -361.3 -371.3 -348.0 -344.4 -345.6
Angio. R. Blockers -372.5 -419.7 -398.9 -410.2 -450.2 -419.1
COX inhibitors -412.2 -328.6 -372.3 -349.9 -360.4 -363.7
D2 antagonists -436.2 -381.5 -404.0 -413.0 -434.6 -411.3
HIV P. inhibitors -297.6 -272.7 -304.8 -304.8 -339.3 -307.1
5HT1A agonists -398.1 -391.1 -384.7 -383.6 -383.6 -403.7
5HT3 antagonists -565.8 -500.7 -488.5 -476.2 -488.8 -480.9
5HT reup. inhibitors -364.9 -405.1 -417.6 -413.5 -404.6 -421.4
PKC inhibitors -153.4 -238.0 -236.7 -216.4 -249.8 -251.3
Renin inhibitors -548.2 -608.9 -671.8 -642.6 -694.5 -679.3
Subst. P inhibitors -294.5 -264.4 -303.3 -280.3 -281.5 -289.5
Thrombin inhibitors -344.7 -345.3 -339.5 -375.6 -310.5 -316.0
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Table A.2: ΣS for all sub-samples in simple descriptor space.
Minimum Diversity Design
k 50 100 150 200 250 300
ACE inhibitors -319.6 -348.8 -319.6 -320.5 -319.2 k
AChE Inhibitors -451.8 -386.2 -431.4 -393.8 -396.7 -402.2
Angio. R. Blockers -694.1 -489.5 -502.6 -493.6 -484.3 -482.9
COX inhibitors -524.8 -423.1 -432.5 -417.6 -403.6 -403.2
D2 antagonists -524.5 -444.8 -444.2 -455.9 -450.3 -446.8
HIV P. inhibitors -597.2 -567.9 -502.6 -451.7 -434.6 -438.0
5HT1A agonists -498.4 -485.0 -446.5 -446.9 -435.6 -437.2
5HT3 antagonists -503.2 -528.0 -512.8 -511.4 -500.0 -502.4
5HT reup. inhibitors -496.1 -502.8 -468.7 -452.5 -445.2 -450.7
PKC inhibitors -389.6 -328.9 -353.6 -351.4 -347.5 -331.7
Renin inhibitors -690.3 -722.4 -745.2 -762.4 -761.9 -770.4
Subst. P inhibitors -714.6 -659.9 -564.0 -547.9 -530.9 -521.3
Thrombin inhibitors -461.0 -513.0 -432.7 -420.1 -424.8 -364.5
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Table A.3: VS Figures of Merit for dataset sub-samples.
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D-Opt. Design k = 50
ACE inhibitors 0.06 0.0346 0.0012 0.0016 0.0004 0.56 0.0434 0.00188542 0.00272387 0.00083846 0.07 0.58
AChE Inhibitors 0.00 0.0077 0.0001 0.0001 0.0000 0.57 0.0215 0.00046274 0.00087050 0.00040776 0.08 0.73
Angio. R. Blockers 0.01 0.0228 0.0005 0.0006 0.0001 0.50 0.0819 0.00670022 0.00717879 0.00047857 0.18 0.82
COX inhibitors 0.01 0.0138 0.0002 0.0003 0.0001 0.55 0.0313 0.00097924 0.00142867 0.00044943 0.09 0.81
D2 antagonists 0.02 0.0139 0.0002 0.0003 0.0001 0.69 0.0199 0.00039661 0.00078683 0.00039022 0.12 0.81
HIV P. inhibitors 0.01 0.0176 0.0003 0.0004 0.0000 0.43 0.1314 0.01726312 0.01767817 0.00041505 0.07 0.67
5HT1A agonists 0.02 0.0156 0.0002 0.0004 0.0001 0.68 0.0240 0.00057529 0.00092912 0.00035383 0.12 0.81
5HT3 antagonists 0.02 0.0129 0.0002 0.0003 0.0001 0.74 0.0186 0.00034567 0.00062965 0.00028398 0.25 0.91
5HT reup. inhibitors 0.05 0.0266 0.0007 0.0010 0.0003 0.72 0.0270 0.00072867 0.00102555 0.00029688 0.19 0.77
PKC inhibitors 0.01 0.0160 0.0003 0.0003 0.0001 0.34 0.0448 0.00200424 0.00250596 0.00050171 0.06 0.53
Renin inhibitors 0.06 0.0718 0.0052 0.0055 0.0003 0.59 0.1574 0.02475913 0.02526723 0.00050811 0.57 0.93
Subst. P inhibitors 0.01 0.0220 0.0005 0.0006 0.0001 0.42 0.0657 0.00431307 0.00484167 0.00052860 0.03 0.55
Thrombin inhibitors 0.02 0.0210 0.0004 0.0005 0.0001 0.47 0.1009 0.01017476 0.01067812 0.00050336 0.12 0.76
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Onion design k = 50
ACE inhibitors 0.26 0.0432 0.0019 0.0031 0.0013 0.76 0.0329 0.00108133 0.00175339 0.00067206 0.07 0.62
AChE Inhibitors 0.10 0.0366 0.0013 0.0019 0.0006 0.75 0.0123 0.00015086 0.00061892 0.00046806 0.14 0.78
Angio. R. Blockers 0.16 0.0614 0.0038 0.0046 0.0009 0.77 0.0347 0.00120445 0.00168928 0.00048483 0.12 0.81
COX inhibitors 0.04 0.0228 0.0005 0.0008 0.0003 0.74 0.0256 0.00065290 0.00096970 0.00031680 0.09 0.85
D2 antagonists 0.11 0.0428 0.0018 0.0025 0.0007 0.83 0.0139 0.00019306 0.00043574 0.00024268 0.12 0.87
HIV P. inhibitors 0.16 0.0979 0.0096 0.0104 0.0008 0.72 0.1071 0.01146227 0.01198401 0.00052175 0.07 0.69
5HT1A agonists 0.13 0.0468 0.0022 0.0029 0.0008 0.85 0.0205 0.00041833 0.00067704 0.00025871 0.12 0.86
5HT3 antagonists 0.23 0.0615 0.0038 0.0049 0.0011 0.88 0.0000 0.00000000 0.00021873 0.00023009 0.34 0.93
5HT reup. inhibitors 0.12 0.0354 0.0013 0.0020 0.0007 0.82 0.0203 0.00041007 0.00063091 0.00022084 0.13 0.82
PKC inhibitors 0.13 0.0509 0.0026 0.0033 0.0007 0.63 0.0224 0.00050343 0.00123253 0.00072911 0.07 0.59
Renin inhibitors 0.58 0.0788 0.0062 0.0078 0.0016 0.88 0.0194 0.00037720 0.00083615 0.00045894 0.64 0.97
Subst. P inhibitors 0.12 0.0835 0.0070 0.0076 0.0007 0.73 0.0506 0.00256052 0.00307238 0.00051186 0.06 0.71
Thrombin inhibitors 0.12 0.0387 0.0015 0.0022 0.0007 0.78 0.0369 0.00135829 0.00183358 0.00047529 0.18 0.79
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Min. Div. Des. k = 50
ACE inhibitors 0.99 0.0122 0.0001 0.0002 0.0000 1.00 0.0003 0.00000007 0.00000009 0.00000002 0.13 0.75
AChE Inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0001 0.00000002 0.00000002 0.00000000 0.31 0.86
Angio. R. Blockers 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0001 0.00000000 0.00000000 0.00000000 0.61 0.95
COX inhibitors 0.82 0.0810 0.0066 0.0075 0.0010 0.99 0.0031 0.00000931 0.00001008 0.00000077 0.29 0.90
D2 antagonists 0.96 0.0264 0.0007 0.0009 0.0002 1.00 0.0005 0.00000025 0.00000030 0.00000006 0.25 0.89
HIV P. inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0000 0.00000000 0.00000000 0.00000000 0.48 0.92
5HT1A agonists 1.00 0.0075 0.0001 0.0001 0.0000 1.00 0.0002 0.00000004 0.00000004 0.00000001 0.31 0.88
5HT3 antagonists 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0001 0.00000001 0.00000001 0.00000000 0.28 0.92
5HT reup. inhibitors 0.86 0.0562 0.0032 0.0040 0.0008 1.00 0.0011 0.00000131 0.00000152 0.00000021 0.31 0.89
PKC inhibitors 0.99 0.0357 0.0013 0.0014 0.0001 1.00 0.0008 0.00000070 0.00000073 0.00000004 0.29 0.73
Renin inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0000 0.00000000 0.00000000 0.00000000 0.81 0.99
Subst. P inhibitors 1.00 0.0121 0.0001 0.0002 0.0000 1.00 0.0003 0.00000011 0.00000012 0.00000001 0.66 0.98
Thrombin inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0000 0.00000000 0.00000000 0.00000000 0.30 0.88
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D-Opt. Des. k = 100
ACE inhibitors 0.12 0.0289 0.0008 0.0011 0.0003 0.60 0.0474 0.00225017 0.00260941 0.00035924 0.09 0.63
AChE Inhibitors 0.03 0.0226 0.0005 0.0006 0.0001 0.61 0.0319 0.00101844 0.00120421 0.00018578 0.07 0.75
Angio. R. Blockers 0.04 0.0240 0.0006 0.0007 0.0001 0.58 0.0779 0.00607216 0.00627618 0.00020402 0.18 0.83
COX inhibitors 0.03 0.0158 0.0003 0.0003 0.0001 0.59 0.0269 0.00072097 0.00091009 0.00018912 0.07 0.79
D2 antagonists 0.05 0.0219 0.0005 0.0006 0.0001 0.72 0.0272 0.00073803 0.00088580 0.00014777 0.12 0.80
HIV P. inhibitors 0.02 0.0192 0.0004 0.0004 0.0000 0.46 0.1100 0.01209111 0.01228463 0.00019352 0.09 0.74
5HT1A agonists 0.04 0.0168 0.0003 0.0004 0.0001 0.71 0.0239 0.00057309 0.00072725 0.00015416 0.10 0.81
5HT3 antagonists 0.05 0.0215 0.0005 0.0006 0.0001 0.77 0.0244 0.00059470 0.00071081 0.00011611 0.27 0.92
5HT reup. inhibitors 0.06 0.0274 0.0007 0.0009 0.0002 0.75 0.0281 0.00078936 0.00090458 0.00011522 0.12 0.78
PKC inhibitors 0.03 0.0176 0.0003 0.0004 0.0001 0.43 0.0421 0.00177485 0.00202707 0.00025222 0.05 0.52
Renin inhibitors 0.09 0.1075 0.0116 0.0118 0.0002 0.67 0.1420 0.02016941 0.02038481 0.00021540 0.54 0.95
Subst. P inhibitors 0.03 0.0264 0.0007 0.0008 0.0001 0.45 0.0759 0.00575920 0.00599660 0.00023740 0.02 0.55
Thrombin inhibitors 0.05 0.0408 0.0017 0.0018 0.0001 0.58 0.1008 0.01015641 0.01040041 0.00024400 0.12 0.73
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Onion Des. k = 100
ACE inhibitors 0.24 0.0478 0.0023 0.0028 0.0005 0.76 0.0330 0.00109001 0.00137826 0.00028825 0.09 0.65
AChE Inhibitors 0.08 0.0262 0.0007 0.0009 0.0002 0.77 0.0157 0.00024545 0.00039691 0.00015147 0.11 0.77
Angio. R. Blockers 0.19 0.0619 0.0038 0.0043 0.0004 0.81 0.0362 0.00131244 0.00148617 0.00017373 0.19 0.83
COX inhibitors 0.06 0.0221 0.0005 0.0006 0.0002 0.75 0.0282 0.00079422 0.00094824 0.00015402 0.06 0.81
D2 antagonists 0.15 0.0372 0.0014 0.0017 0.0004 0.85 0.0120 0.00014418 0.00024673 0.00010255 0.12 0.82
HIV P. inhibitors 0.14 0.1024 0.0105 0.0108 0.0003 0.76 0.0754 0.00569229 0.00587799 0.00018570 0.09 0.71
5HT1A agonists 0.10 0.0361 0.0013 0.0016 0.0003 0.83 0.0165 0.00027097 0.00038006 0.00010909 0.12 0.81
5HT3 antagonists 0.26 0.0488 0.0024 0.0029 0.0006 0.90 0.0116 0.00013374 0.00019772 0.00006398 0.32 0.92
5HT reup. inhibitors 0.14 0.0452 0.0020 0.0024 0.0003 0.83 0.0207 0.00042812 0.00052608 0.00009796 0.13 0.81
PKC inhibitors 0.12 0.0396 0.0016 0.0019 0.0003 0.64 0.0189 0.00035549 0.00065529 0.00029980 0.09 0.62
Renin inhibitors 0.51 0.1034 0.0107 0.0114 0.0007 0.92 0.0222 0.00049227 0.00058565 0.00009338 0.58 0.95
Subst. P inhibitors 0.07 0.0356 0.0013 0.0015 0.0002 0.68 0.0610 0.00371864 0.00392793 0.00020928 0.05 0.71
Thrombin inhibitors 0.16 0.0715 0.0051 0.0055 0.0004 0.78 0.0471 0.00221576 0.00242902 0.00021327 0.15 0.77
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Min. Div. Des. k = 100
ACE inhibitors 0.88 0.0542 0.0029 0.0032 0.0003 1.00 0.0015 0.00000221 0.00002364 0.00000014 0.14 0.73
AChE Inhibitors 0.85 0.0574 0.0033 0.0037 0.0004 1.00 0.0014 0.00000196 0.00002136 0.00000012 0.13 0.79
Angio. R. Blockers 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0001 0.00000002 0.00000006 0.00000001 0.22 0.87
COX inhibitors 0.38 0.0716 0.0051 0.0058 0.0007 0.96 0.0107 0.00011464 0.00010258 0.00000571 0.09 0.85
D2 antagonists 0.63 0.0610 0.0037 0.0044 0.0007 0.99 0.0022 0.00000485 0.00001628 0.00000042 0.16 0.86
HIV P. inhibitors 0.91 0.0618 0.0038 0.0040 0.0002 1.00 0.0013 0.00000157 0.00000077 0.00000007 0.31 0.82
5HT1A agonists 0.89 0.0477 0.0023 0.0026 0.0003 1.00 0.0009 0.00000079 0.00000260 0.00000007 0.26 0.87
5HT3 antagonists 0.99 0.0159 0.0003 0.0003 0.0000 1.00 0.0003 0.00000010 0.00000042 0.00000001 0.34 0.93
5HT reup. inhibitors 0.74 0.0689 0.0048 0.0053 0.0005 0.99 0.0023 0.00000530 0.00004965 0.00000035 0.26 0.89
PKC inhibitors 0.79 0.0694 0.0048 0.0053 0.0005 0.99 0.0042 0.00001782 0.00011250 0.00000094 0.19 0.71
Renin inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0000 0.00000000 0.00000000 0.00000000 0.83 0.99
Subst. P inhibitors 0.85 0.0653 0.0043 0.0046 0.0004 1.00 0.0017 0.00000291 0.00001412 0.00000015 0.35 0.95
Thrombin inhibitors 1.00 0.0007 0.0000 0.0000 0.0000 1.00 0.0002 0.00000003 0.00000070 0.00000000 0.30 0.88
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Table A.3: VS Figures of Merit for dataset sub-samples.
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D-Opt. Des. k = 150
ACE inhibitors 0.15 0.0289 0.0014 0.0016 0.0002 0.66 0.0574 0.00329734 0.00350967 0.00021233 0.08 0.64
AChE Inhibitors 0.05 0.0226 0.0006 0.0007 0.0001 0.64 0.0282 0.00079684 0.00091966 0.00012283 0.10 0.75
Angio. R. Blockers 0.05 0.0240 0.0010 0.0011 0.0001 0.61 0.0787 0.00620083 0.00633161 0.00013078 0.18 0.83
COX inhibitors 0.04 0.0158 0.0003 0.0004 0.0001 0.61 0.0302 0.00091329 0.00103210 0.00011881 0.06 0.79
D2 antagonists 0.06 0.0219 0.0005 0.0006 0.0001 0.77 0.0204 0.00041744 0.00050433 0.00008689 0.11 0.82
HIV P. inhibitors 0.04 0.0192 0.0008 0.0009 0.0001 0.51 0.1040 0.01080688 0.01093469 0.00012781 0.09 0.71
5HT1A agonists 0.05 0.0168 0.0004 0.0005 0.0001 0.73 0.0221 0.00048999 0.00058000 0.00009001 0.11 0.81
5HT3 antagonists 0.08 0.0215 0.0005 0.0007 0.0001 0.79 0.0196 0.00038468 0.00045430 0.00006961 0.26 0.93
5HT reup. inhibitors 0.08 0.0274 0.0003 0.0005 0.0001 0.77 0.0254 0.00064477 0.00071842 0.00007365 0.13 0.79
PKC inhibitors 0.06 0.0176 0.0005 0.0006 0.0001 0.49 0.0458 0.00209649 0.00227637 0.00017988 0.05 0.52
Renin inhibitors 0.13 0.1075 0.0120 0.0122 0.0002 0.72 0.1296 0.01680517 0.01692903 0.00012386 0.46 0.92
Subst. P inhibitors 0.05 0.0264 0.0012 0.0013 0.0001 0.49 0.0645 0.00415871 0.00431501 0.00015630 0.03 0.58
Thrombin inhibitors 0.06 0.0408 0.0011 0.0012 0.0001 0.59 0.0881 0.00776055 0.00791522 0.00015467 0.11 0.74
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Onion Des. k = 150
ACE inhibitors 0.24 0.0478 0.0025 0.0028 0.0003 0.76 0.0359 0.00129092 0.00147656 0.00018564 0.09 0.65
AChE Inhibitors 0.06 0.0262 0.0004 0.0005 0.0001 0.76 0.0141 0.00019793 0.00029980 0.00010187 0.11 0.79
Angio. R. Blockers 0.17 0.0619 0.0038 0.0041 0.0003 0.82 0.0473 0.00224015 0.00232599 0.00008584 0.13 0.83
COX inhibitors 0.06 0.0221 0.0005 0.0006 0.0001 0.73 0.0231 0.00053503 0.00062594 0.00009091 0.08 0.82
D2 antagonists 0.12 0.0372 0.0011 0.0013 0.0002 0.85 0.0125 0.00015513 0.00021950 0.00006437 0.13 0.83
HIV P. inhibitors 0.14 0.1024 0.0101 0.0103 0.0002 0.76 0.0952 0.00907102 0.00917928 0.00010826 0.12 0.75
5HT1A agonists 0.10 0.0361 0.0008 0.0010 0.0002 0.84 0.0139 0.00019290 0.00025638 0.00006348 0.10 0.81
5HT3 antagonists 0.23 0.0488 0.0025 0.0028 0.0003 0.90 0.0082 0.00006719 0.00010897 0.00004178 0.27 0.92
5HT reup. inhibitors 0.14 0.0452 0.0009 0.0011 0.0002 0.84 0.0156 0.00024420 0.00029732 0.00005312 0.15 0.83
PKC inhibitors 0.10 0.0396 0.0011 0.0013 0.0002 0.63 0.0288 0.00083171 0.00101262 0.00018091 0.07 0.59
Renin inhibitors 0.46 0.1034 0.0351 0.0355 0.0004 0.90 0.0449 0.00201362 0.00208902 0.00007540 0.65 0.96
Subst. P inhibitors 0.10 0.0356 0.0036 0.0038 0.0002 0.71 0.0653 0.00425937 0.00438983 0.00013045 0.06 0.70
Thrombin inhibitors 0.15 0.0715 0.0041 0.0043 0.0002 0.80 0.0465 0.00215936 0.00228704 0.00012768 0.12 0.76
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Table A.3: VS Figures of Merit for dataset sub-samples.
MOE Simple
m
ea
n(
R
T
R
1%
)
σ t
op
(R
T
R
1%
)
σ
2 to
p
(R
T
R
1%
)
σ
2 (
R
T
R
1%
)
σ
2 bt
(R
T
R
1%
)
m
ea
n(
AU
C
RO
C
)
σ t
op
(A
U
C
RO
C
)
σ
2 to
p
(A
U
C
RO
C
)
σ
2 (
AU
C
RO
C
)
σ
2 bt
(A
U
C
RO
C
)
m
ea
n(
R
T
R
1%
)
m
ea
n(
AU
C
RO
C
)
Min. Div. Des. k = 150
ACE inhibitors 0.71 0.0542 0.0037 0.0041 0.0004 0.99 0.0048 0.00002284 0.00002364 0.00000080 0.12 0.68
AChE Inhibitors 0.67 0.0574 0.0085 0.0089 0.0004 0.99 0.0046 0.00002073 0.00002136 0.00000063 0.13 0.82
Angio. R. Blockers 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0002 0.00000005 0.00000006 0.00000001 0.24 0.88
COX inhibitors 0.30 0.0716 0.0026 0.0030 0.0004 0.95 0.0098 0.00009622 0.00010258 0.00000636 0.09 0.84
D2 antagonists 0.46 0.0610 0.0045 0.0049 0.0004 0.98 0.0039 0.00001543 0.00001628 0.00000085 0.14 0.85
HIV P. inhibitors 0.93 0.0618 0.0022 0.0023 0.0001 1.00 0.0009 0.00000074 0.00000077 0.00000003 0.26 0.84
5HT1A agonists 0.74 0.0477 0.0031 0.0035 0.0003 0.99 0.0016 0.00000242 0.00000260 0.00000017 0.19 0.85
5HT3 antagonists 0.94 0.0159 0.0012 0.0013 0.0001 1.00 0.0006 0.00000040 0.00000042 0.00000002 0.33 0.93
5HT reup. inhibitors 0.48 0.0689 0.0042 0.0046 0.0004 0.97 0.0068 0.00004600 0.00004965 0.00000365 0.24 0.87
PKC inhibitors 0.58 0.0694 0.0085 0.0090 0.0004 0.97 0.0105 0.00010922 0.00011250 0.00000329 0.15 0.69
Renin inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0000 0.00000000 0.00000000 0.00000000 0.79 0.99
Subst. P inhibitors 0.72 0.0653 0.0040 0.0043 0.0004 0.99 0.0037 0.00001365 0.00001412 0.00000047 0.27 0.91
Thrombin inhibitors 0.95 0.0007 0.0017 0.0018 0.0001 1.00 0.0008 0.00000068 0.00000070 0.00000002 0.25 0.85
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Table A.3: VS Figures of Merit for dataset sub-samples.
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D-Opt. Des. k = 200
ACE inhibitors 0.18 0.0371 0.0014 0.0016 0.0002 0.70 0.0551 0.00303955 0.00319145 0.00015190 0.08 0.63
AChE Inhibitors 0.06 0.0239 0.0004 0.0005 0.0001 0.66 0.0243 0.00059266 0.00067860 0.00008594 0.09 0.75
Angio. R. Blockers 0.06 0.0314 0.0010 0.0011 0.0001 0.65 0.0747 0.00557715 0.00567237 0.00009522 0.15 0.82
COX inhibitors 0.05 0.0173 0.0003 0.0004 0.0001 0.64 0.0264 0.00069790 0.00078024 0.00008234 0.07 0.79
D2 antagonists 0.09 0.0230 0.0009 0.0010 0.0001 0.80 0.0200 0.00039954 0.00045367 0.00005413 0.10 0.82
HIV P. inhibitors 0.05 0.0286 0.0009 0.0010 0.0001 0.56 0.1152 0.01327318 0.01336583 0.00009265 0.08 0.71
5HT1A agonists 0.06 0.0199 0.0003 0.0004 0.0001 0.75 0.0185 0.00034366 0.00040276 0.00005910 0.11 0.82
5HT3 antagonists 0.09 0.0231 0.0004 0.0005 0.0001 0.81 0.0186 0.00034731 0.00039316 0.00004585 0.28 0.93
5HT reup. inhibitors 0.11 0.0182 0.0003 0.0004 0.0001 0.80 0.0273 0.00074460 0.00079304 0.00004844 0.12 0.80
PKC inhibitors 0.09 0.0224 0.0007 0.0008 0.0001 0.53 0.0404 0.00162870 0.00176363 0.00013493 0.05 0.54
Renin inhibitors 0.11 0.1094 0.0071 0.0072 0.0001 0.72 0.1117 0.01247628 0.01256707 0.00009079 0.50 0.93
Subst. P inhibitors 0.04 0.0349 0.0005 0.0006 0.0001 0.51 0.0654 0.00427405 0.00438491 0.00011085 0.03 0.58
Thrombin inhibitors 0.08 0.0334 0.0015 0.0016 0.0001 0.63 0.0840 0.00706386 0.00717715 0.00011329 0.10 0.72
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Onion Des. k = 200
ACE inhibitors 0.32 0.0501 0.0024 0.0027 0.0003 0.82 0.0451 0.00203558 0.00214184 0.00010626 0.08 0.65
AChE Inhibitors 0.08 0.0199 0.0004 0.0005 0.0001 0.77 0.0143 0.00020519 0.00027167 0.00006648 0.08 0.76
Angio. R. Blockers 0.16 0.0620 0.0046 0.0048 0.0002 0.81 0.0463 0.00214242 0.00221533 0.00007291 0.14 0.85
COX inhibitors 0.05 0.0213 0.0002 0.0003 0.0001 0.73 0.0250 0.00062656 0.00068957 0.00006300 0.10 0.80
D2 antagonists 0.15 0.0339 0.0015 0.0016 0.0002 0.86 0.0147 0.00021605 0.00025628 0.00004023 0.13 0.84
HIV P. inhibitors 0.12 0.1003 0.0078 0.0079 0.0001 0.75 0.0963 0.00927280 0.00935274 0.00007994 0.11 0.73
5HT1A agonists 0.11 0.0289 0.0005 0.0006 0.0001 0.84 0.0132 0.00017445 0.00021954 0.00004509 0.12 0.82
5HT3 antagonists 0.23 0.0497 0.0022 0.0024 0.0002 0.90 0.0095 0.00009090 0.00012157 0.00003067 0.30 0.91
5HT reup. inhibitors 0.15 0.0301 0.0011 0.0013 0.0002 0.85 0.0263 0.00069179 0.00073252 0.00004073 0.14 0.82
PKC inhibitors 0.11 0.0332 0.0013 0.0015 0.0001 0.63 0.0272 0.00073757 0.00088492 0.00014735 0.07 0.57
Renin inhibitors 0.48 0.1875 0.0282 0.0285 0.0003 0.91 0.0457 0.00208439 0.00213210 0.00004772 0.58 0.96
Subst. P inhibitors 0.06 0.0602 0.0015 0.0016 0.0001 0.69 0.0629 0.00395472 0.00404993 0.00009522 0.05 0.69
Thrombin inhibitors 0.16 0.0641 0.0065 0.0067 0.0002 0.79 0.0500 0.00250375 0.00259342 0.00008967 0.16 0.81
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Min. Div. Des. k = 200
ACE inhibitors 0.58 0.0608 0.0037 0.0040 0.0003 0.98 0.0080 0.00006333 0.00006619 0.00000286 0.11 0.67
AChE Inhibitors 0.49 0.0923 0.0045 0.0048 0.0003 0.98 0.0055 0.00003008 0.00003136 0.00000128 0.13 0.79
Angio. R. Blockers 0.98 0.0016 0.0004 0.0004 0.0000 1.00 0.0003 0.00000010 0.00000011 0.00000001 0.23 0.88
COX inhibitors 0.22 0.0508 0.0024 0.0026 0.0002 0.93 0.0136 0.00018488 0.00019163 0.00000675 0.10 0.83
D2 antagonists 0.35 0.0669 0.0040 0.0043 0.0003 0.97 0.0070 0.00004961 0.00005109 0.00000148 0.13 0.86
HIV P. inhibitors 0.79 0.0465 0.0070 0.0072 0.0002 0.99 0.0030 0.00000923 0.00000938 0.00000014 0.19 0.80
5HT1A agonists 0.56 0.0561 0.0029 0.0032 0.0003 0.99 0.0026 0.00000657 0.00000693 0.00000036 0.16 0.83
5HT3 antagonists 0.87 0.0343 0.0019 0.0021 0.0002 1.00 0.0009 0.00000085 0.00000089 0.00000004 0.33 0.92
5HT reup. inhibitors 0.38 0.0645 0.0038 0.0041 0.0003 0.94 0.0093 0.00008578 0.00009331 0.00000754 0.20 0.85
PKC inhibitors 0.44 0.0924 0.0053 0.0056 0.0003 0.95 0.0116 0.00013405 0.00014213 0.00000808 0.14 0.69
Renin inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0001 0.00000001 0.00000001 0.00000000 0.76 0.98
Subst. P inhibitors 0.59 0.0630 0.0057 0.0060 0.0003 0.98 0.0062 0.00003898 0.00003984 0.00000086 0.21 0.89
Thrombin inhibitors 0.87 0.0413 0.0051 0.0052 0.0001 1.00 0.0017 0.00000278 0.00000284 0.00000006 0.21 0.83
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Table A.3: VS Figures of Merit for dataset sub-samples.
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D-Opt. Design k = 250
ACE inhibitors 0.23 0.0370 0.0021 0.0023 0.0002 0.74 0.0539 0.00290673 0.00301699 0.00011026 0.09 0.63
AChE Inhibitors 0.07 0.0205 0.0006 0.0007 0.0001 0.68 0.0272 0.00074102 0.00080638 0.00006536 0.08 0.74
Angio. R. Blockers 0.08 0.0318 0.0020 0.0020 0.0001 0.69 0.0758 0.00575232 0.00582277 0.00007044 0.16 0.83
COX inhibitors 0.05 0.0183 0.0002 0.0003 0.0000 0.66 0.0278 0.00077361 0.00083350 0.00005989 0.06 0.80
D2 antagonists 0.12 0.0306 0.0013 0.0014 0.0001 0.82 0.0170 0.00028914 0.00032829 0.00003915 0.11 0.82
HIV P. inhibitors 0.05 0.0307 0.0013 0.0013 0.0001 0.56 0.1108 0.01227170 0.01234420 0.00007250 0.10 0.73
5HT1A agonists 0.06 0.0170 0.0003 0.0004 0.0001 0.76 0.0217 0.00047176 0.00051705 0.00004529 0.11 0.82
5HT3 antagonists 0.11 0.0208 0.0007 0.0008 0.0001 0.83 0.0188 0.00035201 0.00038600 0.00003399 0.28 0.92
5HT reup. inhibitors 0.13 0.0171 0.0008 0.0010 0.0001 0.81 0.0256 0.00065320 0.00069109 0.00003789 0.13 0.81
PKC inhibitors 0.10 0.0259 0.0007 0.0008 0.0001 0.56 0.0389 0.00151234 0.00161888 0.00010654 0.05 0.55
Renin inhibitors 0.14 0.0840 0.0124 0.0125 0.0001 0.74 0.1116 0.01244580 0.01251775 0.00007195 0.49 0.93
Subst. P inhibitors 0.06 0.0234 0.0010 0.0010 0.0001 0.54 0.0743 0.00551629 0.00560093 0.00008464 0.03 0.60
Thrombin inhibitors 0.08 0.0388 0.0010 0.0011 0.0001 0.65 0.0712 0.00506424 0.00515145 0.00008721 0.10 0.73
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Table A.3: VS Figures of Merit for dataset sub-samples.
MOE Simple
m
ea
n(
R
T
R
1%
)
σ t
op
(R
T
R
1%
)
σ
2 to
p
(R
T
R
1%
)
σ
2 (
R
T
R
1%
)
σ
2 bt
(R
T
R
1%
)
m
ea
n(
AU
C
RO
C
)
σ t
op
(A
U
C
RO
C
)
σ
2 to
p
(A
U
C
RO
C
)
σ
2 (
AU
C
RO
C
)
σ
2 bt
(A
U
C
RO
C
)
m
ea
n(
R
T
R
1%
)
m
ea
n(
AU
C
RO
C
)
Onion Des. k = 250
ACE inhibitors 0.35 0.0489 0.0039 0.0042 0.0003 0.80 0.0431 0.00185434 0.00199421 0.00013987 0.09 0.65
AChE Inhibitors 0.09 0.0209 0.0004 0.0005 0.0001 0.79 0.0145 0.00020906 0.00025921 0.00005015 0.08 0.76
Angio. R. Blockers 0.15 0.0680 0.0028 0.0030 0.0001 0.82 0.0430 0.00185025 0.00190018 0.00004993 0.17 0.86
COX inhibitors 0.07 0.0154 0.0007 0.0008 0.0001 0.74 0.0228 0.00051845 0.00057598 0.00005753 0.09 0.81
D2 antagonists 0.18 0.0384 0.0016 0.0018 0.0002 0.88 0.0147 0.00021686 0.00024747 0.00003061 0.14 0.86
HIV P. inhibitors 0.14 0.0884 0.0076 0.0077 0.0001 0.77 0.0848 0.00719824 0.00725846 0.00006022 0.09 0.70
5HT1A agonists 0.13 0.0221 0.0007 0.0008 0.0001 0.84 0.0121 0.00014760 0.00018438 0.00003678 0.11 0.81
5HT3 antagonists 0.24 0.0469 0.0018 0.0020 0.0002 0.90 0.0068 0.00004672 0.00007168 0.00002497 0.28 0.91
5HT reup. inhibitors 0.22 0.0339 0.0024 0.0027 0.0002 0.86 0.0219 0.00047975 0.00052646 0.00004671 0.14 0.82
PKC inhibitors 0.16 0.0366 0.0020 0.0022 0.0002 0.70 0.0293 0.00086115 0.00096948 0.00010833 0.07 0.58
Renin inhibitors 0.48 0.1679 0.0310 0.0312 0.0002 0.90 0.0561 0.00314301 0.00318415 0.00004114 0.66 0.97
Subst. P inhibitors 0.08 0.0390 0.0027 0.0028 0.0001 0.69 0.0765 0.00585373 0.00592444 0.00007071 0.05 0.70
Thrombin inhibitors 0.17 0.0806 0.0067 0.0069 0.0001 0.81 0.0572 0.00327369 0.00333496 0.00006127 0.13 0.77
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Min. Div. Des. k = 250
ACE inhibitors 0.48 0.0610 0.0031 0.0034 0.0002 0.94 0.0216 0.00046691 0.00047912 0.00001221 0.09 0.66
AChE Inhibitors 0.47 0.0671 0.0047 0.0049 0.0003 0.97 0.0086 0.00007317 0.00007465 0.00000148 0.13 0.80
Angio. R. Blockers 0.93 0.0200 0.0011 0.0012 0.0001 1.00 0.0003 0.00000007 0.00000009 0.00000001 0.21 0.87
COX inhibitors 0.22 0.0490 0.0020 0.0022 0.0002 0.92 0.0128 0.00016511 0.00017210 0.00000699 0.09 0.82
D2 antagonists 0.30 0.0629 0.0032 0.0034 0.0002 0.96 0.0087 0.00007598 0.00007830 0.00000232 0.12 0.85
HIV P. inhibitors 0.71 0.0835 0.0086 0.0088 0.0002 0.99 0.0045 0.00002062 0.00002083 0.00000021 0.17 0.78
5HT1A agonists 0.50 0.0536 0.0029 0.0032 0.0003 0.98 0.0032 0.00001022 0.00001058 0.00000036 0.14 0.83
5HT3 antagonists 0.77 0.0441 0.0037 0.0039 0.0002 0.99 0.0018 0.00000326 0.00000335 0.00000009 0.30 0.92
5HT reup. inhibitors 0.28 0.0620 0.0026 0.0028 0.0002 0.92 0.0108 0.00011765 0.00012747 0.00000982 0.17 0.84
PKC inhibitors 0.34 0.0728 0.0060 0.0063 0.0002 0.90 0.0198 0.00039108 0.00040815 0.00001707 0.11 0.68
Renin inhibitors 1.00 0.0000 0.0000 0.0000 0.0000 1.00 0.0001 0.00000002 0.00000002 0.00000000 0.76 0.98
Subst. P inhibitors 0.48 0.0755 0.0041 0.0044 0.0002 0.97 0.0085 0.00007223 0.00007454 0.00000231 0.19 0.89
Thrombin inhibitors 0.77 0.0711 0.0063 0.0065 0.0002 0.99 0.0030 0.00000894 0.00000908 0.00000014 0.22 0.83
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Table A.3: VS Figures of Merit for dataset sub-samples.
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D-Opt. Des. k = 300
ACE inhibitors 0.26 0.0456 0.0019 0.0021 0.0002 0.76 0.0458 0.00209809 0.00218962 0.00009153 0.09 0.64
AChE Inhibitors 0.08 0.0251 0.0006 0.0007 0.0001 0.70 0.0239 0.00057041 0.00062388 0.00005346 0.08 0.74
Angio. R. Blockers 0.09 0.0442 0.0019 0.0019 0.0001 0.71 0.0767 0.00587782 0.00593557 0.00005775 0.17 0.84
COX inhibitors 0.06 0.0155 0.0004 0.0004 0.0000 0.68 0.0237 0.00056005 0.00060894 0.00004889 0.08 0.81
D2 antagonists 0.14 0.0361 0.0018 0.0019 0.0001 0.84 0.0133 0.00017725 0.00020681 0.00002957 0.11 0.82
HIV P. inhibitors 0.06 0.0359 0.0009 0.0010 0.0001 0.60 0.1040 0.01082398 0.01088338 0.00005940 0.09 0.72
5HT1A agonists 0.07 0.0181 0.0005 0.0005 0.0001 0.78 0.0205 0.00042105 0.00045482 0.00003377 0.12 0.82
5HT3 antagonists 0.12 0.0270 0.0007 0.0008 0.0001 0.84 0.0184 0.00033787 0.00036269 0.00002481 0.28 0.92
5HT reup. inhibitors 0.16 0.0288 0.0008 0.0009 0.0001 0.84 0.0195 0.00037833 0.00040546 0.00002714 0.14 0.82
PKC inhibitors 0.10 0.0259 0.0008 0.0009 0.0001 0.59 0.0411 0.00169064 0.00177776 0.00008711 0.06 0.55
Renin inhibitors 0.19 0.1115 0.0171 0.0172 0.0001 0.79 0.1085 0.01177901 0.01182956 0.00005056 0.49 0.94
Subst. P inhibitors 0.07 0.0312 0.0016 0.0016 0.0001 0.57 0.0706 0.00497884 0.00505026 0.00007143 0.04 0.62
Thrombin inhibitors 0.09 0.0321 0.0013 0.0014 0.0001 0.67 0.0672 0.00451275 0.00458393 0.00007118 0.12 0.75
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Onion Des. k = 300
ACE inhibitors 0.32 0.0624 0.0021 0.0023 0.0002 0.78 0.0398 0.00158501 0.00167292 0.00008790 0.09 0.64
AChE Inhibitors 0.09 0.0204 0.0006 0.0006 0.0001 0.79 0.0151 0.00022718 0.00026992 0.00004274 0.08 0.76
Angio. R. Blockers 0.17 0.0534 0.0038 0.0039 0.0001 0.82 0.0360 0.00129505 0.00133864 0.00004358 0.15 0.84
COX inhibitors 0.06 0.0263 0.0003 0.0004 0.0001 0.75 0.0252 0.00063733 0.00067830 0.00004097 0.08 0.81
D2 antagonists 0.16 0.0394 0.0014 0.0015 0.0001 0.86 0.0128 0.00016374 0.00019079 0.00002705 0.11 0.83
HIV P. inhibitors 0.13 0.0873 0.0070 0.0071 0.0001 0.75 0.0959 0.00918977 0.00924022 0.00005046 0.10 0.73
5HT1A agonists 0.12 0.0266 0.0007 0.0008 0.0001 0.85 0.0160 0.00025488 0.00028198 0.00002710 0.12 0.82
5HT3 antagonists 0.24 0.0426 0.0024 0.0025 0.0002 0.90 0.0107 0.00011439 0.00013284 0.00001845 0.29 0.92
5HT reup. inhibitors 0.18 0.0495 0.0012 0.0013 0.0001 0.85 0.0219 0.00048061 0.00050609 0.00002547 0.14 0.82
PKC inhibitors 0.15 0.0450 0.0021 0.0022 0.0001 0.66 0.0281 0.00079130 0.00087905 0.00008775 0.07 0.57
Renin inhibitors 0.44 0.1761 0.0390 0.0392 0.0002 0.90 0.0569 0.00324273 0.00327734 0.00003461 0.55 0.95
Subst. P inhibitors 0.08 0.0523 0.0022 0.0023 0.0001 0.70 0.0702 0.00492756 0.00498563 0.00005807 0.05 0.71
Thrombin inhibitors 0.16 0.0820 0.0057 0.0058 0.0001 0.79 0.0494 0.00244499 0.00249905 0.00005406 0.11 0.76
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Table A.3: VS Figures of Merit for dataset sub-samples.
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Min. Div. Des. k = 300
ACE inhibitors 0.40 0.0560 0.0023 0.0025 0.0002 0.89 0.0307 0.00094494 0.00097405 0.00002911 0.08 0.64
AChE Inhibitors 0.39 0.0682 0.0055 0.0057 0.0002 0.96 0.0096 0.00009121 0.00009310 0.00000188 0.11 0.80
Angio. R. Blockers 0.86 0.0330 0.0018 0.0019 0.0001 1.00 0.0005 0.00000029 0.00000031 0.00000001 0.19 0.86
COX inhibitors 0.19 0.0451 0.0020 0.0022 0.0001 0.91 0.0139 0.00019428 0.00020124 0.00000696 0.10 0.82
D2 antagonists 0.25 0.0567 0.0022 0.0024 0.0002 0.94 0.0094 0.00008752 0.00009108 0.00000356 0.13 0.85
HIV P. inhibitors 0.63 0.0926 0.0093 0.0095 0.0002 0.99 0.0061 0.00003711 0.00003750 0.00000039 0.16 0.78
5HT1A agonists 0.44 0.0542 0.0025 0.0027 0.0002 0.98 0.0038 0.00001433 0.00001479 0.00000046 0.14 0.84
5HT3 antagonists 0.70 0.0607 0.0028 0.0030 0.0002 0.99 0.0018 0.00000307 0.00000319 0.00000012 0.31 0.92
5HT reup. inhibitors 0.24 0.0511 0.0017 0.0019 0.0002 0.90 0.0152 0.00023023 0.00024106 0.00001084 0.16 0.84
PKC inhibitors 0.27 0.0778 0.0051 0.0053 0.0002 0.85 0.0242 0.00058382 0.00061249 0.00002868 0.10 0.67
Renin inhibitors 1.00 0.0005 0.0000 0.0000 0.0000 1.00 0.0002 0.00000003 0.00000003 0.00000000 0.74 0.98
Subst. P inhibitors 0.40 0.0643 0.0032 0.0034 0.0002 0.95 0.0106 0.00011248 0.00011598 0.00000350 0.17 0.88
Thrombin inhibitors 0.64 0.0795 0.0086 0.0088 0.0002 0.99 0.0053 0.00002843 0.00002876 0.00000033 0.20 0.81
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Supplementary Tables: Chapter 3
Table B.1: Potential False Negatives. Overview.
AID CID # Refs. Found Target Mode of Interaction
429 661647 - - -
429 666976 - - -
429 2124942 - - -
429 2221829 - - -
429 3236183 - - -
449 797232 - - -
449 1219876 - - -
449 2140504 2 IRE1 endonuclease inhibitor
449 3241605 - - -
552 650276 1 - (decreased activity in motor activity test)
552 713182 - - -
552 762456 1 - -
552 951589 - - -
552 3235718 - - -
524 645763 - - -
524 667157 - - -
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Table B.1: Potential False Negatives. Overview.
AID CID # Refs. Found Target Mode of Interaction
524 870802 - - -
524 974684 - - -
524 2155052 1 p34cdc2 kinase inhibition
525 644570 - - -
525 664796 - - -
525 2977461 - - -
525 6602980 - - -
565 664948 - - -
565 2945948 - - -
565 3236904 - - -
565 3240663 - - -
565 4094173 - - -
581 663452 - - -
581 741168 - - -
581 3237217 - - -
581 3238135 - - -
581 3244793 - - -
604 397588 2 - -
604 870802 - - -
604 972417 - - -
604 2841612 1 - -
604 5389712 - - -
628 653541 - - -
628 663038 - - -
628 1363188 - - -
628 2001334 - - -
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Table B.1: Potential False Negatives. Overview.
AID CID # Refs. Found Target Mode of Interaction
628 2973815 - - -
629 654182 - - -
629 655077 - - -
629 725878 - - -
629 787302 - - -
629 3193162 1 stearoyl-CoA desaturase (SCD) enzymes (preferably SCD1) inhibition
633 665223 - - -
633 795871 - - -
633 1247306 - - -
633 2632776 - - -
633 2646358 - - -
639 651906 - - -
639 795916 - - -
639 866943 - - -
639 2345962 - - -
639 3237613 - - -
641 291754 23 KDR, DANN-PK, RTK, CTK, STK inhibition
641 646307 - - -
641 694544 1 - -
641 717657 - - -
641 888381 - - -
689 403074 1 - -
689 653588 - - -
689 1415442 - - -
689 2115030 - - -
689 2354012 - - -
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Table B.1: Potential False Negatives. Overview.
AID CID # Refs. Found Target Mode of Interaction
727 286547 10 liver X receptors, p38, 5HT1-rec, vasopressin 1 rec. activation/inhibition
727 657722 1 - -
727 661489 1 E. coli primase inhibition
727 807549 - - -
727 889075 - - -
736 658992 - - -
736 662422 - - -
736 1352540 - - -
736 2107624 - - -
736 2221133 2 - -
798 951167 - - -
798 1280861 - - -
798 1444742 - - -
798 1444809 - - -
798 1718171 - - -
800 653266 - - -
800 714424 3 HIV-1 reverse transcriptase inhibition
800 764249 - - -
800 2284606 - - -
800 2291974 - - -
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Table B.2: Potential False Negatives. References.
AID CID References
449 2140504 141,142
552 650276 143
552 762456 144
524 2155052 145
604 397588 146,147
604 2841612 148
629 3193162 149
641 291754 150–172
641 694544 173
689 403074 174
727 286547 175–184
727 657722 185
727 661489 186
736 2221133 187,188
800 714424 189–191
800 764249 192
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
AUCROC, 1Q., Orig.
S1P1 rec. 466 0.551 0.053 0.620 0.078 0.544 0.035 0.568 0.075
PKA 548 0.718 0.106 0.711 0.125 0.678 0.074 0.744 0.096
SF1 600 0.564 0.056 0.538 0.028 0.580 0.048 0.545 0.049
Rho-Kinase2 644 0.615 0.090 0.581 0.095 0.601 0.045 0.627 0.073
HIV RT-RNase 652 0.596 0.084 0.513 0.068 0.500 0.098 0.550 0.071
Eph rec. A4 689 0.495 0.091 0.575 0.083 0.448 0.074 0.548 0.055
SF1 692 0.588 0.074 0.620 0.080 0.509 0.048 0.596 0.091
HSP 90 712 0.583 0.069 0.498 0.067 0.583 0.037 0.552 0.107
ER-a-Coact. Bind. Inh. 713 0.483 0.054 0.592 0.064 0.469 0.053 0.537 0.056
ER-ß-Coact. Bind. Inh. 733 0.519 0.067 0.523 0.067 0.471 0.053 0.534 0.073
ER-a-Coact. Bind. Pot. 737 0.553 0.095 0.680 0.064 0.552 0.083 0.616 0.086
FAK 810 0.510 0.060 0.518 0.064 0.587 0.064 0.597 0.085
Cathepsin G 832 0.638 0.052 0.638 0.080 0.613 0.061 0.736 0.066
FXIa 846 0.654 0.068 0.797 0.085 0.596 0.042 0.711 0.059
S1P2 rec. 851 0.484 0.153 0.522 0.072 0.443 0.105 0.494 0.121
FXIIa 852 0.646 0.057 0.766 0.065 0.667 0.077 0.769 0.063
D1 Rec. 858 0.504 0.026 0.524 0.052 0.451 0.027 0.502 0.066
M1 Rec. 859 0.560 0.076 0.583 0.084 0.580 0.047 0.589 0.113
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
AUCROC, 10Q., Orig.
S1P1 rec. 466 0.584 0.033 0.699 0.022 0.564 0.015 0.649 0.033
PKA 548 0.798 0.034 0.861 0.031 0.745 0.029 0.844 0.021
SF1 600 0.593 0.032 0.642 0.042 0.633 0.025 0.657 0.048
Rho-Kinase2 644 0.729 0.040 0.770 0.054 0.679 0.037 0.802 0.039
HIV RT-RNase 652 0.650 0.055 0.592 0.029 0.465 0.087 0.638 0.036
Eph rec. A4 689 0.601 0.052 0.657 0.043 0.491 0.037 0.615 0.043
SF1 692 0.639 0.038 0.704 0.032 0.511 0.038 0.639 0.033
HSP 90 712 0.633 0.045 0.620 0.051 0.639 0.030 0.701 0.062
ER-a-Coact. Bind. Inh. 713 0.505 0.040 0.646 0.026 0.442 0.024 0.573 0.039
ER-ß-Coact. Bind. Inh. 733 0.529 0.036 0.560 0.034 0.453 0.023 0.572 0.036
ER-a-Coact. Bind. Pot. 737 0.605 0.048 0.782 0.039 0.538 0.040 0.698 0.043
FAK 810 0.576 0.031 0.600 0.035 0.627 0.033 0.687 0.039
Cathepsin G 832 0.724 0.035 0.785 0.049 0.693 0.030 0.880 0.045
FXIa 846 0.765 0.033 0.884 0.024 0.659 0.043 0.860 0.044
S1P2 rec. 851 0.627 0.082 0.676 0.075 0.577 0.088 0.702 0.093
FXIIa 852 0.759 0.023 0.845 0.018 0.753 0.022 0.879 0.029
D1 Rec. 858 0.513 0.021 0.556 0.025 0.456 0.015 0.538 0.038
M1 Rec. 859 0.615 0.026 0.655 0.039 0.631 0.012 0.691 0.034
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
RT R1%, 1Q., Orig.
S1P1 rec. 466 0.020 0.019 0.025 0.020 0.021 0.019 0.034 0.037
PKA 548 0.086 0.088 0.132 0.140 0.092 0.086 0.123 0.109
SF1 600 0.016 0.019 0.029 0.029 0.025 0.026 0.032 0.036
Rho-Kinase2 644 0.053 0.065 0.071 0.072 0.067 0.070 0.089 0.067
HIV RT-RNase 652 0.031 0.028 0.037 0.046 0.043 0.035 0.042 0.050
Eph rec. A4 689 0.030 0.027 0.026 0.022 0.041 0.045 0.025 0.030
SF1 692 0.025 0.026 0.021 0.029 0.022 0.026 0.018 0.025
HSP 90 712 0.019 0.025 0.034 0.034 0.025 0.026 0.042 0.041
ER-a-Coact. Bind. Inh. 713 0.013 0.012 0.018 0.015 0.013 0.013 0.015 0.015
ER-ß-Coact. Bind. Inh. 733 0.012 0.013 0.015 0.015 0.017 0.014 0.021 0.015
ER-a-Coact. Bind. Pot. 737 0.033 0.033 0.056 0.043 0.027 0.020 0.028 0.024
FAK 810 0.023 0.021 0.026 0.023 0.036 0.027 0.036 0.027
Cathepsin G 832 0.042 0.031 0.070 0.045 0.063 0.055 0.131 0.084
FXIa 846 0.051 0.032 0.126 0.069 0.050 0.028 0.084 0.039
S1P2 rec. 851 0.067 0.076 0.069 0.074 0.065 0.073 0.074 0.069
FXIIa 852 0.072 0.072 0.122 0.094 0.094 0.088 0.192 0.137
D1 Rec. 858 0.011 0.008 0.013 0.012 0.013 0.009 0.014 0.015
M1 Rec. 859 0.022 0.023 0.029 0.025 0.031 0.033 0.035 0.036
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
RT R1%, 10Q., Orig.
S1P1 rec. 466 0.041 0.019 0.059 0.024 0.059 0.027 0.093 0.038
PKA 548 0.215 0.061 0.198 0.066 0.301 0.080 0.281 0.081
SF1 600 0.047 0.024 0.097 0.041 0.069 0.033 0.129 0.048
Rho-Kinase2 644 0.080 0.036 0.101 0.038 0.135 0.062 0.208 0.057
HIV RT-RNase 652 0.054 0.027 0.112 0.042 0.044 0.040 0.133 0.046
Eph rec. A4 689 0.075 0.041 0.065 0.031 0.045 0.027 0.073 0.028
SF1 692 0.026 0.025 0.014 0.018 0.027 0.023 0.007 0.015
HSP 90 712 0.079 0.038 0.109 0.048 0.104 0.046 0.192 0.073
ER-a-Coact. Bind. Inh. 713 0.013 0.013 0.028 0.018 0.013 0.013 0.030 0.019
ER-ß-Coact. Bind. Inh. 733 0.010 0.010 0.031 0.018 0.015 0.010 0.065 0.024
ER-a-Coact. Bind. Pot. 737 0.023 0.021 0.112 0.045 0.037 0.026 0.042 0.034
FAK 810 0.059 0.027 0.063 0.024 0.068 0.027 0.089 0.036
Cathepsin G 832 0.111 0.037 0.189 0.054 0.218 0.065 0.404 0.083
FXIa 846 0.161 0.049 0.337 0.062 0.141 0.051 0.339 0.076
S1P2 rec. 851 0.231 0.097 0.285 0.114 0.238 0.097 0.323 0.123
FXIIa 852 0.193 0.055 0.301 0.056 0.218 0.061 0.436 0.062
D1 Rec. 858 0.013 0.011 0.022 0.013 0.021 0.012 0.024 0.013
M1 Rec. 859 0.049 0.023 0.046 0.021 0.094 0.027 0.061 0.030
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
AUCROC, 1Q., MUV
S1P1 rec. 466 0.467 0.032 0.538 0.056 0.479 0.039 0.524 0.075
PKA 548 0.578 0.085 0.654 0.098 0.599 0.051 0.636 0.085
SF1 600 0.502 0.051 0.523 0.047 0.550 0.027 0.545 0.048
Rho-Kinase2 644 0.524 0.069 0.619 0.073 0.542 0.040 0.580 0.073
HIV RT-RNase 652 0.425 0.034 0.443 0.077 0.492 0.056 0.486 0.101
Eph rec. A4 689 0.514 0.093 0.549 0.089 0.457 0.095 0.544 0.065
SF1 692 0.503 0.052 0.563 0.067 0.462 0.037 0.544 0.083
HSP 90 712 0.473 0.059 0.485 0.095 0.517 0.049 0.536 0.120
ER-a-Coact. Bind. Inh. 713 0.425 0.038 0.512 0.085 0.452 0.033 0.491 0.068
ER-ß-Coact. Bind. Inh. 733 0.445 0.069 0.451 0.042 0.432 0.053 0.523 0.075
ER-a-Coact. Bind. Pot. 737 0.520 0.077 0.660 0.061 0.525 0.074 0.639 0.080
FAK 810 0.489 0.045 0.470 0.045 0.513 0.054 0.541 0.070
Cathepsin G 832 0.516 0.029 0.553 0.090 0.507 0.029 0.680 0.083
FXIa 846 0.515 0.059 0.692 0.116 0.492 0.040 0.616 0.064
S1P2 rec. 851 0.427 0.081 0.467 0.049 0.451 0.056 0.471 0.085
FXIIa 852 0.499 0.028 0.647 0.104 0.530 0.068 0.687 0.104
D1 Rec. 858 0.458 0.026 0.492 0.065 0.488 0.029 0.461 0.070
M1 Rec. 859 0.438 0.033 0.513 0.057 0.525 0.034 0.518 0.067
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
AUCROC, 10Q., MUV
S1P1 rec. 466 0.462 0.054 0.553 0.050 0.525 0.050 0.580 0.061
PKA 548 0.571 0.059 0.732 0.045 0.626 0.041 0.718 0.039
SF1 600 0.494 0.056 0.600 0.051 0.582 0.038 0.594 0.052
Rho-Kinase2 644 0.528 0.048 0.696 0.043 0.601 0.047 0.743 0.056
HIV RT-RNase 652 0.458 0.060 0.502 0.054 0.498 0.047 0.530 0.066
Eph rec. A4 689 0.535 0.065 0.627 0.054 0.460 0.069 0.617 0.057
SF1 692 0.485 0.045 0.623 0.040 0.453 0.041 0.592 0.043
HSP 90 712 0.497 0.065 0.570 0.060 0.568 0.037 0.658 0.074
ER-a-Coact. Bind. Inh. 713 0.458 0.058 0.611 0.047 0.496 0.045 0.502 0.046
ER-ß-Coact. Bind. Inh. 733 0.482 0.045 0.510 0.049 0.445 0.042 0.565 0.041
ER-a-Coact. Bind. Pot. 737 0.510 0.054 0.739 0.044 0.503 0.052 0.709 0.047
FAK 810 0.524 0.042 0.524 0.048 0.543 0.050 0.672 0.039
Cathepsin G 832 0.535 0.054 0.711 0.066 0.554 0.048 0.864 0.059
FXIa 846 0.524 0.038 0.824 0.041 0.533 0.057 0.793 0.054
S1P2 rec. 851 0.465 0.065 0.579 0.076 0.589 0.072 0.660 0.092
FXIIa 852 0.522 0.044 0.739 0.038 0.620 0.044 0.796 0.038
D1 Rec. 858 0.490 0.055 0.605 0.055 0.521 0.051 0.546 0.066
M1 Rec. 859 0.467 0.057 0.550 0.053 0.527 0.038 0.603 0.053
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
RT R1%, 1Q, MUV
S1P1 rec. 466 0.012 0.016 0.020 0.026 0.024 0.029 0.020 0.026
PKA 548 0.015 0.024 0.043 0.060 0.029 0.032 0.036 0.040
SF1 600 0.012 0.016 0.022 0.030 0.021 0.036 0.029 0.047
Rho-Kinase2 644 0.011 0.018 0.036 0.031 0.033 0.033 0.038 0.038
HIV RT-RNase 652 0.016 0.021 0.013 0.024 0.023 0.023 0.018 0.022
Eph rec. A4 689 0.013 0.020 0.021 0.028 0.031 0.038 0.020 0.031
SF1 692 0.008 0.014 0.012 0.017 0.007 0.016 0.009 0.019
HSP 90 712 0.011 0.021 0.027 0.040 0.014 0.018 0.029 0.036
ER-a-Coact. Bind. Inh. 713 0.009 0.015 0.020 0.024 0.012 0.018 0.017 0.021
ER-ß-Coact. Bind. Inh. 733 0.006 0.016 0.015 0.024 0.018 0.027 0.021 0.025
ER-a-Coact. Bind. Pot. 737 0.014 0.018 0.033 0.032 0.019 0.019 0.024 0.027
FAK 810 0.006 0.017 0.013 0.017 0.014 0.022 0.027 0.029
Cathepsin G 832 0.010 0.021 0.048 0.044 0.027 0.038 0.081 0.055
FXIa 846 0.003 0.009 0.068 0.061 0.023 0.022 0.040 0.033
S1P2 rec. 851 0.033 0.050 0.044 0.056 0.043 0.056 0.052 0.052
FXIIa 852 0.008 0.015 0.040 0.054 0.027 0.033 0.073 0.075
D1 Rec. 858 0.014 0.020 0.022 0.024 0.017 0.022 0.018 0.024
M1 Rec. 859 0.012 0.018 0.018 0.026 0.014 0.022 0.014 0.024
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Table B.3: VS Figures of Merit for PubChem Datasets.
Simple MOE SESP MACCS
Target AID mean std mean std mean std mean std
RT R1%, 10Q., MUV
S1P1 rec. 466 0.001 0.007 0.042 0.032 0.042 0.038 0.077 0.047
PKA 548 0.000 0.000 0.042 0.035 0.097 0.057 0.047 0.040
SF1 600 0.000 0.000 0.050 0.038 0.026 0.029 0.063 0.051
Rho-Kinase2 644 0.000 0.000 0.079 0.050 0.079 0.049 0.083 0.037
HIV RT-RNase 652 0.000 0.000 0.026 0.028 0.054 0.039 0.041 0.032
Eph rec. A4 689 0.001 0.005 0.027 0.025 0.002 0.009 0.048 0.035
SF1 692 0.000 0.000 0.006 0.016 0.000 0.000 0.001 0.007
HSP 90 712 0.000 0.000 0.043 0.037 0.036 0.030 0.051 0.048
ER-a-Coact. Bind. Inh. 713 0.000 0.000 0.077 0.043 0.012 0.025 0.064 0.041
ER-ß-Coact. Bind. Inh. 733 0.000 0.000 0.021 0.025 0.026 0.025 0.057 0.052
ER-a-Coact. Bind. Pot. 737 0.000 0.000 0.025 0.026 0.018 0.025 0.014 0.022
FAK 810 0.000 0.000 0.004 0.015 0.024 0.025 0.074 0.047
Cathepsin G 832 0.000 0.000 0.126 0.053 0.085 0.048 0.331 0.095
FXIa 846 0.000 0.000 0.230 0.086 0.010 0.021 0.227 0.089
S1P2 rec. 851 0.101 0.055 0.253 0.093 0.185 0.072 0.306 0.116
FXIIa 852 0.000 0.000 0.119 0.062 0.028 0.036 0.237 0.071
D1 Rec. 858 0.000 0.000 0.084 0.049 0.029 0.036 0.087 0.052
M1 Rec. 859 0.000 0.000 0.017 0.024 0.052 0.035 0.044 0.030
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Appendix C
MUV Datasets
The MUV datasets are completely based on structural information and bioactivity data
from PubChem. This data is freely available, but it is not allowed to re-distribute the
structures in SDF format. The MUV datasets can be automatically downloaded using
the MUV_Downloader, a JAVA program that queries the PubChem Power User Gate-
way (PUG) for the structures and downloads the datasets in .sdf.gz format to a specified
directory on your computer.
The MUV downloader is available on the enclosed CD-ROM in the directory
/MUV_Downloader
or via the internet at
http://www.pharmchem.tu-bs.de/lehre/baumann/download.html
A Sun JAVA SE6 compatible JRE must be installed on your system for the MUV_Downloader
to work. It can be downloaded free of charge from Sun:
http://www.java.com/en/download/manual.jsp
Once you have downloaded MUV_Downloader.jar and JAVA is installed correctly on your
system, you can start the program by typing
~/$ java -jar MUV_Downloader.jar
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at your system’s command prompt. On most systems you should also be able to run the
MUV_Downloader by simply double clicking its symbol in the file manager.
The complete collection of MUV datasets contains 255510 compounds (17 * 30 ac-
tives + 17*15000 decoys), so the download will take quite a while.
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Appendix D
Spatial Statistics Toolbox for
MATLAB 7
D.1 Installation
The implementation of the algorithms for the spatial statistics analysis of chemical datasets
constituted a major effort in the completion of this study. The programs for the calcula-
tion of G(t), F(t) and the resulting scalars ΣG, ΣF and ΣS, as well as those for the design
of datasets with given topological properties are the core of a Toolbox for The Math-
works MATLAB 790 that is provided on the enclosed CD-ROM. The source code of the
most important programs will be listed in print in the following sections. (Sections D.2.1,
D.2.2, D.2.3 and D.2.4)
In addition to the algorithms and programs utilized and discussed in this study, the
toolbox provides a number of programs for the calculation of other established statis-
tics for the analysis of mapped point patterns. For a comprehensive review of these
methodologies refer to Ref.94 Moreover, the toolbox features a JAVA helper library for
the handling of chemical structures and the calculation of molecular descriptors, which
is a prerequisite for the conduction of spatial statistics analyses of chemical data. Using
the Spatial Statistics Toolbox and the JAVA helper library, users can apply the methods
introduced in this study to their own datasets. For example, the toolbox can be used to
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design custom MUV datasets from user-provided datasets. Section D.3 features a HowTo
tutorial demonstrating the generation of MUV datasets based on two example datasets.
In order to install the Spatial Statistics Toolbox copy the folder
/SpSt
from the root directory of the CD-ROM to your hard drive. Alternatively, you can down-
load the toolbox as a .tar.gz archive from
http://www.pharmchem.tu-bs.de/lehre/baumann/SpaceStatsToolbox.html
In this case please extract the contents of the archive to a location of your choice. Finally,
include the folder
SpSt/
on your disk recursively into your MATLAB path. You can do so by clicking File->Set
Path...->Include with subfolders... in the MATLAB workspace.
As mentioned before, the toolbox is complemented by a JAVA library jMUV.jar man-
aging SD-file I/O and descriptor calculation. jMUV itself is based on the Chemistry
Development Kit CDK. (Version 1.0.3, Download) Both libraries have to be included in
your MATLAB classpath. They are available in the directory
/jar
on the enclosed CD-ROM or can be downloaded from
http://www.pharmchem.tu-bs.de/lehre/baumann/jMUV.jar
http://downloads.sourceforge.net/cdk/cdk-1.0.3.jar
respectively. Both libraries have to be included in the MATLAB classpath. Please be
aware, that jMUV.jar is built based on Version 1.0.3 of the CDK. Other versions might
not work properly.
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D.2 Source Code
D.2.1 G(t) - spst_G
function G = spst_G(D, map, options)
%
% G = spst_G(D, map, options)
%
% Input: D Data matrix with rows = observations, columns=variables
%
% map Hypercubic map for uniform csr. For higher data
% dimensions (>3) the use of a map and corresponding edge
% correction is strongly advised against. Use map = [] instead.
%
% options Options struct variable. Default values are indicated
% by *asterisks*.
%
% options.distmode: *’euc’*, ’city’, ’cheby’
% options.step: *0.01*, any decimal
% options.maxD: *10*, any integer
%
% Copyright: Sebastian Rohrer
% University of Braunschweig, Institute of Technology
% Department of Pharmaceutical Chemistry
% 2008
[m n] = size(D);
% if options is omitted, set default values
if (nargin < 3)
options.distmode=’euc’;
options.step=0.01;
options.maxD=10;
end
% set x-axis and preallocate G
x = 0:options.step:options.maxD;
G = zeros(size(x,2), 1);
% if a map is used calculate distance to border for edge correction
if (max(size(map))>0)
d2b_events = dist2border(D, map);
d2b_events = d2b_events * ones(1,size(x,2));
end
% For each event calculate distance to nearest neighbor
dist = nndist(D, D, 1, options.distmode);
dist = dist*ones(1,size(x,2));
% calculate cumulative distribution
w = ones(m,1)*x;
dnn = dist < w;
% if a map is used, apply edge correction
if (map)
in_center = d2b_events <= w;
nn = dnn & in_center;
else
nn = dnn;
end
G = (sum(nn)./m)’; % We want the fraction of events
G = [x’ G]; % Append x-axis
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D.2.2 F(t) - spst_F
function F = spst_F(D, map, I, options)
% F = spst_F(D, map, I, options)
%
% Input: D Data matrix with rows = observations, columns=variables
%
% map Hypercubic map for uniform csr. For higher data
% dimensions (>3) the use of a map and corresponding uniform csr
% is strongly advised against. Use map = [] and
% options.csr = ’bt’ instead.
%
% I Background data for the generation of bootstrap or
% convex pseudo-data csr.
%
% options Options struct variable. Default values are indicated
% by *asterisks*.
%
% options.distmode: *’euc’*, ’city’, ’cheby’
% options.csr: *’bt’*, ’pseudo’, ’disc’, ’dec’, ’all’
% options.nP: *10000*, any integer
% options.iter: *20*, any integer
% options.step: *0.01*, any decimal
% options.maxD: *10*, any integer
%
% Copyright: Sebastian Rohrer
% University of Braunschweig, Institute of Technology
% Department of Pharmaceutical Chemistry
% 2008
%initialize random numbers algorithm
old = rand(’state’);
rand(’state’, 0);
% if options is omitted, set default values
if (nargin < 4)
options.distmode=’euc’;
options.csr=’bt’;
options.nP=10000;
options.iter=1;
options.step=0.01;
options.maxD=10;
end
% set x-axis and preallocate F
x = 0:options.step:options.maxD;
F = zeros(size(x,2), options.iter);
% start calculation
for j=1:options.iter
nP = options.nP;
% generate random points
if strcmpi(options.csr, ’bt’)
sP = bootstrap(nP, I,options.replacement);
elseif strcmpi(options.csr, ’all’)
sP = I;
nP = size(sP,1);
elseif strcmpi(options.csr, ’pseudo’)
sP = convex_pseudo_data(nP, I);
elseif strcmpi(options.csr, ’dec’)
sP = unifcsr(map, nP, ’dec’);
elseif strcmpi(options.csr, ’disc’)
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sP = unifcsr(map, nP, ’disc’);
else
error(’spst_F: CSR (options.csr) mode not supported.’);
end
% if a map is used calculate distance of each point to all events
% else compute only distance to nearest event
if (max(size(map))>0)
dist = distance(sP, D, options.distmode);
% calculate distance to border for edge correction
d2b_events = dist2border(D, map);
d2b_points = dist2border(sP, map);
else
dist = nndist(sP, D, 1, options.distmode);
end
% calculate cumulative distribution
for i=1:size(x,2);
w = x(i);
% if a map is used, apply edge correction
if (map)
events = d2b_events <= w;
points = d2b_points <= w;
dnn = min(dist(points,events), [], 2);
else
dnn = dist;
end
nn = dnn < w;
num_set = sum(nn);
F(i,j) = num_set;
end
end
F= F./nP; % We want the fraction of points
F=mean(F,2); % Get the mean from the iterations
F = [x’ F]; % Append x-axis
rand(’state’, old); % Return random number generator to its original state.
D.2.3 Design of Datasets of Actives with Given ΣG - spst_RX
function [R, sgs] = spst_RX(A, Red, nsel, options)
%
% [R, sff] = spst_RX(A, Red, nsel, options)
%
% Row-exchange algorithm to optimize a sample of actives towards a preset value
% of SigmaG
%
%
% Input: A Data matrix of actives with rows = compounds,
% columns=descriptors
%
% Red Logical array constituting the starting design of
% actives generated by spst_ksnn
%
% nsel Number of actives to select
%
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% options Options struct variable. Default values are indicated
% by *asterisks*.
%
% options.distmode: *’euc’*, ’city’, ’cheby’
% options.iter: *20*, any integer
% options.step: *0.01*, any positive number
% options.maxD: *10*, any positive number
% options.targetG: *312*, any positive number
% options.deltaSigmaG *2*, any positive number
% options.r *0.8*, any positive number
% options.verbose *true*, boolean
%
% Copyright: Sebastian Rohrer
% University of Braunschweig, Institute of Technology
% Department of Pharmaceutical Chemistry
% 2008
% initialize random numbers generator
old = rand(’state’);
rand(’state’, 0);
% get dataset size
[m n] = size(A);
% initialize return values
R = false(m,1);
sgs = zeros(options.iter,2);
% initialize design variables
d = zeros(nsel,1);
sG = options.targetG;
% Starting design from previous step (Kennard-Stone)
d(:,1) = find(Red);
% get stopping criterion
threshold=options.deltaSigmaG;
% initiate tabu matrix
% 0 means tabu for next iteration
tabu = ones(m,1);
tabu(d,1) = 0;
% initialize loop variables and off we go...
iter = 1;
has_changed = 1;
is_optimized = 0;
while(iter <= options.iter & has_changed == 1 & is_optimized == 0)
has_changed = 0;
% loop over all actives in the currently selected set
for i=1:nsel
% compute of the set d(SigmaG) before exchange
G = spst_G(A(d,:), [], options);
G = sum(G(:,2));
old_DsG = abs(G - sG);
% throw out row i without using setdiff (terribly slow)
d2 = [d(1:(i-1),1);d((i+1):end)];
% find rows not yet in set
nd = find(tabu);
% calculate nearest neighbor distances
nndistance = nndist(A(nd,:), A(d,:), 1, options.distmode);
% remove candidates below similarity cutoff and outliers
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nd = nd(nndistance >= options.r);
if(nd) % proceed only if there are selectable candidates left
% compute sG for exchange
sgg = zeros(size(nd,1),1);
for j=1:size(nd,1)
gg = spst_G(A([d2;nd(j,1)],:), [], options);
sgg(j,1) = sum(gg(:,2));
end
% the row that produces the lowest difference from sG is the best for exchange
dsgg = abs(sG-sgg);
% Now we want the point creates the smallest differences from
% sG
[mdsgg, ind] = min(dsgg);
new_DsG = dsgg(ind,1);
new_sG = sgg(ind,1);
new_member = nd(ind,1);
% make exchange only if DsG decreases
if (old_DsG - new_DsG > 0)
tabu(d(i,1),1) = 1; % allow replaced candidate to replace the other rows
d(i,1) = new_member; % replace old candidate by new one
tabu(new_member,1) = 0; % disallow new_member for following replacements
sgs(iter,1) = new_DsG; % record old and new DsG
sgs(iter,2) = new_sG;
has_changed = 1; % indicate that the current iteration has changed the set
if(new_DsG <= threshold) % if optimization criterion is reached exit the loop
is_optimized = 1;
break;
end
else % if the exchange is not
% favorable (and therefore not made)...
sgs(iter,1) = old_DsG; % record DsG
sgs(iter,2) = G;
end
else
sgs(iter,1) = old_DsG; % record DsG
sgs(iter,2) = G;
end
end
iter = iter + 1; % increment interation counter
end
if (options.verbose)
disp(strcat(’Optimized after:’, num2str(iter), ’ Iterations. delta(SigmaG)=’
, num2str(sgs(iter-1,1)), ’ SigmaG=’, num2str(sgs(iter-1,2))));
end
if(iter == options.iter && options.verbose)
disp(’Maximum Iterations reached’);
end
d = sort(d,’ascend’);
R(d,1) = true;
rand(’state’, old);
D.2.4 Design of Datasets of Decoys with Given ΣF - spst_GA
function [R, sff] = spst_GA(A, I, Red, nsel, options)
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%
% [R, sff] = spst_GA(A, I, Red, nsel, options)
%
% Genetic algorithm to optimize a sample of decoys towards a preset value
% of SigmaF
%
%
% Input: A Data matrix of actives with rows = compounds,
% columns=descriptors
%
% I Data matrix of decoys
%
% Red Logical array constituting the starting design of
% decoys generated by spst_ksnn
%
% nsel Number of decoys to select
%
% options Options struct variable. Default values are indicated
% by *asterisks*.
%
% options.distmode: *’euc’*, ’city’, ’cheby’
% options.iter: *20*, any integer
% options.step: *0.01*, any decimal
% options.maxD: *10*, any integer
% options.targetG: *312*, any positive number
% options.deltaSigmaG *2*, any positive number
% options.verbose *true*, boolean
%
% Copyright: Sebastian Rohrer
% University of Braunschweig, Institute of Technology
% Department of Pharmaceutical Chemistry
% 2008
% initialize random numbers generator
% This will generate reproducible results
% If you want true randomness, comment out the following two and the last
% line (reset rand) of the function.
old = rand(’state’);
rand(’state’, 0);
% get fitness threshold from options
threshold = options.deltaSigmaG;
% initialize iteration counter
iter = 0;
% set optimization state
optimized = false;
% initialize return values
R = false(size(I,1),1);
sff = zeros(options.iter,1);
% initialize the genepool (all potential decoys)
gp = true(size(I,1),1);
if(options.verbose)
disp(’Calculating NN-Distances...’);
end
% remove candidates too far off (farther than maximum NN-Dist in A);
annd = max(nndist(A, A, 1, options.distmode));
% Innd (precalculated NN distances of Inactives) is also used later for
% fitness calculation see function sigmaF = sigmaF_precompNND (below)
Innd = nndist(I, A, 1, options.distmode);
gp(Innd > annd,1) = false;
% convert logical to indices
gpi = find(gp);
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% exit with error, if number of candidates too small
if(size(gpi,1) <= nsel)
error(’spst_Fga: number of candidates too small!’);
end
% get reasonable parent from kNN design prduced in previous step
PRI = find(Red);
% generate npop starting individuals by mutating the parent
P = [PRI spst_ga_mutate(PRI, gpi, 0.3, options.npop-1)];
% compute fitness of starting population
% (the smaller, the better!)
if(options.verbose)
disp(’Calculating first fitness vector...’);
end
f = spst_Fga_fitness(Innd, P, options);
% sort ascending
[f, ind] = sort(f);
P = P(:,ind);
bestF = f(1);
if(options.verbose)
% output fitness of the five best individuals
disp(strcat(’Fitness of starting design:’, num2str(f(1:5))));
end
if (bestF <= threshold)
optimized = true;
end
if (options.verbose)
disp(’Start evolution...’);
end
no_change_count=0;
while(iter < options.iter && not(optimized) && no_change_count <=3)
% initialize children
P2 = zeros(size(P));
% keep the 3 best individuals for the next generation
P2(:,1:3) = P(:,1:3);
% generate 10 children by mutating best five with low mutation rate
P2(:,4:13) = spst_ga_mutate(P(:,1:5), gpi, 0.1, 10);
% generate 10 children by mutating best five with high mutation rate
P2(:,14:23) = spst_ga_mutate(P(:,1:5),gpi, 0.3, 10);
% generate 60 children with very five mutation rate
P2(:,24:83) = spst_ga_mutate(P(:,1:5),gpi, 0.05, 60);
% generate remaining children by crossover of best 10
P2(:,84:end)= spst_ga_crossover(P(:,1:10), options.npop-83);
% add a slight level of mutation to a third of the crossover-children
h = floor(size(P2(:,84:end),2)/3);
P2(:,84:(83+h)) = spst_ga_mutate(P2(:,84:(83+h)),gpi, 0.02, h);
% fitness of new population (the smaller, the better!)
f2 = spst_Fga_fitness(Innd, P2, options);
% sort ascending
[f2, ind] = sort(f2);
P2 = P2(:,ind);
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% get best fitness
bestF2 = f2(1);
% log best fitness value for later analysis
sff(iter+1,1) = bestF2;
% set new population
P = P2;
% exit loop if optimization threshold is reached;
if (bestF2 < bestF)
bestF = bestF2;
no_change_count=0;
else
no_change_count=no_change_count+1;
end
if (options.verbose)
% output fitness of the five best individuals
disp(strcat(num2str(iter+1), ’ Iterations. Fitness:’, num2str(f2(1:5)),
’, NoChangeCount:’, num2str(no_change_count)));
end
if (bestF <= threshold)
optimized = true;
end
iter = iter+1;
end
if (options.verbose)
% output optimization result
disp(strcat(’spst_Fga converged after:’, num2str(iter),
’ Iterations. With a final fitness of:’, num2str(bestF)));
end
R(P(:,1),1) = true;
% reset rand
rand(’state’, old);
function f = spst_Fga_fitness(Innd, P, options)
%
% This function calculates SigmaF for all individuals of a population and
% compares it to the target value. The difference between SigmaF of each
% individual and the target value (options.targetG) is the fitness of the
% individual.
% initialize
sf = zeros(1, size(P,2));
% loop through individuals and compute sigmaF (see below)
for i=1:size(P,2)
sf(1,i) = sigmaF_precompNND(Innd(P(:,i),:), options);
end
% fitness = absolute difference
f = abs(options.targetG - sf);
function sigmaF = sigmaF_precompNND(nndist, options)
%
% By using a precomputed vector of the distance of each decoy to its
% nearest neighbor active, this function calculates F and sigmaF for a
% sample of decoys much faster than spst_F.
% determine dataset sizes
[m n] = size(nndist);
% Initialize x-Axis
x = ones(m,1)*(0:options.step:options.maxD);
% Inflate the distance vector to a matrix the same size as x
d = nndist*ones(1,size(x,2));
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% Calculate F
nn = d < x;
num_set = sum(nn);
F= num_set./m;
% Calculate and return SigmaF
sigmaF = sum(F);
function C = spst_ga_mutate(P, gpi, mutRate, numC)
%
% This function mutates a sample of decoys (an individual) by replacing
% part of it by random decoys selected from the genepool (all other
% potential decoys).
% determine population size
[m n] = size(P);
% if we want to produce more children than parents
if (numC>n)
% repeat P until there are more than enough parents
size_factor = ceil(numC/n);
P = repmat(P,1,size_factor);
% randomly select enough parents
r = randperm(size_factor*n);
P=P(:,r(1:numC));
end
% if we want to produce less children than parents
if(numC<n)
r = randperm(n);
P = P(:,r(1:numC));
end
C = zeros(m,numC);
for i=1:numC
% disallow decoys already present in the current set
gpii = setdiff(gpi, P(:,i));
% mutate according to mutation rate
num_keep = floor(m*(1-mutRate));
num_get = m-num_keep;
% randomly select the decoys to keep
r1 = randperm(m);
k = P(r1(1:num_keep),i);
% fill up other places with randomly chosen decoys from the pool.
r2 = randperm(size(gpii,1));
g = gpii(r2(1:num_get));
C(:,i) = [k; g];
end
function C = spst_ga_crossover(P, numC)
%
% This function generates a new sample of decoys (child chromosome) by
% randomly combining two other samples of decoys (parent chromosomes).
[m n] = size(P);
C = zeros(m,numC);
% if we want to produce more children than parents
if (numC>n)
% repeat P until there are more than enough parents
size_factor = ceil(numC/n);
P = repmat(P,1,size_factor);
% randomly select enough parents
r = randperm(size_factor*n);
P=P(:,r(1:numC));
end
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% generate random pairs for crossover.
p = zeros(2,numC);
p(1,:) = randperm(numC);
p(2,:) = randperm(numC);
% do actual crossover
for j=1:numC
% combine both parents
sex = unique([P(:,p(1,j));P(:,p(2,j))]);
% mix randomly
r = randperm(size(sex,1));
sex = sex(r);
% create the child
C(:,j) = sex(1:m,1);
end
D.3 How To Generate Your Own MUV Datasets
D.3.1 Basic Preparations
This tutorial relies on two example datasets. These datasets are available on the enclosed
CD-ROM in the directory
/example_data
or as a .tar.gz archive from
http://www.pharmchem.tu-bs.de/lehre/baumann/examples.tar.gz
Please copy the files to a folder on your hard drive. We will refer to the respective folder
as
’example_dir’
from now on.
The MUV workflow is designed to generate a collection of VS benchmarking datasets
from a collection of datasets with bioactivity against several biological targets. We will
refer to these datasets as activity classes. We will refer to the name of such an activity
class by the variable
classe
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(class is a MATLAB keyword and can not be used as a variable name) from now on. Each
activity class consists of one SD-file of compounds that are known to be active against
the respective target and another SD-file of compounds that are known or assumed to be
inactive against the target. Since the MUV workflow selects corresponding subsets of
actives and inactives to generate spatially optimal active and decoy datasets, we will refer
to the initial files as potential actives (PA) and potential decoys (PD) respectively. For
MUV to work, all files of potential actives and potential decoys have to be collected in a
common directory and be named following certain conventions. Each corresponding pair
of potential actives and decoys must be named like:
classe_suffix.sdf
with classe the class name (e.g. ACE or Renin, Bioassay456, ...) and suffix identifying
actives and inactives (e.g. suffix=’actives.sdf’)
The files in the ’example_dir’ directory adhere to these conventions:
classe1_actives.sdf - Example dataset classe1, actives
classe1_decoys.sdf - Example dataset classe1, decoys
classe2_actives.sdf - Example dataset classe2, actives
classe2_decoys.sdf - Example dataset classe1, decoys
Before you start, you have to provide MATLAB with a cell-array of the class names and
the suffixes. For the example datasets type
>> classes = {’classe1’; ’classe2’};
>> suffix = {’actives’; ’decoys’};
at the MATLAB prompt.
The spatial statistics toolbox manages options that are needed in multiple function
using a MATLAB struct variable called options. In order to obtain an options struct with
default values, type
>> options=spst_getDefaults
at the MATLAB prompt, which will produce the following output:
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options =
distmode: ’euc’
csr: ’bt’
nP: 10000
iter: 20
step: 0.0100
maxD: 10
weight: ’fortin’
normalize: 1
sort: 0
replacement: 1
r: 0.8000
npop: 150
deltaSigmaG: 2
verbose: 1
targetG: 312
sep: ’/’
So far, the only important options are .normalize which should be left in its default state of
’true’ and .sep which constitutes the directory separator on your system. On Unix systems
it can be left ’/’ on Windows systems, it should be changed to ’\’.
D.3.2 Calculate Simple Descriptors
As mentioned above, Maximum Unbiased Validation is based on a spatial optimization
of datasets in simple descriptor space. Therefore you have to calculate these descriptors
for your datasets first. There are two ways of doing so: (i) If you are lucky enough to
have a valid license for FILTER and BABEL by OpenEye Inc., MUV provides a wrapper
that utilizes these tools for simple descriptor calculation. (ii) If you don’t have access to
OpenEye’s tools, MUV also provides an implementation of simple descriptors based on
the open source Chemistry Development Kit (CDK).
At the present state, simple descriptor calculation is much faster and reliable using the
OpenEye tools. Apparently, there are problems in the CDK with the correct detection of
chiral centers and the correct prediction of the logP, which are both important variables in
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simple descriptors. The respective bug reports have been filed to the CDK bug tracking
system.
The function muv_simple_descriptors provides functionality for the calculation of
simple descriptors using both, OpenEye tools and the CDK.
D.3.2.1 Calculating Simple Descriptors using OpenEye FILTER and BABEL
As a first measure you need to provide the function with your system’s commands to FIL-
TER and BABEL. These are hard-coded in lines 43 and 44 of the function. Before first
use, you must edit these two lines to match your system. On my system, FILTER and BA-
BEL are linked to /usr/bin and therefore the respective lines in muv_simple_descriptors
simply are:
filtercmd=’filter’;
(or filtercmd=’/opt/OpenEye/bin/filter...)
babelcmd=’babel’;
(or babelcmd=’C:\OpenEye\bin\babel’, ... )
Furthermore, you have to provide a scratch directory with read and write access. This is
necessary for saving the text output of FILTER and BABEL, which is parsed to yield the
descriptors. The location of the scratch directory is specified in line 47 of the function, on
my system it is:
scratch=’/home/baschti/scratch’;
(Don’t use abbreviations like ’~/scratch’)
The numerical values of ranges of the variables in simple descriptors are different. There-
fore the descriptor matrices should be autoscaled columnwise. In order to do so, the mean
and standard deviation for each simple descriptor variable have been determined for a
very large and comprehensive collection of compounds. The respective values are hard-
coded in muv_simple_descriptors and can be readily used for normalizing your data. In
order to do so set
>>options.normalize=true;
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which is also the default. Now you’re good to go. At the MATLAB prompt type
>>act = muv_simple_descriptors(’example_dir’, classes, suffix{1}, ’OE’, options)
Output:
This program calculates simple descriptors for a directory of SD-files.
The content of the descriptor vectors is:
#B #Br #C #Cl #F #I...
Calucalting simple descriptors for:example_data/classe1_actives.sdf...
Calculating Properties.
Calculating AtomCounts.
...done.
Scaling data...
Calucalting simple descriptors for:example_data/sdf/classe2_actives.sdf...
Calculating Properties.
Calculating AtomCounts.
...done.
Scaling data...
act =
classe1: [1x1 struct]
classe2: [1x1 struct]
>>dec = muv_simple_descriptors(’example_dir’, classes, suffix{2}, ’OE’, options)
Output:
This program calculates simple descriptors for a directory of SD-files.
The content of the descriptor vectors is:
#B #Br #C #Cl #F #I...
Calucalting simple descriptors for:example_data/classe1_decoys.sdf...
Calculating Properties.
Calculating AtomCounts.
...done. Scaling data...
Calucalting simple descriptors for:example_data/classe2_decoys.sdf...
Calculating Properties.
Calculating AtomCounts.
...done.
Scaling data...
dec =
classe1: [1x1 struct]
classe2: [1x1 struct]
What you did was calling muv_simple_desc first for the actives (suffix{1}) and then for
the decoys (suffix{2}). This will provide you with two struct variables act and dec con-
taining a field for each activity class, each with a subfield .dsc containing the actual de-
scriptors and .ids the compound IDs as given by the first line in each molecule block in
the SD-files. The descriptor calculation should be done in a moment for the actives (~500
compounds), but might take quite a while for the decoys (~130000 compounds) depend-
ing on your hardware. First benchmarks indicate a processing time of roughly 0.01 sec
per compound on an Intel Core2Duo (1.66 GHz, 4GB RAM, Ubuntu Linux 7.10).
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D.3.2.2 Calculating Simple Descriptors Using the CDK
With jMUV.jar and cdk-1.0.3.jar in your MATLAB classpath, there are no further prepa-
rations necessary for the calculation of simple descriptors using the CDK. Set
>>options.normalize=true;
and call
>>act = muv_simple_descriptors(’example_dir’, classes, suffix{1}, ’CDK’, options)
>>dec = muv_simple_descriptors(’example_dir’, classes, suffix{2}, ’CDK’, options)
As with the OpenEye tools, this will provide you with two struct variables act and dec
containing a field for each activity class, each with a subfield .dsc containing the actual
descriptors and .ids the compound IDs as given by the first line in each molecule block in
the SD-files. As stated above, we discourage the use of the CDK for simple descriptor cal-
culation at the present state. In addition to the lower quality of the descriptors calculated
by the CDK, descriptor calculation is about 10x slower than with the OpenEye Tools.
D.3.3 Generating Maximally Diverse Sets of Actives and Minimally
Separated Sets of Decoys
The goal of MUV design is to adjust all benchmark datasets in a collection to a common
degree of clumping (ΣS) in simple descriptor space. The state of spatial randomness
ΣS = 0 has proven to be especially advantageous. In the MUV workflow, all datasets
of actives are first adjusted to a common level of self-similarity measured by ΣG. Then
corresponding decoy datasets are selected in a way so that ΣF = ΣG=⇒ ΣS= 0. But first,
you have to determine which is the maximum common diversity that you can achieve with
your datasets of actives given the size of the subset of actives you want to select. (In the
original MUV datasets, k = 30 actives proved to be a reasonable choice.) In order to do
so, the maximally diverse subset of with k members has to be selected from each dataset
of actives. This can be done using the well established Kennard-Stone algorithm. At the
MATLAB prompt type:
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>>[Rksnn, Sksnn] = spst_ksnn(act, dec, classes, 30, 15000, options)
Output:
Generating datasets of actives with maximum spread. (Kennard-Stone Design)
classe1
classe2
Generating datasets of decoys with minimum separation. (k-Nearest Neighbor Design)
classe1
classe2
Rksnn =
mode: [1x1 struct]
act: [1x1 struct]
dec: [1x1 struct]
Sksnn =
sigmaG: [2x1 double]
sigmaF: [2x1 double]
This selects a subset of k = 30 maximally diverse actives and a subset of d = 15000
decoys minimally separated from the actives for each activity class. The struct variable
Rksnn provides logical indices into act and dec to identify the selected compounds. The
struct variable Sksnn provides ΣG and ΣF values for these selected subsets.
We will use a target value of ΣG = 312 in this tutorial, since this is the target value of
the original MUV datasets. Of course, you could use any value larger than the largest one
in Sksnn. In order to set the target value of ΣG for the following final generation of MUV
datasets type
>>options.targetG=313; (This is also the Default)
D.3.4 Generating MUV Datasets
Now we can generate the actual MUV datasets. The workflow will first adjust all datasets
of actives to the common value of ΣG = 312 using a row exchange algorithm. Then it
will employ a genetic algorithm to select a corresponding subset of decoys with ΣF = 312.
The Kennard-Stone design from the previous step is used as a starting design. Type:
>>[Rmuv, Smuv] = spst_muv(act, dec, classes, Rksnn, 30, 15000, options)
Output:
Generating datasets of actives with common spread. (MUV Design, Row-Exchange Algorithm)
classe1
Optimized after:2 Iterations. delta(SigmaG)=6.8212e-13 SigmaG=312
classe2
Optimized after:2 Iterations. delta(SigmaG)=0.1 SigmaG=312.1
Generating datasets of decoys with common separation. (MUV Design, Genetic Algorithm)
classe1
Calculating NN-Distances...
Calculating first fitness vector...
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Fitness of starting design:5.67247 20.5051 20.7805 20.8441 20.9285
Start evolution...
1 Iterations. Fitness:0.74127 0.91213 1.0014 1.0025 1.0198, NoChangeCount:0
spst_Fga converged after:1 Iterations. With a final fitness of:0.74127
classe2
Calculating NN-Distances...
Calculating first fitness vector...
Fitness of starting design:0.961133 26.5592 26.6961 26.7561 26.9576
Start evolution...
spst_Fga converged after:0 Iterations. With a final fitness of:0.96113
Rmuv =
mode: [1x1 struct]
act: [1x1 struct]
dec: [1x1 struct]
Smuv =
sigmaG: [2x1 double]
sigmaF: [2x1 double]
sigmaS: [2x1 double]
Done! You just generated MUV datasets for the two example datasets. Again, Rmuv con-
stitutes a struct providing logical indices into act and Smuv provides the spatial statistics
data of the generated datasets. Let’s have a look:
>> Smuv.sigmaG
ans =
312.0000
312.1000
>> Smuv.sigmaF
ans =
313.1793
312.7685
>> Smuv.sigmaS
ans =
1.1793
0.6685
Both ΣG and ΣF converged to a value very near 312. Accordingly, ΣS ≈ 0 for both
datasets.
D.3.5 Exporting the Datasets to SD-Files
In order to use your newly generated MUV datasets for VS validations, you can export
them to SD-files on your disk. This is facilitated by the function spst_muv_extractSD.
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As arguments it takes the act and dec structs, the just generated Rmuv, the path to the
directory of the original SD-Files (’example_dir’, in our case), the path where the new
MUV SD-Files shall be created, the suffix cell array and the options struct. Before running
the script, you have to create the output directory and ensure that you have write access.
Let’s assume that you chose
/home/your_username/muv_sdf
as the output directory. Then you would call spst_muv_extractSD as:
>> spst_muv_extractSD(act, dec, Rmuv, classes, example_dir, ’/home/your_username/muv_sdf’, suffix, options)
Have fun validating with your brand-new MUV datasets!
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stdtop(FoM) Standard deviation component caused by dataset topology
ACE Angiotensin Converting Enzyme
AChE Acetylcholineesterase
AID Assay Identity
ANN Artificial Neural Network
CID Compound Identity
Conf. Itv. Confidence Interval
COX Cyclooxygenase
COX2 Cyclooxygenase 2
D1 Rec. Dopamine D1 Receptor
DUD Directory of Useful Decoys
EF Enrichment Factor
Eph rec. A4 Eph Receptor A4
ER-α-Coact. Estrogen Receptor-α Coactivator
ER-β -Coact. Estrogen Receptor-β Coactivator
FAK Focal Adhesion Kinase
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FoH Frequency of Hits
FXIa Factor XIa
FXIIa Factor XIIa
GPCR G-Protein Coupled Receptor
HIV Human Immunodeficiency Virus
HSP90 Heat Shock Protein 90
HTS High-Throughput Screening
LBVS Ligand Based Virtual Screening
MDDR MDL Drug Data Report
MLI Molecular Libraries Initiative
MLSCN Molecular Libraries Screening Centers Network
MOE Molecular Operating Environment
MUV Maximum Unbiased Validation
NIH National Institutes of Health
PA Potential Actives
PCA Principal Components Analysis
PD Potential Decoys
PDB Protein Data Bank
PKA Protein Kinase A
PKC Protein Kinase C
PPI Protein Protein Interaction
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PUG PubChem Power User Gateway
qHTS Quantitative High-Throughput Screening
Rec. Tyr. Kinase Receptor Tyrosine Kinase
ROC Receiver Operating Characteristic
RT Reverse Transcriptase
RTR Retrieval Rate
S1P1 Sphingosine-1-Phosphate Receptor 1
S1P2 Sphingosine-1-Phosphate Receptor 2
SBVS Structure Based Virtual Screening
SF1 Nuclear Receptor Steroidogenic Factor 1
SVD Singular Value Decomposition
SVM Support Vector Machine
TAC Tested Assay Count
UID Unique Identity
VS Virtual Screening
wAAC Weighted Active Assay Count
ZINC ZINC Is Not Commercial
dE Euclidean Distance
EC50 Half maximal effective concentration
λ Goodness of a VS ranking
N Number of decoys in a validation set
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Ra Fraction of actives in a validtation set
AUCROC Area under the Receiver Operating Characterisitc curve
RT R1% Retrieval Rate at 1 percent of the ranking
%SI Percent Sequence Identity
σ2 Variance
σ2bt,i Bootstrapping variance component
ΣS Dataset Clumping
σ2top Variance component introduced by dataset topology
Tc Tanimoto-Jaquard coefficient
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AUCROC, 17, 31
EC50, 67
Ra, 32
Activity space, 21
Analogue bias, 21, 24, 28
Artificial enrichment, 20, 24, 28
Autoscaling, 28, 77
Basic tasks of VS validation, 15
Benchmark Datasets, 19
Benchmarking, 15, 62
CACTVS, 97
Cellular Growth and Proliferation Assays, 4
Chemical similarity, 10
Chemical Space, 21
ClustalW, 72
Clustering, 23
Concentrated, 33
Confirmatory screen, 67
Correlation, 41
Cumulative probability distribution, 34
D-optimal Design, 29
Decoys, 15, 20
Descriptor, 10
Descriptor space, 23
descriptor space, 13
Deterministic Design, 29
Dispersed, 33
Distance measures, 13
Docking, 8
Dose-response relationship, 67
DrugBank, 75
DUD, 20, 97
Dumb descriptor, 20
E-Utilities, 72
Eigenvalues, 28
Embedding, 75
Empty space function, 34
Enrichment factors, 17
Enzymatic Assays, 4
Euclidean distance, 13
Event, 33
F(t), 34
Fingerprints, 11
FoH, 71, 104
FoM, 84
Frequency of hits, 71
Functional Cell-based Assays, 4
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G(t), 34
Guide tree, 72
Hert-Willett datasets, 19, 25
Histogram, 72
HTS, 62, 72, 88
HTS Assay Formats, 4
λ , 31
LBVS, 6
Lock and Key, 6
MACCS, 77
MAX-rule data fusion, 14
MDDR, 19, 20, 25, 75
Minimum Diversity Design, 29
MLSCN, 5
MOE, 27
MOE descriptors, 27, 77
Molecular Libraries Initiative, 5, 65
Molecular Libraries Screening Centers Net-
work, 5
MUV, 62, 67
N, 31
Nearest neighbor function, 34
Onion design, 29
Patchiness, 23
Patchy, 33
PCA, 77
PCBioAssay, 5, 65
PCCompound, 5, 65
PDB, 19
Perl, 72
Pharmacophore, 10
Points, 32
Posing, 8
Primary screen, 67
Property descriptors, 11, 27
Prous Drugs of the Future, 75
PubChem, 62, 65
PubChem Power User Gateway, 67
PUG, 67
qHTS, 74
Query, 15
Ranking, 15
Retrieval rate, 17
Roadmap, 5, 65
Row exchange algorithm, 29, 82
RTR, 17, 20
RT R1%, 17, 30
SBVS, 6, 19
Scaffold, 20, 23
Scoring, 8
Self-similarity, 23
SESP, 77
ΣS, 35
Sigma-Aldrich Catalogue, 75
σ2, 32
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σ2bt,i, 32
σ2top, 32
Simple descriptors, 28
Spatial Statistics, 32
Spread, 23
Standard deviation, 32
Structure based virtual screening, 6
Suitability testing, 15
SVD, 77
Tanimoto-Jaquard coefficient, 13
Topological descriptors, 11
Topology, 23, 32
Topology prototypes, 29
Validation, 14
Validation set, 15
Variance, 28
Variance decomposition, 31
Weights, 72
ZINC, 19, 97
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